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ABSTRACT 
The development of vaccines is one of the most important public health 
achievements. The goal of immunization is to protect individuals and the population 
from vaccine-preventable diseases (VPD). Although modern vaccines generally are 
safe, there is always a risk of adverse events, as is the case with any medical 
technology. Vaccines licensed by the National Regulatory Authorities are considered 
safe, but rare adverse reactions cannot be detected in pre-licensure clinical trials 
because of their limited size and duration. Once vaccines are licensed and used 
widely in the population, the main way to evaluate their safety is by conducting post-
licensure surveillance and related observational epidemiology studies. An adverse 
event following immunization (AEFI) is defined as a reaction or an event occurring 
after vaccine administration that is suspected to be related to the vaccination. All 
detected AEFIs do not have a causal relationship with vaccines, but the public may 
perceive them to be related to vaccination, which may raise concern, influence public 
confidence and hamper the implementation of immunization programs. As more 
vaccines are being introduced worldwide, high quality safety surveillance is becoming 
even more important to maintain public confidence in vaccines and vaccine 
programs. 
Many developed countries have established well-functioning AEFI surveillance 
systems, such as the Vaccine Adverse Event Reporting System (VAERS) in the U.S. 
However, it may be difficult to compare the safety profiles of vaccines used in 
developed countries to those in low and middle-income countries because the 
vaccines used and the types of serious AEFIs may be different due to local 
programmatic, health care system, environmental and genetic differences. China has 
a total population of over 1.3 billion people and an annual birth cohort of 16 million. 
With the increasing demand for vaccines and the development of vaccine 
manufacturing, China now ranks among the world’s largest vaccine manufacturers 
producing more than one billion vaccine doses annually. In 2010, the Chinese Food 
and Drug Administration’s (CFDA) website listed 46 registered Chinese vaccine 
manufacturers of public or private status, collectively manufacturing 24 licensed 
vaccines. 
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In mainland China, vaccine safety surveillance began first in provinces with 
enough economic resources, such as Shanghai and Jiangsu, in the 1980s. However, 
varying guidelines and definitions made comparing the collected data between 
provinces difficult. Based on National AEFI guideline issued by CFDA and the 
Ministry of Health (MoH) in 2010, the National Immunization Program (NIP) of 
the Chinese Center for Disease Control and Prevention (CDC) implemented the 
National AEFI Surveillance System (CNAEFIS) to establish a uniform nation-wide 
monitoring system which covers all NIP vaccines as well as those administered in 
private practices. The CNAEFIS is currently the only data source available for post-
licensure safety monitoring for vaccines manufactured and used in mainland China.  
The studies in this dissertation focus on evaluating the performance of the 
CNAEFIS and on using the collected data to assess vaccine safety issues. The four 
studies (I to IV) describe and evaluate the national AEFI surveillance system and 
assess the safety of selected vaccines used in mainland China. Study I described the 
CNAEFIS and its performance attributes to understand its overall functioning and 
to identify areas needing strengthening. Studies II to IV are case studies that evaluate 
vaccine safety in the following topics: recipient vaccine-associated paralytic 
poliomyelitis (VAPP), AEFI-associated deaths and, the AEFIs associated with the 
Japanese Encephalitis (JE) vaccines manufactured and used in China. The findings 
from these studies helped to identify vaccine-related safety concerns, assess whether 
these concerns were associated with vaccines and find ways to strengthen 
surveillance and investigation capacity for the immunization services in China. 
The CNAEFIS is a passive surveillance system that can collect timely national 
AEFI data and detect rare and severe events. With cumulating experience and data 
since its implementation in 2005, the CNAEFIS provides baseline data on AEFIs in 
the world’s largest population. By using different sources of denominator data, the 
CNAEFIS may also have the unique ability and statistical power to detect changes 
in reporting rates of known adverse events to help determine whether potential 
changes in observed rates may reflect uneven reporting.  
With the end game in progress for global eradication of polio, the schedule of 
polio vaccine administration in China was changed in 2016: one dose of inactivated 
polio vaccine (IPV) was introduced as the first polio vaccine dose and the subsequent 
three doses of trivalent Oral Poliovirus Vaccine (OPV) were replaced with bivalent 
OPV. The evaluation of VAPP cases reported in CNAEFIS provided information 
on the safety of trivalent OPV and will serve as reference data for VAPP occurrence 
after bivalent OPV in future evaluations. In Study II, the epidemiological 
characteristics of recipient VAPP cases, such as age distribution, were comparable 
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to those in previous studies from other countries. The risk of recipient VAPP, using 
either estimated births or vaccination doses as the denominator, was comparable to 
that observed in the U.S. and Japan. To further decrease the number of recipients 
VAPP cases in China, use of IPV was recommended. 
Study III was initiated because of media reports of deaths following 
administration of hepatitis B vaccine in Hunan province in December 2013. These 
reports had raised concerns about safety of vaccines among parents and the public 
and had resulted in marked decline in parental and public confidence in vaccines in 
the province. Childhood deaths are very rare and concerning events, but vaccinations 
in childhood are common. Therefore, a temporal association of reported fatalities 
with hepatitis B vaccination may have occurred by chance, without a causal link to 
vaccination. Our analysis provided reassuring information about the small risk of 
death following immunization. The reporting peak of AEFI-associated deaths in late 
2013 to early 2014 illustrated the sensitivity of passive reporting systems to public 
information. It also highlighted the caution that should be exercised in interpreting 
peaks in reports of serious AEFIs. Although the analysis was limited by small 
number of cases, our review of the characteristics of AEFIs and causes of death 
identified no vaccine safety concerns. This finding addressed the public’s concerns 
and should bolster confidence in the vaccine program.   
JE vaccines were introduced in the national immunization schedule in the 
mainland of China at the end of 2007. In 2013, the Japanese Encephalitis Vaccine 
Live (JEV-L) was the first Chinese-produced vaccine to be prequalified by the World 
Health Organization (WHO). Limited data were available on the safety of JE 
vaccines after their inclusion in the national immunization schedule and, 
consequently, on its large-scale use in China. In Study IV, the majority of AEFIs 
following JE vaccines were minor and comprised common adverse reactions. There 
were no significant differences between the estimated reported rates of serious 
AEFIs following JE Inactivated (JEV-I) and JEV-L. Most patients with serious 
AEFIs recovered fully. We recommended further studies to differentiate the effects 
of concurrent vaccination of other vaccines from those of JE vaccines and adoption 
of more sensitive methods to detect safety signals. 
This dissertation illustrates the progress made with vaccine safety monitoring 
during recent years in China. In these studies, we found that national AEFI 
surveillance was functional and able to provide useful data to evaluate safety of 
vaccines in the world’s largest population. The assessment of recipient VAPP, AEFI-
associated deaths, and the safety of JE vaccines suggested acceptable vaccine safety 
profiles. However, we also identified several challenges, such as lack of standard 
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international diseases and symptoms coding system and case definitions, which 
should be introduced to reduce misclassification and strengthen the system. In 
addition, the causality assessment procedures should be standardized and made more 
rigorous. Finally, new statistical methods should be introduced for safety signal 
detection and hypothesis generation in future studies. These scientific improvements 
in the world’ largest vaccine safety data source would continue building public 
confidence in vaccine programs in China, and perhaps serve as a model to 
surveillance system development in other countries. 
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TIIVISTELMÄ 
Rokotukset ovat yksi tärkeimmistä kansanterveyden saavutuksista. 
Rokotusohjelmien tavoitteena on suojata yksilöä ja väestöä vakavilta, rokotuksilla 
estettävissä olevilta taudeilta. Vaikka nykyiset rokotteet ovat yleisesti ottaen 
turvallisia, niihin voi liittyä haittavaikutuksia, kuten mihin tahansa lääketieteen 
teknologian käyttöön. Kansallisten viranomaisten hyväksymät rokotteet on todettu 
turvallisiksi ja tehokkaiksi ennen myyntiluvan myöntämistä tehdyissä kliinisissä 
tutkimuksissa. Harvinaisia haittavaikutuksia ei näissä tutkimuksissa kuitenkaan voida 
havaita niiden rajoitetun koon ja keston vuoksi. Rokotusten väestövaikutusten 
arviointi sekä harvinaisten haittavaikutusten havaitseminen on mahdollista vain, kun 
rokotteita on käytetty väestössä laajasti ja tarpeeksi pitkän aikaa. Kehittyneet 
seurantajärjestelmät ja niihin perustuvat epidemiologiset tutkimukset ovat tärkein 
tapa arvioida ja varmistaa rokotteiden turvallisuus. Rokotusten haittavaikutus 
määritellään reaktioksi tai tapahtumaksi, jonka epäillään liittyvän rokotukseen. 
Kaikilla rokotteilla voi olla haittavaikutuksia, mutta niitä esiintyy vain pienellä osalla 
rokotetuista. Kaikilla havaituilla haittavaikutuksilla ei myöskään ole syy-yhteyttä 
rokotteisiin. Koska rokotukset ovat yleisiä, niiden saatetaan kuitenkin olettaa liittyvän 
rokotuksiin ajallisen yhteyden perusteella. Tämä voi aiheuttaa huolta, vaikuttaa 
yleiseen luottamukseen rokotusohjelmaa kohtaan sekä haitata sen toteuttamista. 
Maailmanlaajuisesti otetaan jatkuvasti käyttöön uusia rokotteita. Tällöin 
korkealaatuisen turvallisuus seurannan rooli tulee entistä tärkeämmäksi, jotta väestön 
luottamus rokotteisiin ja rokoteohjelmiin säilyy. 
Useimmissa kehittyneissä maissa on hyvin toimivat, pitkäaikaiset rokotusten 
haittavaikutusten seurantajärjestelmät. Kehittyneissä maissa käytettyjen rokotteiden 
turvallisuuden seurannan tietoja on kuitenkin vaikea verrata ja soveltaa pieni- ja 
keskituloisiin maihin: Käytetyt rokotteet ja vakavat haittavaikutukset voivat poiketa 
toisistaan muun muassa rokotusohjelman, terveydenhuoltojärjestelmän, ympäristön 
ja väestön geneettisten erojen takia. Kiinassa on yli 1,3 miljardia ihmistä ja sen 
vuotuinen syntymäkohortti on 16 miljoonaa lasta. Rokotteiden kasvavan kysynnän 
ja rokotevalmistuksen menetelmien kehittymisen myötä Kiina on nykyään yksi 
maailman suurimmista rokotevalmistajista, joka valmistaa yli miljardi rokoteannosta 
vuodessa. Vuonna 2010 Kiinan elintarvike- ja lääkehallinnon verkkosivusto listasi 46 
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rekisteröityä kiinalaista rokotevalmistajaa, jotka valmistivat yhteensä 24:ttä eri 
rokotetta. 
Manner-Kiinan rokoteturvallisuuden seuranta aloitettiin 1980-luvulla 
provinsseissa, joilla oli riittävästi taloudellisia resursseja, kuten Shanghaissa ja 
Jiangsussa. Ohjeistuksen, tapausmääritelmien ja protokollien eroavaisuudet 
kuitenkin hankaloittivat tietojen vertailua maakuntien välillä. Kansallinen rokotusten 
haittavaikutusten seurantajärjestelmä (CNAEFIS) perustettiin vuonna 2010 Kiinan 
tautikeskuksen (Chinese Center for Disease Control and Prevention, CDC), 
kansallisen rokotusohjelman (National Immunization Program, NIP) ja 
terveysministeriön yhteistyössä kehittämän kansallisen ohjeistuksen perusteella. 
Yhdenmukainen, valtakunnallinen seurantajärjestelmä kattaa kansallisen 
rokotusohjelman rokotteiden lisäksi myös yksityisellä puolella annetut rokotteet. 
Tämä maailman suurimman väestön rokotteiden turvallisuustietokanta on ainoa 
kattava tietolähde, jonka avulla Manner-Kiinassa valmistettujen ja käytettyjen 
rokotteiden turvallisuutta voidaan seurata.  
Tämän väitöskirjan tutkimukset keskittyvät Kansallisen rokotusten turvallisuuden 
seurantajärjestelmän toiminnan arviointiin sekä kerätyn tiedon hyödyntämiseen 
tieteellisessä tutkimuksessa vastaamaan rokotusten turvallisuuteen liittyviin 
tieteellisiin kysymyksiin. Neljä tutkimusta (I – IV) kuvaavat ja arvioivat kansallisen 
seurantajärjestelmän toimintaa ja sekä kahta tautia vastaan kehitettyjen rokotteiden 
turvallisuutta. Nämä taudit ovat Japanin aivotulehdus, joka on vakava hyttysten 
levittämä virusinfektio sekä poliovirus infektio, joka aiheuttaa poliomyeliittiä eli 
lapsihalvausta. Ensimmäisessä tutkimuksessa kuvataan seurantajärjestelmän toiminta 
ja tunnistetaan vahvistettavia alueita. Tutkimukset II – IV ovat tapaustutkimuksia, 
joissa arvioidaan a) elävään poliorokotteeseen liittyvän halvausoireen yleisyyttä 
(Recipient Vaccine Associated Paralytic Polio);  b) haittavaikutusilmoituksia, joihin 
oli liittynyt kuolema sekä Kiinassa valmistettuihin, Japanin aivotulehdusta vastaan 
kehitettyihin rokotteisiin liittyviä haittavaikutuksia. Nämä tutkimukset tunnistivat 
rokotteisiin liittyviä turvallisuuskysymyksiä, arvioivat tieteellistä näyttöä siitä oliko 
haittavaikutuksilla yhteys rokotteisiin sekä tunnistivat kohtia joissa Kiinan kansallisen 
rokotusohjelman seurannan- ja tutkimuksen kapasiteettia voidaan vahvistaa.  
Kiinan kansallinen rokotusten haittavaikutusten seurantajärjestelmä on 
passiivinen järjestelmä, joka on ollut toiminnassa vuodesta 2005 lähtien. Se kerää 
ajantasaisia tietoja ja kykenee havaitsemaan harvinaisia tai vakavia tapahtumia 
maailman suurimmassa väestössä. Hyödyntämällä useita nimittäjätietojen lähteitä, 
järjestelmällä on riittävästi tilastollista voimaa verrata ilmoitettujen haittavaikutusten 
havaittua määrää niiden odotettuun määrään. Tämän perusteella voidaan muun 
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muassa arvioida heijastelevatko havaitut muutokset haittavaikutusilmoitusten 
määrässä muutoksia raportointiaktiivisuudessa todellisten haittavaikutusten sijaan. 
Polion maailmanlaajuiset hävittämistalkoot alkoivat Maailman terveysjärjestön 
(WHO) johdolla vuonna 1988. Laajamittaisten, elävää virusta sisältävien 
poliorokotusten ansiosta villi poliovirus ja sen aiheuttama halvausoireinen tauti on 
hävinnyt melkein kaikista maista ja maanosista, myös Kiinasta. Vuonna 2016 
poliorokotteiden aikataulua muutettiin Kiinassa siten, että ensimmäiseksi annokseksi 
otettiin käyttöön inaktivoitu, pistettävä poliorokote. Seuraavat kolme annosta 
kolmevalenttista suun kautta otettavaa elävää poliovirusrokotetta korvattiin 
kaksivalenttisiella rokotteella. Seurantajärjestelmä on kerännyt tietoa 
kolmivalenttisen rokotteen turvallisuudesta jo vuodesta 2010 lähtien. Tutkimuksessa 
II suun kautta otettavaan poliorokotteeseen liittyneiden halvausoire-tapausten 
epidemiologiset ominaisuudet, esim.  ikäjakauma, eivät poikenneet muiden maiden 
tuloksista. Halvausoireen riski, käytettäessä nimittäjänä joko arvioitua syntymien 
määrää tai annettuja rokotusannoksia, oli samaa luokkaa kuin aiemmin 
Yhdysvalloissa ja Japanissa tehdyissä tutkimuksissa. Harvinaisen halvausoireen (n. 4 
tapausta per miljoona) ilmaantuvuutta uuden, kaksivalenttisen rokotteen 
käyttöönoton jälkeen verrattaan jatkossa aiempaan rokotteeseen. Tulokset tukevat 
pistettävän poliorokotteen käyttöä Kiinassa haittavaikutusten riskin edelleen 
vähentämiseksi. 
Tutkimus III aloitettiin koska joulukuussa 2013 tiedotusvälineissä raportoitiin 
kuolemantapauksista, joiden oletettiin liittyvän hepatiitti B -rokotuksiin Hunanin 
maakunnassa. Nämä uutisjutut herättivät runsaasti huolta rokotteiden 
turvallisuudesta vanhempien ja kansalaisten keskuudessa ja väestön luottamus 
rokotteisiin heikkeni selvästi. Lapsen kuolema on erittäin harvinainen ja traaginen 
tapahtuma – rokotukset taas ovat lapsuudessa hyvin yleisiä. Tämän takia 
ilmoitettujen kuolemantapausten ajallinen yhteys hepatiitti B -rokotuksiin on voinut 
olla sattuma, jolla ei ollut syy-yhteyttä rokotukseen. Tutkimus tuotti rauhoittavaa 
tietoa rokotusten jälkeisestä kuoleman riskistä, joka oli äärimmäisen pieni. 
Haittavaikutusten ilmoitushuippu vuosien 2013-2014 vaihteessa havainnollisti 
kuinka herkkä passiivinen seurantajärjestelmä saattaa olla median raportoimille 
tiedoille, jotka eivät perustuneet tieteelliseen tutkimukseen. Tulokset myös 
korostivat, että on noudatettava erityistä varovaisuutta tulkittaessa nopeita muutoksia 
vakavien haittailmoitusten määrässä. Vaikka pieni tapausmäärä rajoitti 
mahdollisuuksia tehdä tuloksista varmoja johtopäätöksiä, rokoteturvallisuuteen 
liittyviä ongelmia ei havaittu. Näiden tulosten arvioitiin lievittäneen yleisön 
huolenaiheita ja palauttaneen luottamusta rokoteohjelmaan.  
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Rokotukset Japanin aivotulehdusta vastaan aloitettiin Kiinan kansallisessa 
rokotusohjelmassa vuoden 2007 lopulla. Elävä Japanin aivotulehdusrokote oli 
ensimmäinen Maailman terveysjärjestön (WHO) hyväksymä Kiinassa valmistettu 
rokote (2013). Tietoa Japanin aivotulehdusrokotteiden turvallisuudesta 
laajamittaisessa käytössä Kiinassa oli ennen tutkimustamme rajoitetusti. 
Tutkimuksessa IV suurin osa havaituista haittavaikutuksista oli vähäisiä, tiedossa 
olevia yleisiä haittavaikutuksia (esim. kuume, pistoskohdan kipu). Ilmoitettujen 
vakavien haittavaikutusten ilmaantuvuudessa ei ollut merkittäviä eroja elävän ja 
inaktivoidun rokotteen välillä. Useimmat potilaat toipuivat täysin myös vakavista 
haittavaikutuksista. Lisätutkimuksia tarvitaan erottelemaan muiden, samanaikaisesti 
annettujen rokotteiden vaikutukset Japanin aivotulehdusrokotteen vaikutuksista. On 
myös kehitettävä herkempiä menetelmiä turvallisuussignaalien havaitsemiseksi. 
Tämä väitöskirja tarjoaa kokonaiskuvan rokoteturvallisuuden seurannan ja 
tieteellisen arvioinnin viimeaikaisesta kehityksestä Kiinassa. Tutkimuksissa 
osoitettiin, että kansallinen haittavaikutusten seurantajärjestelmä on toimiva ja 
tuottaa tärkeää tietoa rokotteiden turvallisuudesta maailman suurimmassa väestössä. 
Tutkimukset vahvistivat, että rokotusten jälkeiset tapahtumat tai havaitut oireet eivät 
välttämättä johtuneet rokotuksesta. Tutkimukset tunnistivat kuitenkin myös useita 
haasteita, kuten yhdenmukaisen, kansainvälisen sairauksien ja oireiden 
luokittelujärjestelmän sekä tapausmäärittelyjen puuttuminen. Nämä tulisi ottaa 
käyttöön virheellisten luokittelujen vähentämiseksi ja järjestelmän vahvistamiseksi. 
Lisäksi syy-yhteyden arviointimenettely olisi yhtenäistettävä ja ohjeistusta 
tarkennettava. Tulevissa tutkimuksissa tulisi ottaa käyttöön uusia tilastollisia 
menetelmiä signaalien havaitsemiseksi sekä niiden erottamiseksi datan 
taustakohinasta uusien tutkimuskysymysten ja -hypoteesien luomiseksi. Nämä 
kokemukset maailman suurimmasta rokoteturvallisuuden tietolähteestä voivat 
edesauttaa luottamuksen säilymistä rokotusohjelmiin. Ne voivat myös toimia mallina 
seurantajärjestelmien kehittämiselle muissa pieni- ja keskituloisissa maissa. 
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1 INTRODUCTION 
Immunization is one of the most powerful and cost-effective health interventions. 
It prevents related illnesses and disabilities and saves millions of lives every 
year(Plotkin, S. A., Orenstein, W. A. & Offit P. A., 2013). With the exception of safe 
water, no other modality—not even antibiotics—has had such a major effect on 
mortality reduction and population growth(Plotkin et al., 2013; WHO, UNICEF, & 
World Bank, 2009). Typically, the administration of a vaccine makes a person 
immune or resistant to an infectious disease. Since the first vaccine that was used to 
prevent smallpox, there has been over 200 years of development of vaccines(Plotkin 
& Plotkin, 2011).  
With the help of vaccines, smallpox, which was a naturally occurring disease, was 
eradicated from the world; cases of poliomyelitis have been reduced by 99%, and it 
promises to be the next disease to be completely eradicated. At the same time, 
endemic measles, rubella, and congenital rubella syndrome are target diseases of the 
World Health Organization’s (WHO) elimination program in the near future; these 
diseases have been virtually eliminated from the Americas since 2010(Plotkin et al., 
2013).  
In 1974, the 27th World Health Assembly (WHA) established the Expanded 
Program on Immunization (EPI) to ensure that all children in all countries can 
benefit from lifesaving vaccines(WHO, 2014b). Nowadays, almost all the countries 
in the world have their own immunization programs, and the vaccines used in the 
National Immunization Program (NIP) are no longer limited to the 6 vaccines 
recommend at that time: diphtheria, pertussis, tetanus, measles, poliomyelitis, and 
tuberculosis. Vaccines for rubella, mumps, Hepatitis A, Hepatitis B, Haemophilus 
influenza type B, rotavirus, Japanese encephalitis, influenza, meningococcal diseases, 
pneumococcal diseases, rabies, typhoid fever, human papillomavirus, varicella, and 
herpes zoster are also  used in some countries or can be easily purchased(Plotkin et 
al., 2013; WHO, 2014b; WHO et al., 2009).  
A vaccine is a biological product that improves and enhances immunity against a 
given disease. It contains a disease-causing microorganism—or a portion of it—and 
is often made from either live-attenuated or inactivated forms of the microbe, its 
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toxin, or one of its surface proteins(CIOMS & WHO, 2012; WHO/WPRO, 2013). 
Apart from the microorganism, vaccines usually also have other components, such 
as an adjuvant to enhance the immune response, antibiotics to prevent bacterial 
contamination, preservatives used to kill or subunit vaccines in order to inactivate 
the virus, detoxifying bacterial toxins to prevent serious secondary infections, and 
stabilizers to confirm vaccine quality or stability(WHO/WPRO, 2013). Through 
prequalification and other regulatory systems, the quality of the vaccines currently 
used is relatively assured(WHO, 2014b). However, just like drugs, vaccines are also 
medical products that are “foreign substances” to the human body, which means 
they might have adverse effects, especially given that vaccines are usually 
administered to healthy people, including infants(CIOMS & WHO, 2012; 
WHO/WPRO, 2013). Especially with the development of the NIP and EPI, certain 
vaccines have been mandated in some countries to prevent vaccine preventable 
diseases (VPDs), and the target population is typically a whole birth cohort(CIOMS 
& WHO, 2012). The first few years of a child’s life constitutes the period of the 
greatest vulnerability to diseases and of the early manifestations of other problems 
(congenital diseases, developmental disorders, hearing impairments, and 
others)(WHO/PAHO, 2002). Therefore, a very high level of safety is required from 
vaccines. 
With the growing success of vaccines and the development of other 
immunization programs, VPDs have become less frequent and even rare, due to 
which the public attention has shifted from VPDs to the safety of vaccines and 
adverse events following vaccines(S. Black & Zuber, 2009). Widespread concern 
about vaccine safety may lead to a loss of confidence in immunization and vaccines, 
which would lead to low vaccination coverage, and even a resurgence of VPDs 
(Figure 1)(Chen et al., 2015). This was seen in the case of the pertussis vaccine in 
Japan, the hepatitis B vaccine (HepB) in France, and the measles-mumps-rubella 
combined vaccine (MMR) in the UK and elsewhere. This has not only happened in 
developed countries but also in low- and middle-income countries (LMICs). A safety 
scare regarding the oral polio vaccine significantly impacted the progress of the 
eradication program for this disease, particularly in western Africa(S. Black & Zuber, 
2009; Wilson & Marcuse, 2001). The “Hepatitis B vaccine event” that took place in 
2013–2014 in Mainland China also caused a vaccine confidence crisis among the 
public. In fact, a telephone survey on publics showed that the percentage of vaccine 
confidence reduced from 85% to 26.7% during the event(W. Yu et al., 2016). 
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Figure 1 The evolution of immunization programs and the prominence of vaccine safety 
(Chen et al., 2015) 
According to the Council for International Organizations of Medical Sciences 
(CIOMS)/WHO working group on vaccine pharmacovigilance(CIOMS & WHO, 
2012), vaccine pharmacovigilance is defined as “the science and activities relating to 
the detection, assessment, understanding and communication of adverse event 
following immunization (AEFI) and other vaccine- or immunization-related issues, 
and to the prevention of untoward effects of the vaccine or immunization.” This not 
only includes pre-licensure clinical studies but also post-licensure surveillance 
systems. Pre-licensure clinical trials may demonstrate that common adverse events 
associated with licensed vaccines are minor and that serious adverse events are not 
common. However, rare, serious events are much less likely to be detected before 
licensure, even in relatively large clinical trials(Griffin, Braun, & Kenneth, 2009; 
Lopalco et al., 2010) .  
China is the most populous country in the world. The annual birth cohort is over 
16 million(Guo et al., 2013) and this number is set to go up following the change in 
the family planning policy in 2016 (from a one-child policy to a two-children policy). 
Currently, China administers an average of more than 500 million vaccine doses 
annually. Its NIP started in 1978 and provides government-purchased vaccines at no 
cost to all children under age of 7 years, regardless of socioeconomic status(Guo et 
al., 2013). From 2008, the NIP has included 14 types of vaccines targeting 15 
VPDs(Zheng et al., 2010). China’s high demand for vaccines is fulfilled by more than 
60 vaccine formulations that are licensed for the Chinese market; more than 80% of 
these vaccines are made domestically and are administered through NIP(Hendriks, 
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Liang, & Zeng, 2010). Adequate pharmacovigilance for this large number of vaccines 
and the hundreds of millions of vaccine doses administered requires a credible 
system of monitoring adverse reactions, detecting and responding to emerging 
vaccine safety signals, and addressing the concerns of the public and the media(Guo 
et al., 2013). Therefore, post-licensure monitoring of AEFI is critically important in 
China. 
Although Chinese Ministry of Health (MoH) issued guidelines for handling 
adverse reactions to vaccines in 1980, nationwide AEFI surveillance was not 
implemented until 2005(D. Liu et al., 2015). Since its establishment in 2005, and its 
expansion to all Chinese provinces in 2008, as a public health surveillance system, 
the AEFI cases collected by the Chinese online National AEFI Information System 
(CNAEFIS) has increased by approximately 30% each year. The CNAEFIS—
responsible for monitoring AEFIs in China—has become an important public health 
surveillance system since its establishment. According to the Guidelines for 
Evaluating Public Health Surveillance Systems(US CDC, 2001), public health 
surveillance systems should be evaluated periodically. With more than 6 years having 
passed since its establishment, it is necessary to review the CNAEFIS and determine 
how this public health surveillance system is operating and how it can be improved 
in the future. 
Moreover, the CNAEFIS is a spontaneous reporting system (SRS). The primary 
purpose of an SRS is to identify safety signals after a product has been 
marketed(CIOMS & WHO, 2012). In the past decade, various data mining methods 
have been used to evaluate vaccine safety signals from adverse event reporting 
systems(J. R. Curtis et al., 2009). In developed countries, data mining statistics have 
already been used in the analysis of the safety of vaccines(R. Harpaz et al., 2012), 
such as in case of human papillomavirus vaccine(Slade et al., 2009), rotavirus 
vaccination(M T Niu, Erwin, & Braun, 2001), and influenza vaccine.(Leroy  et al., 
2012a) Since the CNAEFIS has already collected several years’ data on AEFIs, it is 
time to apply novel data mining methods to assess the safety signals of some of the 
vaccines used in China.  
In summary, the CNAEFIS, which has served as a national passive AEFI 
surveillance system in China since 2008, has operated for more than 6 years, over 
which time it has gathered unique database on AEFI cases. It is time to review the 
entire system to better understand its limitations and strengths, which could provide 
information on how to improve vaccine safety surveillance in China. Meanwhile, in 
order to enhance the utility of the AEFI data collected by the CNAEFIS, we have 
applied commonly used data mining algorithms to signal detection in 
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pharmacovigilance using AEFI data on the Japanese Encephalitis(JE) Vaccine, and 
epidemiology analysis on recipient VAPP and fatalities captured by AEFI 
surveillance, to identify vaccine safety concerns which could  lead to hypotheses on 
vaccine safety and provide evidence on vaccine safety in China.  
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2 REVIEW OF LITERATURE 
2.1 Post-licensure vaccine safety 
2.1.1 Vaccine safety monitoring 
In May 2012, on its 65th anniversary, the WHA endorsed the Global Vaccine Action 
Plan (GVAP)—the final framework to achieve its vision of the Decade of Vaccines 
(DoV; 2011–2020). The GVAP (2011–2020)(WHO, 2013) builds on the success of 
the Global Immunization Vision and Strategy (GISV) (2006–2015) and aimed to 
improve health by extending the full benefits of immunization to all people, 
regardless of where they are born, who they are, or where they live—achieve by 
extending the program until 2020 and beyond. Among all six strategic objectives, the 
fourth one is, “Strong immunization systems are an integral part of a well-
functioning health system.” As part of this objective, in order to “ensure that 
everyone everywhere receives the safest vaccines possible and that safety concerns 
are not a cause of hesitancy in using vaccines,” the Global Vaccine Safety Blueprint 
(GVSB) strategies were developed to build capacity for vaccine safety surveillance 
during 2011–2020(WHO, 2013). 
The GVSB has eight objectives that aim to build and support effective vaccine 
pharmacovigilance in all LMICs. The first and second objectives were to strengthen 
vaccine safety monitoring in all countries and to strengthen the ability of countries 
to investigate vaccine safety signals. According to the GVSB, all countries should 
regularly assess the performance of their vaccine safety systems and development 
plans to close any identified gaps(WHO, 2012c). 
2.1.2 Definition of Adverse Events Following Immunization 
According to CIOMS(CIOMS & WHO, 2012), Adverse Events Following 
Immunization (AEFI) are defined as any untoward medical occurrences following 
immunization. Although AEFIs do not necessarily have a causal relationship with 
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the vaccine, they may be considered to be related to vaccination and may influence 
public confidence and make the implementation of an immunization program 
difficult(CIOMS & WHO, 2012; WHO/WPRO, 2013). This definition is similar to 
WHO’s definition of AEFIs in their Immunization Safety Surveillance 
Guidelines(WHO/WPRO, 1999, 2013).  
In the US, an “adverse event” is any health problem that occurs after a shot or 
other vaccine has been administered. An adverse event might be truly caused by a 
vaccine or it might be pure coincidence 
(https://www.cdc.gov/vaccinesafety/ensuringsafety/sideeffects/index.html). In China, 
an AEFI refers to a reaction or an event after a vaccination that is suspected to be 
related to the vaccination(China MoH & China FDA, 2010).  
Although there are only minute differences in these two definitions, they share 
two key factors: i) it includes any event following immunization; ii) it does not 
necessarily have a causal relationship with the usage of the vaccine.  
2.1.3 Methods of post-licensure vaccine safety surveillance 
There are several methods of conducting post-licensure vaccine safety surveillance: 
passive reporting, active surveillance, global vaccine safety networks, and different 
epidemiological methods(S. Black & Zuber, 2009; Verma & Lahon, 2013). Passive 
surveillance systems rely on health care professionals (or vaccine recipients) to 
voluntarily submit reports of illness after vaccination. In active surveillance, the 
health department, such as national authorities, maintains regular contact with health 
care providers or related stakeholders to identify cases of adverse events following 
immunization. For LMICs with limited resources, the passive reporting system 
would be the most cost-effective method to evaluate vaccine safety(Breugelmans & 
Gessner, 2011). 
Many developed countries have established well-functioning AEFI surveillance 
systems, such as the Vaccine Adverse Event Reporting System (VAERS) in the 
US(Zhou et al., 2003; Shimabukuro et al., 2015), the EudraVigilance system in the 
European Union (EU) and European Economic Area (EEA) countries(Lopalco et 
al., 2010), and the UK’s Yellow Card Scheme (YCS),a national spontaneous 
reporting system(Hawcutt et al., 2012). However, it might be difficult to apply 
developed countries’ vaccine safety profiles to developing countries where the 
vaccines used and the types of serious AEFIs may differ greatly due to local 
environmental and genetic differences(Breugelmans & Gessner, 2011). In many 
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LMICs, no regular surveillance for vaccine safety exists, as the primary immunization 
program focus continues to be on increasing coverage in the target 
population(WHO, 2012b). 
2.2 Global post-licensure vaccine safety surveillance systems  
2.2.1 WHO and the European Union (EU) 
2.2.1.1 WHO 
The WHO’s Program for International Drug Monitoring (PIDM) is an international 
adverse event monitoring system, which was set up at the WHO Headquarters in 
Geneva in 1971. It was then moved to Uppsala, Sweden, in 1978. Countries 
participating in the PIDM submit not only adverse drug reaction (ADR) reports but 
also AEFI reports. In 2007, in over 3.7 million reports, around 8% of AEFIs were 
found to be vaccine related(Letourneau et al., 2008).  
In order to enhance the monitoring, reporting, and sharing of vaccine safety data 
among countries introducing new prequalified vaccines, the Global Advisory 
Committee on Vaccine Safety (GACVS), an expert clinical and scientific advisory 
body established by WHO, started a WHO-led pilot project in 2007—a global 
network for the post-marketing surveillance (PMS network) of AEFIs(WHO, 
2012a). According to the terms of the project, all surveillance data should be reported 
into a central database (i.e., Vigibase) located at the WHO Collaborating Center for 
international drug monitoring—the Uppsala Monitoring Center (UMC) in Sweden. 
For this, the UMC provided a software platform called Vigiflow to report and upload 
AEFI cases and methods of causality assessment for vaccine AEFI 
classification(WHO, 2012a). In this pilot study, since some of the participating 
countries already had their own AEFI surveillance systems, the different reporting 
variables and definitions made it difficult to harmonize the database. Furthermore, 
due to the heterogeneous nature of the surveillance data, it was hard to generate 
global safety signals and the study therefore only provided limited information on 
vaccine safety.  
To improve the efficiency and quality of AEFI surveillance activities at national 
and regional levels, under the guidance of the GACVS, WHO developed a global 
manual on the surveillance of AEFIs in 2014(WHO, 2014a). Parts of WHO’s 
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regional office, such as those in the South-East Asia Region (SEAR) and the Western 
Pacific Region (WPR), also had their own guidelines for AEFI 
surveillance(WHO/SEARO, 2014; WHO/WPRO, 2013). These global and regional 
manuals provide guidance on every aspect of AEFI surveillance systems, including 
reporting, investigation, causality assessment, and the classification of AEFIs.  
2.2.1.2 The European Union (EU) 
Over the past few decades, immunization programs have achieved great success in 
EU countries, which has brought about a remarkable reduction there in child 
mortality(WHO/EURO, 2015). However, with the development of vaccination and 
immunization, today the most important threat in Europe is the perceived risk of 
immunization adverse events among the public. There have been several such 
examples in European countries, such as in the UK regarding the suspected 
association of MMR and autism, and in France regarding multiple sclerosis and the 
HepB vaccine. In both countries, the related vaccination coverage dropped 
significantly following public outcry, and even after the casual association was 
rejected, rumors about it still appear now and then among the general public(Lopalco 
et al., 2010).  
The AEFI cases from Finland’s passive vaccine safety reporting system was 
reported by health care providers, mainly by nurses or physicians working in baby 
clinics. Health centers and referral hospitals sent in 500–600 reports per year. At the 
National Institute for Health and Welfare of Finland (THL), there is a full-time 
vaccine safety physician working with a part-time nurse on assessing the 
reports(Postila & Kilpi, 2004). Other countries in the EU either have their own 
surveillance systems for vaccines or use their ADR surveillance systems. In 2007, the 
Vaccine European New Integrated Collaboration Effort (VENICE) project, which 
was funded by the EU Directorate General for Health and Consumers (DG 
SANCO) and later by the European Centre for Disease Prevention and Control 
(ECDC), conducted a survey on vaccine adverse event monitoring systems across 
EU countries. According to the survey, 18 of 26 responding countries have a specific 
safety monitoring system for AEFIs in place, and only 9 countries (i.e., Finland, 
Germany, Hungary, Iceland, Latvia, Lithuania, Netherlands, Romania, and Slovakia) 
have such a system in addition to pharmacovigilance(Zanoni et al., 2009). It is 
advised that since immunization is different from drug treatment for many issues, 
monitoring of AEFIs should be done with the involvement of health authorities 
dealing with vaccine administration(Zanoni et al., 2009). Also, the AEFI case 
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definitions, reporting forms, and investigation procedures were found to be different 
among the many EU countries(Lankinen et al., 2004), which made it nearly 
impossible to achieve data integration and sharing.  
At the EU level, there is a unified pharmacovigilance surveillance system called 
EudraVigilance, which was established by the European Medicines Agency (EMA). 
The EudraVigilance post-authorization module (EVPM) served as the surveillance 
system for all reports of suspected serious adverse reactions related to medicines 
subject to marketing authorization in the EU, including vaccines(Kurz et al., 2011). 
European pharmacovigilance researchers not only used the term of  “AEFI,” they 
also defined lists of “adverse events of special interest (AESI)” for surveillance 
purposes: these are syndromes, diseases, or special conditions that could theoretically 
or potentially be linked to specific vaccines(Kurz et al., 2011; Lopalco et al., 2010). 
For example, during the pandemic A/H1N1 influenza vaccination program, they 
used the EVPM to monitor AESIs using standard case definitions (such as 
anaphylaxis, convulsions, demyelination, and facial palsy). This spontaneous 
reporting system was shown to be effective for monitoring the safety of A/H1N1 
vaccines during the 2009–2010 influenza pandemic(Kurz et al., 2011).  
Besides the passive surveillance of AEFIs or AESIs, the ECDC and its related 
stakeholders launched the Vaccine Adverse Events, Surveillance and 
Communication (VAESCO) I and II projects in the EU countries. During the two 
phases of the VAESCO project, data linkage of large computerized clinical databases 
and immunization registries was developed to complement the routine passive 
surveillance system, EVPM. The establishment of this European vaccine safety data 
linkage system known as E-VSD was prompted by the US Vaccine Safety Data 
Linkage system (VSD) to conduct a risk assessment and safety signal 
verifications(Chen et al., 2015; Lopalco et al., 2010).  
2.2.2 US, Canada, and Australia 
In the US, there were a series of vaccine crises during the 1970s and 1980s, which 
resulted in lawsuits, a rise in vaccine prices, and a threat to the NIP. As a result, 
Congress issued the National Childhood Vaccine Injury Act (NCVIA) in 
1986(Smith, 1988). This act mandated post-marketing surveillance for vaccine safety. 
Initially, there were two surveillance systems: a monitoring system for AEFIs 
maintained by the US CDC for public providers, and a spontaneous reporting system 
maintained by the US Food and Drug Administration (FDA) for private providers 
33 
 
and vaccine manufacturers. These two systems finally merged into one—the 
VAERS—and began to act as the national passive vaccine surveillance system in 
1990(Singleton et al., 1999). The VAERS, jointly sponsored by the FDA and CDC, 
covered all adverse events following the receipt of vaccines licensed in the US.  
As part of its post-marketing vaccine safety surveillance efforts, VAERS accepts 
voluntary reports from health care providers, parents, patients, or just about anyone 
else, as well as a smaller number of mandated reports of specific events(Varricchio 
et al., 2004). The flow chart of information of VAERS is shown in Figure 2. 
 
Figure 2 Flow of information within VAERS from reporters to VAERS contractors and then 
to the FDA, CDC, and other interested parties (Singleton et al., 1999) 
The primary function of VAERS is to detect early safety signals and generate 
hypotheses on possible new vaccine adverse events or changes in the frequency of 
known events(Varricchio et al., 2004). An analysis of VAERS data from 1991–2001 
showed that 128,717 cases were reported and more than 1.9 billion net doses of 
human vaccines were distributed, with overall reporting rates for 27 vaccine types 
with 11.4 reports per 100,000 net doses distributed(Zhou, Weigong Pool, Vitali 
Iskander, 2003). VAERS played an important role in vaccine safety evaluation, 
detecting rare adverse events that were either not found or not completely 
understood during clinical trials. One famous example is the withdrawal of the first 
generation rotavirus vaccine (RotV)  due to VAERS’ detection of intussusception 
reports associated with this vaccine(Zanardi et al., 2001). In this case, the 
manufacturer voluntarily withdrew the vaccine from the market. Also, the 
surveillance data records the increase and decrease in known adverse events, thereby 
acting as the baseline of interest events nationally and in a timely manner. After the 
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oral poliomyelitis vaccine (OPV) in the NIP was replaced with the Inactivated Polio 
Vaccine (IPV) in the 1990s, VAERS has documented the disappearance of vaccine-
associated paralytic poliomyelitis (VAPP) in the US(Varricchio et al., 2004).  
The post-marketing vaccine safety surveillance infrastructure in the US not only 
includes the passive surveillance system VAERS but also VSD, an active surveillance 
system(Baggs et al., 2011; Chen et al., 1997). VSD started in 1990, with eight 
managed care organizations (MCOs) participating in the research, covering a large 
population of 8.8 million members annually (about 3% of the US population). From 
2000 onward, the number of MCOs increased along with improvements in data 
collection procedures, and it evolved into a near real-time surveillance system. VSD 
data can now be used to generate the background rate of interested events, and it 
collaborates with VAERS to evaluate vaccine safety, especially for newly licensed 
vaccines. After symptoms of intussusception following the administration of the 
RotV were detected by VAERS, in order to determine the expected number of 
intussusception cases that would occur by chance alone, the background rates of 
intussusception without vaccination could be determined using VSD data(Penina et 
al., 2008). A more recent example is the occurrence of febrile seizures following the 
influenza vaccine. After Australia reported an increased risk of febrile seizures in 
young children following the administration of the 2010 Southern Hemisphere 
trivalent inactivated influenza vaccine (TIV) from one manufacturer, VAERS data 
was used to detect similar signs of a possible increased risk of febrile seizures 
following TIV in the US (Leroy et al., 2012a). A further epidemiologic assessment 
of a possible association between TIV and febrile seizures was thereafter undertaken 
in the VSD system(Tse et al., 2012). Thus, along with individual vaccine safety 
studies, VSD data can also be used to study the safety of the childhood immunization 
schedule(CDC, 2018), such as vaccine schedules and the risk of asthma. 
Apart from VAERS and VSD, the department of Health and Human Services 
also has developed other new research systems for vaccine safety, such as the Post-
licensure Rapid Immunization Safety Monitoring (PRISM) program of the US 
FDA(Baker et al., 2013) and the Clinical Immunization Safety Assessment (CISA) 
network of the US CDC(LaRussa et al., 2011).  
In Canada, located close to the US, the situation is a bit different. In the late 
1980s, in the face of growing societal concern about the relationship between the 
whole-cell pertussis vaccine (wP) and fever among children(Scheifele et al., 2003), 
the health ministry of the federal government of Canada (Health Canada) launched 
Canadian Adverse Event Following Immunization Surveillance System (CAEFISS). 
This collaborative post-marketing federal/provincial/territorial (F/P/T) 
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surveillance system includes spontaneous, enhanced, and active AEFI reporting 
processes(Health Canada, 2014). Passive reports can come from health care 
professionals, market authorization holders, and the public for routine surveillance, 
and enhanced surveillance is conducted by immunization program authorities when 
needed. The Immunization Monitoring Program-ACT-ive (IMPACT) is a pediatric 
hospital-based network funded by the Public Health Agency of Canada (PHAC) and 
administered by the Canadian Paediatric Society, which conducts active surveillance 
on behalf of the CAEFISS(Health Canada, 2014). After years of surveillance and 
study, IMPACT has resulted in the publication of over 60 articles and abstracts along 
with important output on vaccine safety, such as a substantial decrease in the risk of 
the development of febrile seizures and hypotonic-hyporesponsive episodes since 
the country switched from wP to acellular pertussis-containing vaccines, and no 
evidence has been found for encephalopathy resulting from these vaccines(Scheifele 
et al., 2003).  
In Australia, local reporting mechanisms of AEFI have been in place for many 
years. A national passive surveillance system was also established in 2000, and AEFIs 
were reported to the Adverse Drug Reactions Unit (ADRU) of the Therapeutic 
Goods Administration (TGA) of Australia by health care professionals or by the 
public. The AEFI data were further analyzed and evaluated by the National Centre 
for Immunization Research and Surveillance of vaccine-preventable diseases 
(NCIRS)(Isaacs et al., 2005; Wood & Isaacs, 2006). The flow of information in AEFI 
surveillance in Australia is shown in Figure 3. The annual data analysis shows that 
serious adverse events are rare in Australia. 
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Figure 3 The flow of the surveillance of AEFI in Australia 
Like VSD in the US, Australia also tried conducting data linkage as a sophisticated 
form of active surveillance for vaccine safety. A pilot study using data linkage as a 
means of vaccine safety surveillance by linking immunization records from the 
Australian Childhood Immunization Register (ACIR) to hospital outcome data was 
conducted in South Australia (SA). It examined the risk of convulsions following the 
administration of the MMR and Diphtheria-Tetanus-Pertussis combined vaccines 
(DTP). This pilot study showed that the ability and feasibility of safety signal 
evaluation was the same as in the case of VSD(M. Gold et al., 2010).  
2.2.3 Japan, Korea, and India 
In Japan, information on adverse reactions to vaccination were collected in three 
ways: i) sentinel reporting of all health problems after vaccinations (regardless of 
causative relationship with vaccinations); ii) formal reports of vaccine-related injuries 
from local authorities (highly probable causative relationship); and iii) appeals to the 
vaccine injury compensation committee (seeking judgment regarding the causative 
relationship)(Bakatani, Sano, & Iuchi, 2002). The primary method used was the 
national passive AEFI surveillance system known as the National Adverse Reaction 
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Reporting System (NARRS) that has been maintained by the Japanese Ministry of 
Health and Welfare (JMHW) since 1994. All immunization providers, school nurses, 
and parents are required to notify the NARRS in case of any vaccine adverse 
reactions that meet the reporting criteria. There were two reporting channels at the 
time: the legitimate channel and the private manufacturers’ channel. In the legitimate 
channel, physicians were responsible for reporting serious vaccine-associated events 
to the regional government through their regional Public Health Center. Then the 
case should be registered by the JMHW. Also, the cases is reported to the respective 
vaccine manufacturers and should be registered through the private manufacturers’ 
channel (Nakayama & Onoda, 2007).  
 
Figure 4 Japan’s reporting system for serious vaccine-associated adverse events after 
vaccination (Nakayama & Onoda, 2007) 
In Korea, the importance of AEFI surveillance was prompted by reports of 
adverse events associated with JE vaccine, subsequently shown to be due to the poor 
storage of the vaccine in 1994(Cho et al., 2010). A passive electronic reporting system 
was also established, which allowed patients, their guardians, and physicians to 
submit information. At the same time, the investigation of AEFIs by the National 
Regulatory Authority (NRA) and the Vaccine Injury Compensation Program were 
also established(Choe et al., 2011). The Infectious Diseases Prevention Act was 
revised to mandate that all healthcare workers must report AEFIs through passive 
surveillance. However, the number of reports was very low. Although the annual 
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distributed doses of vaccines were more than 16 million, the total number of reports 
in the passive surveillance system from 1994–2010 were 5,339(Choe et al., 2011; 
Choe & Bae, 2013). In 2009, during the 2009–2010 influenza season, the Korean 
CDC conducted active surveillance for the detection of AEFIs against the 2009 
pandemic A(H1N1) influenza vaccine in order to supplement the collection of AEFI 
data from the routine passive surveillance system(Choe et al., 2011). 
India is the largest developing country with many manufacturers of vaccines. The 
tracking of AEFIs in India started in 1985, with the launch of the Universal 
Immunization Program (UIP)(Lahariya, 2014). The first documented AEFI report 
and guidelines were published in 1988(Lahariya, 2014). However, the incidence of 
AEFIs in India was poor until early 2005(Vashishtha & Kumar, 2013). In 2005–
2006, national AEFI surveillance and Response Operational Guidelines were issued 
by the Government of India, which were then further revised and updated in 
2010(Chiekara et al., 2013). From 2007, AEFI events are being linked to the closure 
of three government-owned units (PSUs) in India, and the reporting has slightly 
improved since then(Patile, 2014). In the national AEFI surveillance system (Figure 
5), most reports originate from the public health sectors(Bhaumik, 2013), which were 
covered by the UIP. Since 10–20% of the total immunization in India is provided by 
the private sector, which are not part of the UIP and therefore not covered by the 
AEFI surveillance system, in recent years, stakeholders in India have tried to find 
ways to include the private sector in AEFI surveillance(Bhaumik, 2013; Chiekara et 
al., 2013). According to the 2015 Operational Guidelines for the AEFI Surveillance 
Program in India, common and minor reactions can be reported monthly, but 
serious AEFIs such as death, hospitalization,  prolonged disability, in the form of a 
cluster, or any single event that raises significant community/parental concern, is to 
be reported for investigation within 48 hours(Joshi et al., 2018), which is consistent 
with the WHO guidelines(WHO/WPRO, 2013).  
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Figure 5 The AEFI surveillance system in India (Joshi et al., 2018) 
2.2.4 Mainland China  
2.2.4.1 Vaccines in China 
China initiated its National EPI in 1978. The vaccines covered by the NIP were the 
Bacillus Calmette-Guérin vaccine (BCG), OPV, the measles vaccine (MV), and the 
DTP vaccine, following the recommendations of WHO. In 2002, HepB was added 
into the NIP, and in December 2007, vaccines against meningococcal meningitis, 
Japanese encephalitis, hepatitis A, rubella, and mumps were further included in the 
national immunization schedule(Zheng et al., 2010). Today there are 14 vaccines 
targeting 15 VPDs in the NIP (Table 1). The vaccines included in the NIP are funded 
by the central government and administered to target children free of charge(Guo et 
al., 2013). Currently, about 500 million vaccine doses administered annually in the 
NIP(Guo et al., 2013). There are still vaccines used outside the NIP in the private 
market, produced by manufacturers based on market demand, and these can be 
purchased by consumers on a voluntary basis.  
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Table 1 Vaccines in Chinese national immunization schedule (Hendriks et al., 2010) 
Vaccines Year of Introduction Remarks 
Hepatitis B vaccine (HepB) 2002  
BCG Vaccine (BCG) 1978  
Oral Poliomyelitis vaccine (OPV) 1978  
Combined Vaccine of Pertussis, Diphtheria and Tetanus 
(DTP) 1978  
Measles containing vaccine (MCV)   
Combined vaccine  
introduced in 2007-
2008 
MV  1978 
MR 2007-2008 
MMR 2007-2008 
Combined vaccine of Diphtheria and Tetanus (DT) 2008  
Hepatitis A vaccine (HepA) 2008  
Meningococcus vaccine, A/ A+C (MenA, MenAC) 2008  
Japanese Encephalitis Vaccine (JEV) 2008  
Hemorrhagic Fever Renal Syndrome vaccine (HFV) 2008 
Only for high risk 
population in 
endemic regions  
Anthrax vaccine 2008 
Leptospira vaccine 2008 
With the development of vaccine manufacturing in China and the high demand 
for vaccine doses, China ranks as one of the world’s largest vaccine manufacturing 
countries, with an annual output of more than one billion doses(Hendriks et al., 
2010). Most of the NIP vaccines are manufactured domestically; however, some 
vaccines like MMR and the Hepatitis A vaccine (HepA or HAV) are also produced 
by international manufacturers(Guo et al., 2013). In 2010, the Chinese FDA’s 
website listed 46 Chinese registered vaccine manufacturers of public and private 
status, collectively manufacturing 24 licensed vaccines(Hendriks et al., 2010) (Table 
2). 
41 
 
Table 2 Major vaccines available in China, 2010(Hendriks et al., 2010) 
Vaccines Number of manufacturers 
HepB 8 
BCG 5 
OPV 2 
DTP 6 
MV 5 
DT 6 
DTaP 7 
HepA 6 
MenA and MenAC 9 
JE 9 
MMR 1 
HFV 6 
Anthrax vaccine 2 
Leptospira vaccine 3 
Absorbed Tetanus vaccine 6 
Combined vaccine of HepA and HepB 1 
Rabies vaccine 14 
Tracheitis vaccine 4 
Typhoid Vi Polysaccharide vaccine 6 
Tick-borne encephalitis vaccine 1 
Split A(H1N1) influenza vaccine 10 
Seasonal influenza vaccine 11 
Pandemic (H5N1) influenza vaccine 1 
Brucella vaccine 2 
2.2.4.2 Development of Nationwide AEFI surveillance in China 
AEFI surveillance began in China after it initiated the EPI in 1978(Zheng et al., 
2010). The first formal guidelines for AEFI surveillance issued by Chinese MoH 
have been in place since 1980(Guo et al., 2013). Some of the local CDCs and local 
ADR monitoring agencies in more developed areas like Shanghai began to collect 
AEFI data at that time(Dong, mei Jing, & hua Sun, 2011). The pharmacovigilance 
system in China was initiated in 1989, and after 20 years of development, a relatively 
mature regulatory system has been established(L. Zhang et al., 2014). However, prior 
to 2003, ADR cases were reported to provincial ADR agencies in paper form. It is 
only after 2003 that the online spontaneous reporting system was established. A 
limited number of AEFI cases were reported through this pharmacovigilance 
system, mainly from vaccine manufacturers.  
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China CDC, affiliated with the MoH, was responsible for the implementation of 
the EPI, and a division of the NIP was established in 2002. With the help of the 
WHO/HQ and the WPR regional office (WPRO), NIP office in China CDC 
launched a pilot study for AEFI surveillance, initially in the Hebei and Guangdong 
provinces(Guo et al., 2005), and later expanding to 10 provinces in China(Guo et al., 
2007). This pilot study of passive surveillance in China was based on the first edition 
of the WHO/WPRO’s guidelines called “Immunization Safety Surveillance: 
Guidelines for Managers of Immunization Programme on Reporting and 
Investigating Adverse Events Following Immunization,” which was published in 
1999(WHO/WPRO, 1999). During this pilot study, the China CDC organized 
training workshops on AEFI surveillance not only for staff in pilot provinces but 
also other provinces in China. After two years of development, 16 of China’s 32 
provinces (including Xijiang Corps) reported AEFI cases into the national 
database(D. Liu et al., 2007a). In 2007, to coordinate with the development of the 
EPI and enhance AEFI surveillance, an intensive online surveillance study in five 
counties was launched by the China CDC over two years. In this study, on the basis 
of passive surveillance, intensive surveillance on several vaccines was also implanted, 
similar to a clinical trial: at least three follow-up visits after vaccination by nurses or 
physicians in vaccination clinics. The results of this study showed that the data 
quality and surveillance sensitivity were improved in the pilot counties(Yue et al., 
2012). After these two pilot studies, the China CDC expanded the passive 
surveillance system to include all the provinces in China and utilized an online system 
known as the CNAEFIS. Since its establishment, CNAEFIS has covered AEFIs of 
all vaccines both part of the NIP or purchased on a voluntary basis.  
From 2008, CNAEFIS entered a stage of rapid development. During the 
pandemic A(H1N1) influenza vaccination in 2009–2010, CNAEFIS played a key 
role in collecting data on AEFI cases(Liang et al., 2011). In 2010, China launched a 
nationwide measles supplementary immunization activity (SIA) to further decrease 
the susceptibility to measles(Ma et al., 2011), covering more than 100 million children 
within 10 days. CNAEFIS also served as the AEFI reporting system in this SIA(Wu  
et al., 2012). In the same year, national guidelines of AEFI surveillance(China MoH 
& China FDA, 2010) were also issued together by the MoH and the FDA. According 
to these guidelines, as required by the WHO NRA assessment, all AEFI cases were 
to be reported to the CNAEFIS. This indicated that even AEFI cases in the 
pharmacovigilance system reported by manufacturers should be reported to 
CNAEFIS, making it the only passive surveillance system for AEFIs, with data being 
shared by CDCs and ADRs in China.  
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CNAEFIS is operated in accordance with Chinese national AEFI guidelines. 
These guidelines are, in turn, supported by the Law on the Prevention and Treatment 
of Infectious Diseases of the People’s Republic of China, the Pharmaceutical 
Administration Law of the People’s Republic of China, the Administrative 
Regulation on the Circulation of Vaccines and Vaccination, the Regulations on 
Preparedness for and Responses to Public Health Emergencies, and other laws and 
regulations, with reference to WHO’s guidelines on AEFIs, and with the intent to 
improve vaccine safety and immunization service quality. 
2.3 Surveillance system evaluation 
The plague in London in the seventeenth century is one of the earliest examples of 
surveillance(Declich & Carter, 1994). After decades of development, surveillance has 
evolved into a complete discipline(Declich & Carter, 1994), with its own objectives, 
data sources, methodologies, and evaluation procedures. Vaccines and their adverse 
reactions are one of the several health events under surveillance. Many experts on 
public health surveillance recommend that every surveillance system should be 
evaluated periodically to ensure that it is serving public health functions and is 
meeting its objectives(Declich & Carter, 1994; Thacker et al., 1988).  
2.3.1 Guidelines for public health surveillance system evaluation 
The US CDC’s guidelines for evaluating surveillance systems are the benchmark for 
public health surveillance. The first edition was published in 1988(Klaucke et al., 
1988) to promote the best use of public resources through the development of 
efficient and effective public surveillance systems, and it was then updated in 2001 
to address new needs(US CDC, 2001). WHO also developed a “Protocol for the 
Evaluation of Epidemiological Surveillance System”(WHO, 1997) in 1997 that 
served as a tool for assessing existing systems and identifying areas of improvement. 
Some other guidelines and frameworks for specific surveillance systems were also 
studied and published, such as the WHO’s Assessment Protocol for National 
Communicable Disease Surveillance and Response System(WHO, 2001), the draft 
framework for the evaluation syndromic surveillance system(Sosin, 2003), and the 
evaluation framework for injury surveillance systems(Mitchell, Williamson, & 
O’Connor, 2009). These guidelines have provided valuable information on how to 
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evaluate the performance of a surveillance system based on the widely used 
guidelines developed by US CDC.  
Various surveillance systems were evaluated based on US CDC guidelines, 
including the National Electronic Injury Surveillance System-Cooperative Adverse 
Drug Event Surveillance Projective (NEISS-CADES)(Jhung et al., 2007) and Non-
Name-Bases HIV surveillance(Solomon et al., 1999) in the US; the HIV/AIDS 
surveillance system in Norway(Aavitsland, Nilsen, & Lystad, 2001); the National 
Notifiable Diseases Surveillance System (NNDSS) in Australia(M. Miller et al., 2004); 
the National Health Services (NHS) Direct, a national telephone health advice 
service, in England and Wales(Doroshenko et al., 2005); and syndromic surveillance 
in French Guyana(Jefferson et al., 2008). Apart from the US and European 
countries, the US CDC guidelines were also used in China and Japan to evaluate 
epidemiological surveillance systems. The National HIV sentinel surveillance system 
in China(Lin et al., 2012) and the Japanese School Health Surveillance System for 
Influenza(Takahashi et al., 2001) were evaluated by researchers based on these widely 
used guidelines. Even some researchers in animal health surveillance tried to adopt 
these guidelines to evaluate scrapie surveillance systems in the US(Lynn et al., 2007), 
which indicates the wide application and usefulness of these guidelines. In the field 
of AEFI surveillance, Singleton et al.(Singleton et al., 1999) evaluated VAERS 
according to these guidelines and found that VAERS is simple to use, flexible, and 
timely for AEFI surveillance. This indicates that the evaluation of a passive AEFI 
surveillance system could adopt these widely used guidelines.  
2.3.2 Attributes of surveillance systems  
According to the US CDC’s updated evaluation guidelines, an evaluation involves 
four tasks: i) engage the stakeholders in the evaluation; ii) describe the surveillance 
system to be evaluated; iii) focus on the evaluation design; iv) gather credible 
evidence regarding the performance of the surveillance system(US CDC, 2001). Task 
iv was the key output of this evaluation and can be further divided into two: i) utility 
and cost, including the importance, objective, components, usefulness, and cost; ii) 
system attributes, including simplicity, flexibility, data quality, acceptability, 
sensitivity, predictive value positive (PVP), representativeness, timeliness, and 
stability(US CDC, 2001).   
System attributes represent the quality of the system and can be reviewed 
regularly. They can also be divided into two groups: qualitative and quantitative 
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attributes. Sensitivity, PVP, timeliness, representativeness, and data quality can be 
expressed in numerical terms, while all the other attributes are more subjective 
measures and are thus less easily quantified(Thacker et al., 1988). 
Simplicity 
The simplicity of a surveillance system refers to both its structure and its ease of 
operation(US CDC, 2001). Simplicity should be inherent in a system as a whole as 
well as in each of its individual components (case definition, reporting procedures, 
etc.)(Declich & Carter, 1994). A flowchart of surveillance could demonstrate a 
system’s simplicity. Also, simplicity is closely related to acceptance and timeliness(US 
CDC, 2001), and a more simple system might be more flexible. 
Flexibility 
Flexibility refers to the ability of a surveillance system to accommodate to changes 
in operating conditions or information needs(Declich & Carter, 1994). A flexible 
system can easily adapt to the addition of new diseases or situations or more 
population groups in a short time(Declich & Carter, 1994) and can also integrate 
with other systems(US CDC, 2001). 
Sensitivity and PVP 
The assessment of sensitivity and PVP provides different perspectives on how 
well a system is operating(German, 2000). Sensitivity is defined as the ability of a 
surveillance system to detect a true health event(Thacker et al., 1988). Quantitatively, 
sensitivity is the proportion or ratio of cases of health events detected by a system(US 
CDC, 2001). PVP is the proportion of reported cases that actually have the health 
event under surveillance. Both sensitivity and PVP can be calculated in the form of 
a 2 × 2 table (Table 3). 
Table 3 Calculation of the sensitivity and PVP of a surveillance system 
Detected by surveillance 
Condition present  
Y N  
Y True positive A False positive B A+B 
N False nagative C True negative D C+D 
 A+C B+D  
According to the table above, sensitivity and PVP can be calculated as follows: 
 Sensitivity = A/(A + C)  
PVP = A/(A + B) 
To assess sensitivity, it is necessary to collect and assess data external to the 
system in order to determine the true frequency of the condition in the population 
under surveillance. This is because A+C are confirmed cases collected by the system; 
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therefore, A is a required value. For PVP, since there are already cases detected by 
the surveillance system (i.e., A + B), the important factor needed is the same as 
sensitivity—confirmed cases in the surveillance system. In the evaluation of the 
quality of an injury surveillance system, Macarthur(Macarthur & Pless, 1999a) used 
an independent review to confirm false-positive cases. 
The computation of sensitivity and PVP for a surveillance system can be 
complicated in the absence of an appropriate gold standard(German, 2000). In the 
review study conducted by German(German, 2000) on report sensitivity and PVP 
for public health surveillance systems, it was found that different gold standards have 
been used in different studies. In all 31 studies reviewed, 6 or 19% of the studies 
used the estimation of the total cases. In the AEFI surveillance system, there are two 
studies on sensitivity—VAERS in the US(Rosenthal & Chen, 1995) and CAEFISS 
in Canada(Tadrous, 2010). Although these two studies analyzed different vaccines, 
events, and time periods, the estimation of expected or true case frequency in the 
population under surveillance was calculated in both as “administered doses × event 
incidence rate”. The event incidence rates used in both studies were from literature 
reviews. 
Low sensitivity does not mean the surveillance system is ineffective. It is still 
useful in monitoring trends and providing baselines as long as the sensitivity remains 
constant over time. However, a low PVP does indicate a waste of resources(US 
CDC, 2001). 
Timeliness 
Timeliness reflects the duration between the steps of a public health surveillance 
system(US CDC, 2001). The time interval usually considered is the amount of time 
between the onset of the surveillance event and the reporting of that event to the 
public health agency responsible for instituting control and prevention measures(US 
CDC, 2001). The steps of different surveillance systems are different, which makes 
it difficult to develop a general mathematical equation to calculate timeliness(Dailey, 
Watkins, & Olant, 2007). Usually, timeliness is evaluated in the surveillance of 
infectious diseases, and different countries might adopt different indicators to 
evaluate timeliness, such as time lags used in a Korean study(Yoo et al., 2009) and 
time intervals used in studies in the US(Hedberg et al., 2008; Jajosky & Grosedlose, 
2004) and Sweden(Jansson et al., 2004).  
The key purpose of timeliness evaluation is to understand the steps in a 
surveillance system. In the US CDC guidelines, there is a simplified example of the 
steps in a surveillance system (Figure 6). From this figure, we can identify the steps, 
after which we can analyze time intervals or time lags. The time interval of the onset 
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of events and the receipt of reports was analyzed as the timeliness of 
VAERS(Singleton et al., 1999).  
 
Figure 6  Simplified steps in a surveillance system  
The timeliness of a surveillance system can be improved by using electronic data 
collection and via the Internet(US CDC, 2001; Ward et al., 2005).  
Data quality 
Data quality reflects the completeness and validity of the data recorded in a public 
health surveillance system(US CDC, 2001). The completeness of disease surveillance 
has been evaluated exclusively for infectious diseases(Doyle, Glynn, & Groseclose, 
2002) and Acquired Immune Deficiency Syndrome reporting(Klevens et al., 2001). 
In these evaluations, completeness was calculated as a proportion, dividing the 
number of cases reported into a surveillance system by the total number of cases 
identified through other data sources, using active case detection, capture-recapture 
methods(Doyle et al., 2002), or different secondary data sources(Cronk et al., 2003; 
A. B. Curtis et al., 2001).  
For validity, Leal et al.(Leal & Laupland, 2008) systematically reviewed the validity 
of electronic surveillance systems, and the sensitivity and specificity of electronic 
versus conventional surveillance was reported. The evaluation guidelines also 
recommend that sensitivity and PVP are useful in assessing data quality.  
According to the US CDC guidelines, the percentage of “unknown” or “blank” 
responses to items on surveillance forms is also a more straightforward and easy 
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measure of data quality. Data of a high quality will have a low percentage of such 
responses. In the evaluation of the Australian Sentinel Practice Research Network 
(ASPREN) surveillance for an influenza-like illness, the data quality assessment 
included issues with data recording (i.e., missing variables like the age and condition 
categories)(Clothier, Fielding, & Kelly, 2005). The acceptability and 
representativeness of a public health surveillance system is also related to data 
quality(US CDC, 2001).  
Representativeness 
A surveillance system that is representative accurately describes the occurrence 
of a health-related event over time and its distribution in the population by place and 
person(US CDC, 2001). Generally, it can be measured by comparing the 
characteristics of the reported events to another source of data (e.g., a random 
sample survey)(Declich & Carter, 1994). Some studies have evaluated 
representativeness by comparing surveillance data to survey data that has been 
assumed to cover all actual cases(Kang et al., 2012; lin Li & qing Chen, 2009), or by 
comparing missing data with cases captured by surveillance(Macarthur & Pless, 
1999a; Macarthur & Pless, 1999b; Russell & Conroy, 1991).  
Representativeness is important for the generalizability of information. It is 
related to underreporting when it is not uniform or random(Declich & Carter, 1994). 
Several factors can influence case reporting, for instance, severe illnesses and 
hospitalizations are more likely to be reported than mild cases, and certain cases tend 
to have a higher reporting than others in certain health care settings(Declich & 
Carter, 1994). This is also applicable for AEFI surveillance. Serious events and events 
occurring within shorter intervals from the time of vaccination tend to be reported 
more than others(Singleton et al., 1999). For certain vaccines, especially for influenza 
vaccines, during the vaccination season, there would be a temporary increase in the 
reporting of AEFIs associated with the influenza vaccine. Without general census 
data on AEFIs, which serves as the background, combined with the above-
mentioned influencing factors, it is difficult to assess the representativeness of AEFI 
surveillance systems. 
Geographic representativeness is also an indicator of data generalizability. 
Increasing the geographic areas covered by registries or surveillance systems would 
also increase their representativeness(L. H. Curtis et al., 2009). In the evaluation of 
the ASPREN surveillance for influenza-like illnesses, the geographic 
representativeness of GP recruitment was assessed(Clothier et al., 2005; Clothier & 
Turner, 2006).  
Acceptability  
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Acceptability reflects the willingness of individuals and organizations to 
participate in a system(US CDC, 2001). To assess acceptability, it is necessary to 
consider persons with the health-related events as well as those reporting the cases. 
According to the guidelines, quantitative measures of acceptability include subject or 
agency participation rates; interview completion rates and question refusal rates; 
completeness of report forms; facility reporting rates; and timeliness of data 
reporting.  
The percentage of unknown or blank responses to items on surveillance forms, 
which is a straightforward and easy measure of data quality, could also represent the 
completeness of report forms. Moreover, the timeliness of data reporting can also 
be a measure to evaluate the timeliness of a surveillance system. 
2.4 Using passive surveillance data to evaluate vaccine safety 
Nationwide AEFI passive surveillance is designed to monitor vaccine safety and 
conduct timely investigations of suspected adverse events to support the appropriate 
actions(WHO/WPRO, 2013).  
2.4.1 VAPP in CNAEFIS 
The OPV, which contains live, attenuated poliovirus strain types I, II, and III, has 
served as the primary tool for eradicating polio worldwide(Minor, 2009; WHO, 
2016). Since their introduction, poliovirus vaccines have had a dramatic impact on 
the incidence of polio in developed countries(Minor, 2009). The OPV was 
developed in 1959 and its manufacturing began in 1962 in China, as it was felt that 
an oral vaccine would more closely imitate natural infections due to the similarity in 
the route of ingestion; thus, it was believed it would potentially interrupt 
transmission much more effectively(Minor, 2009).  
China reported 20,000–43,000 polio cases each year in the early 1960s, making it 
a major affected area(Minor, 2009). The Chinese NIP began in 1978, and China 
started to implement the planned immunization schedule in which the OPV was 
recommended for children in certain age brackets(Zheng et al., 2010). According to 
the schedule, the recommended ages at which the OPV was to be administered were 
2 months, 3 months, 4 months, and 4 years old. In order to eliminate the polio cases, 
since 1994, the polio vaccine supplementary immunization activity launched every 
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year targeted children under 4 years old, and the estimated covered more than 800 
million children(Liang, 2003). Subsequently, the number of polio cases declined 
dramatically and, in 2000, WHO’s WPRO certified the nation as being polio-free. 
There have been no reported indigenous wild poliovirus cases in China since 
1994(W.-Z. Yu et al., 2014). In 2011, an outbreak of imported wild-type poliovirus 
occurred in the Xinjiang Uygur Autonomous Region in northwest China. 
Supplementary immunization activity was launched and five rounds of OPV 
vaccination were administered to children and adults. The outbreak ended 1.5 
months after a laboratory confirmation of the index case(Luo et al., 2013), and China 
was again certified by WHO as being polio-free(W.-Z. Yu et al., 2014).  
Despite the great advantages of the OPV in preventing wild poliovirus, a 
reversion of the attenuating mutations during OPV replication could lead to an 
increase in neurovirulence, thus triggering abnormal reactions and even serious 
cases(Minor, 2009).  
In polio eradication environments like China, VAPP, which is the only serious 
adverse event associated with OPV(WHO, 2016), became a public health problem. 
In the second half of 2005, parents from different provinces sought medical 
treatment in Beijing for their children who had developed abnormal limbs(Zuo et 
al., 2010). The Chinese government established several laws and policies aimed to 
compensate VAPP patients. As neonatal immunodeficiency is a rare but natural part 
of infancy, “one in a million” victims cannot be avoided when using OPV.  
VAPP is one of the most important adverse effects of the vaccines that are 
currently in use globally. With the near disappearance of wild-type polio, VAPP has 
emerged as the greatest cause of paralysis from polioviruses. One of the goals of the 
Global Polio Eradication Initiative’s Polio Endgame Strategic Plan 2013–
2018(Global Polio Eradication Initivative, 2012) is the reduction of VAPP. The 
WHO polio vaccine position paper indicates that in countries where VAPP is a 
concern, a sequential inactive poliovirus vaccine (IPV)/OPV schedule can be 
adopted. In response to WHO’s planned global action of switching from trivalent 
OPV (tOPV) to bivalent OPV (bOPV) in April 2016, which was aimed at mitigating 
VAPP following a pilot study with IPV in 2015, the attenuated poliovirus vaccine 
has been switched from tOPV to bOPV, and IPV was included as the first polio 
vaccination dose across China as of May 1, 2016. Consequently, it was expected that 
VAPP cases would decrease significantly and ultimately disappear. Since VAPP is a 
serious and confirmed reaction to the live attenuated polio vaccine and recipient 
VAPP could be captured by CNAEFIS, the analysis of VAPP in CNAEFIS could 
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give some clue regarding the vaccine safety of the live attenuated polio vaccine used 
in China. 
2.4.2 Fatalities in CNAEFIS 
Chinese EPI, which was started in late 2007(Zheng et al., 2010), includes 14 vaccines. 
As part of an expanded immunization program, about 22 vaccination doses are 
administered in the first year of life in China(Guo et al., 2013). Recently, concerns 
have been raised about AEFIs and vaccine safety(Guo et al., 2013). Fatalities that 
occur after immunization, particularly neonatal or infant deaths, frequently attract 
media attention and become a cause of public concern. However, vaccinations are 
common during childhood, and they may not be the direct cause of reported 
pediatric fatalities.  
Generally, parents have their children vaccinated when they are in relatively good 
health. In cases where infants die shortly after immunization, parents and even health 
providers may view the vaccine as the cause or at least as a contributory factor to the 
death(McGarthy et al., 2013). Although vaccines play a vital role in preventing 
diseases in children, vaccine hesitancy has become an issue not only in high-income 
counties, such as the US and UK but also in LMICs(W. Yu et al., 2016; Larson et al., 
2013). Due to vaccine hesitancy, vaccination coverage may not be high enough to 
build herd immunity and prevent disease outbreaks among the population (Brown 
et al., 2012; Casiday, 2006). Experts have placed the reasons for parental refusal to 
have their children vaccinated into the following four categories: religious beliefs, 
personal beliefs, philosophical rationales, and safety concerns, with parents 
expressing a desire for more information from healthcare providers(McKee & 
Bohannon, 2016). Among these, safety concerns accounted for most parental 
refusals(McKee & Bohannon, 2016) . The events in December 2013 in Mainland 
China provide a typical example of how such concerns arise(CFDA & MoH, n.d.). 
Media reports of 17 infant deaths, including 1 case of anaphylactic shock following 
HepB vaccination, raised widespread public concern in China(M.-N. Li, Liu, & 
Zhang, 2014; W. Yu et al., 2016), and HepB vaccinations were suspended during the 
ensuing investigation. After prudent investigation, China FDA claimed that the 
babies’ deaths were not related to the vaccine. There were also various problems 
following the vaccine, including severe pneumonia, suffocation, kidney failure, 
severe diarrhea and congenital heart disease(W. Yu et al., 2016), (M.-N. Li et al., 
2014; Yan et al., 2015). However, this “Hepatitis B vaccine event” caused a vaccine 
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confidence crisis among parents. A telephone survey showed that before the event, 
85% of respondents regarded domestic vaccines as safe and that this decreased to 
just 26.7% during the event(W. Yu et al., 2016). Although confidence increased after 
the investigation, it remained lower than before the event(W. Yu et al., 2016). The 
analysis of fatalities reported in CNAEFIS could provide evidence for vaccine safety 
in China. 
2.4.3 JE vaccines safety 
Japanese Encephalitis (JE) is a mosquito-borne acute viral infection of the central 
nervous system caused by a flavivirus(Wang, Li, Liang, & Liang, 2009). JE is the 
most important cause of vaccine-preventable viral encephalitis in nearly all Asian 
countries, whether temperate, subtropical, or tropical, and it has expanded to new 
areas through the importation of infected-mosquito vectors. Currently, an estimated 
3 billion people living in 24 countries, mainly in South-East Asia and WPR are 
considered at risk of JE(WHO, 2015b). The inactivated JE vaccine (JEV-I) was 
developed in China and has been used since the 1970s, and the live-attenuated 
vaccine (JEV-L) has been in use since the beginning of the 1990s(Wang et al., 2009). 
Since 2007, JE vaccines have been included in the EPI in Mainland China(Wang et 
al., 2009). With the decline in the number of JE cases in China, the public has become 
more concerned with the adverse events following JE vaccination. 
The safety of JE vaccines manufactured in China and abroad has been evaluated 
in previous clinical and post-marketing studies(Nakayama & Onoda, 2007). The 
vaccine safety review of JE vaccines by WHO found that they have acceptable safety 
profiles, and data from multiple studies (including multicenter randomized 
controlled trials and randomized trials) have shown the same conclusion(WHO, 
2015b; D. Liu et al., 2015; Liang et al., 2011). 
However, the JE vaccine used in China was mainly produced by domestic 
manufacturers, and a JEV-L product was prequalified by WHO in 2013, which was 
the first Chinese-produced vaccine to be prequalified by WHO. Limited data are 
available on the safety of JE after its inclusion in the Chinese EPI and, consequently, 
its large-scale use. Therefore, the JE vaccines was chosen as an example to assess 
vaccine safety using passive AEFI surveillance data. 
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2.5 Methods of signal detection using passive surveillance data 
2.5.1 Signals 
Vaccine pharmacovigilance includes a vaccine safety study conducted during clinical 
trials and in the post-licensure period(CIOMS & WHO, 2012). One primary aim of 
passive AEFI surveillance is to identify signals after the vaccine products have been 
marketed. The rapid detection and evaluation of safety signals is essential to ensure 
the continued safety of vaccines(CIOMS & WHO, 2012). In fact, a signal was 
extended from the drug to the vaccine in pharmacovigilance. Dr. Hauben and Dr. 
Aronson systemically reviewed the definition of a signal in 
pharmacovigilance(Hauben & Aronson, 2009) and found that WHO, Council for 
International Organizations of Medical Sciences (CIMOS), and other study groups 
had slightly different definitions: WHO defined a signal as “reported information on 
a possible causal relationship between an adverse event and a drug, the relationship 
being unknown or incompletely documented”; CIMOS defined a signal as “a report 
or reports of an event that may or may not have a causal relationship to one or more 
drugs; it alerts health professionals and should be explored further”; and the US 
FDA defines a signal as “a concern about an apparent excess of an adverse event 
compared to what would be expected.” Despite the different definitions, there are 
two common points: i) the study objective is drug/vaccine-events/diseases pair 
association; ii) the possible causal relationship needs further investigation(Almenoff 
et al., 2005).  
Before powerful computer technology was available, signal detection solely relied 
on a case-by-case study(Egberts, 2007). An experienced assessor had to review every 
single case report in the database, assess the likelihood of whether the event was 
caused by the drug, and try to detect whether the case report was somehow unusual 
or strange(Egberts, 2007). However, with the development of computer science and 
the growing database of surveillance systems, quantitative signal detection became 
possible, and it is now possible to get a complete picture of all the cases in a database. 
Dr. Egbert(Egberts, 2007) concludes that the quantitative assessment of signal 
detection is all about disproportionality, and he enquires, “Is what we observe 
different from what we expect?”  
54 
 
2.5.2 Denominator-based methods 
In passive AEFI surveillance, there are two methods of signal detection(Hauben & 
Zhou, 2003): denominator-based methods and numerator-based methods. 
Denominator-based methods detect temporal changes in reporting rates or 
frequencies by constructing a probability model and a corresponding test statistic to 
assess the probability that the observed temporal changes reflect random sampling 
variability(Hauben & Zhou, 2003). In numerator-based methods, no external data 
sets are needed, and data mining algorithms (DMAs) are used to seek interesting or 
valuable information within a database(Hauben et al., 2005).  
Dr. Hauben (Hauben & Zhou, 2003) concluded that there are several techniques 
of implementing denominator-based methods for signal detection, such as 
cumulative sum techniques, time scans, and Poisson methods. In passive 
surveillance, the application of these methods is difficult, since systems like VAERS 
rely on voluntary submissions. Thus, the underreporting of events represents an 
inherent system limitation(Varricchio et al., 2004) along with different resources of 
vaccination doses (distributed or administered) and unknown background 
information. All of this makes it difficult to compare the observed to the expected 
rates and among different settings. Since the existing vaccine safety surveillance 
systems mostly rely on the passive reporting of events suspected by reporters to be 
vaccine related(Postila & Kilpi, 2004), different surveillance definitions, reporting 
requirements, and settings make it difficult to compare different 
countries(Schumacher, Bourquin, & Heininger, 2010). Any missing denominator 
data or the use of a different proxy of denominator data also creates a barrier to 
comparison. For instance, in the US, the net distributed doses were used as 
denominator data(Zhou et al., 2003), while in Australia(Mahajan et al., 2014), 
Switzerland(Schumacher et al., 2010), and Denmark(Aagaard, Hansen, & Hansen, 
2011), the number of doses administered was used as the denominator data. Another 
big obstacle is the background rates and lack of control groups(S. B. Black et al., 
2009). Overall, there are several limitations in denominator-based methods, but the 
ongoing analysis of AEFI surveillance data could generate the baseline and provide 
useful information on vaccine safety. In CNAEFIS, the annual AEFI surveillance 
data has been analyzed since 2005, and the administered vaccine doses have been 
used to estimate the incidence rates of AEFIs(D. Liu, et al., 2007; Wu et al., 2013; 
Wu et al., 2012; Ye, et al., 2015). However, few signals were detected during these 
years, given the lack of control groups or background rates.  
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2.5.3 Disproportionality analysis 
A commonly used numerator-based technique for signal detection is 
disproportionality analysis (DPAs or DMA)(Johnson et al., 2012). There are several 
review papers on different measures of DPAs( Harpaz et al., 2012; Hauben et al., 
2005; Hauben & Zhou, 2003; Iskander et al., 2006; Johnson et al., 2012; Suling & 
Pigeot, 2012), and the commonly used statistical measures are Proportional 
Reporting Ratios (PRR), Reporting Odds Ratios (ROR), Bayesian Confidence 
Propagation Neural Network (BCPNN), and the Gamma-Poisson Shrinker (GPS) 
algorithm of Empirical Bayes Screening (EBS)(Hauben & Zhou, 2003). The theory 
behind those four methods is similar: use a frequency analysis of 2 × 2 contingency 
tables (Table 4) to estimate surrogate measures of statistical association between 
specific drug-event combinations mentioned in spontaneous reports(Harpaz et al.,  
2012). They intend to quantify the degree to which a drug-event combination co-
occurs “disproportionally” compared to what would be expected if there were no 
association(Harpaz et al., 2012). The signals detected by DPAs were mainly 
dependent on statistical calculations, devoid of any clinical context; therefore, instead 
of signals or safety signals, “signals of disproportionate reporting” (SDR) were 
used(EMA, 2006; Hauben & Reich, 2005).  
Table 4 2 × 2 Contingency table* used in SRS-based DPA (et al Rave Harpaz, William 
DuMouchel, Nigam H. Shah, 2012) 
  
With target adverse 
events 
Without target adverse 
events  
With target drugs or vaccines A B N=A+B 
Without target drugs and vaccines C D C+D 
  M=A+C B+D T=A+B+C+D 
*Reports are classified according to the presence/absence of specific adverse event combinations. Each cell 
contains the report counts. 
In passive surveillance, based on the 2 × 2 tables above (Table 4), different 
algorithms (i.e., PRR, ROR, BCPNN, and GPS) could be used to generate SDRs. 
Since there is no “gold standard” for algorithms, different methods have been used 
in different passive systems(Hauben et al., 2005; Suling & Pigeot, 2012) (Table 5).  
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Table 5 Common DPAs and their related result measures 
DPAs Measure of association (based on Table 4) 
PRR PRR = 
ୟȀሺୟାୠሻ
ୡȀሺୡାୢሻ  
ROR ROR = 
ୟȀୡ
ୠȀୢ 
BCPNN Information Component (IC) = ݈݋݃ଶ ܴܴܴ 
RRR refers to Relatively Reporting Ratio and RRR = ௉ሺಲಶפ೏ೝೠ೒ሻ௉ሺಲಶሻ  
GPS Empirical Bayesian Geometric Mean (EBGM) 
EBGM = ݁ாሺ௟௢௚ሺఒሻሻ 
The observed AE may be assumed as a realization of a Poisson-distributed random variable, 
and the RRR is defined as λ = ఓா and ܧ෠ ൌ
௖ൈ௕
ௗ  
The PRR were used in the ADR online information tracking (ADROIT) 
database, also known as the YCS of the Medicines and Healthcare products 
Regulatory Agency (MHRA) in the UK(Evans, Waller, & Davis, 2001) and the 
EudraVigilance data of EMA(EMA, 2006). The BCPNN (Bate et al., 1998; Orre et 
al., 2000)and ROR(Bruin et al., 2005) were used in the ADR monitoring database of 
UMC WHO. The GPS and PRR were also used in the US ADR surveillance 
system(O’Neill & Szarfman, 2001) and VAERS(Iskander et al., 2006). Although 
some publications use the new names of DPAs, they are all in fact the same method, 
for instance, “Screened PRR” (sPRR) is only PRR with certain screening SDR 
criteria. Another example: “EBGM” and “5th percentile of EBGM” (EB05) are both 
GPS-type DPAs(Banks et al., 2005). Usually, pharmacovigilance researchers classify 
the four algorithms into two categories: i) simple, classical, or frequentist, such as 
PRR and ROR; ii) Bayesian methods, such as BCPNN and GPS(Hauben et al., 2005; 
Stephenson & Hauben, 2007). Apart from these four algorithms, there are other 
DPAs that have also been used, such as the PROFILE analysis (i.e., Probability 
Filtering), which was also based on a 2 × 2 contingency table, using Fisher’s exact 
one-tailed right to calculate association, and mainly in the Australian ADR 
database(Burcell & Barty, 2002).  
Not only are different algorithms used, the threshold criteria for screening SDRs 
also differ. In EMA’s EudraVigilance data analysis system(EMA, 2006), two criteria 
apply to define an SDR: i) when the PRR is displayed with its 95% confidence 
interval (CI)—the lower bound of the 95% CI≥1 and the number of individual cases 
(i.e., a in Table 5) ≥3; ii) when the PRR is displayed with the χ2 statistic—PRR>2, 
χ2>4 and a≥3. In US VAERS, EB05 >2 was used to detect SDRs in some 
studies(Moro et al., 2015). Dr. Deshpande et al.(Deshpande, Gogolak, & Smith, 
2010) found more than 100 English language articles, editorials, and letters on the 
topic of data mining of adverse event databases to identify potential safety signals of 
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pharmacological products, including drugs, biologicals, and vaccines, and different 
thresholds were used among those algorithms (Table 6). 
Table 6 Threshold criteria used in different algorithms in pharmacovigilance literature 
(Deshpande et al., 2010) 
DPAs Threshold criteria used in the literature 
PRR PRR>1;  
PRR>3,χ2≥4,a≥4; 
Lower than 95% CI for PRR >1, a≥2.  
ROR ROR>1;Lower than 95% CI for ROR >1; 
Lower than 95% CI for ROR >2, a>2. 
BCPNN IC >0; 
IC – 2 SD >0. 
GPS/MPGS 5th percentile of EBGM (EB05)≥2,a>0; 
EB05>2, a >0; 
EBGM/2>0, a>0. 
Since there was no “gold standard” for choosing algorithms and their related 
thresholds, several researchers have compared these methods and thresholds. There 
has been disagreement on ROR and PRR(Rothman et al., 2004; Waller, 2004) and 
several studies on the comparison of these DPAs(Almenoff et al., 2006; Berlin et al., 
2012; Harvey, Turville, & Barty, 2004; Kubota, Koide, & Hirai, 2004; C. Li et al., 
2008; Puijenbroek et al., 2002). Van Puijenbroek demonstrated that when there are 
≥4 cases (i.e., a≥4), both SDRs detected by Bayesian and non-Bayesian methods are 
similar(Hauben et al., 2005; Puijenbroek et al., 2002). These algorithms have both 
advantages and disadvantages, as Dr. Hauben concluded in his review articles (Table 
7)(Hauben et al., 2005).  
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Table 7 Characteristics of common algorithms based on DPAs (Hauben et al., 2005) 
 “Simple”/frequentist Bayesian 
Algorithms PRR and ROR BCPNN and GPS/MGPS 
Advantages More sensitive 
Clear, easy to use and understand 
Identifies virtually all SDRs identified by 
Bayesian methods 
Natural metric for logistic regression analysis 
More specific 
Numerous data mining settings and 
configurations maximize exploratory 
capacity 
Configured to perform higher order 
analysis (e. g., drug-drug interactions, 
complex medical syndromes) 
Disadvantages Lower specificity leading to overabundance of 
SDRs that may require additional triage 
criteria for practical implementation 
Lower sensitivity 
Numerous data mining settings and 
configurations raise issues of 
confirmation bias and multiple 
comparisons  
DPAs for SDR detection were not intended to be used in isolation(Almenoff et 
al., 2005). They have their pitfalls, which should be considered when they are used 
for signal detection. According to Dr. Stephenson and Dr. Hauben, the following 
points should be considered when using these methods for SDR detection: i) 
evidence for the predictive value of current data mining methods is lacking; ii) 
limitation of passive surveillance data, such as underreporting and poor data quality, 
will have an impact on the usefulness of data mining; iii) the sampling framework 
for passive surveillance is problematic; iv) there are intrinsic methodological 
limitations in data mining, such as it being susceptible to confounding; v) it is 
important to take a holistic approach to the interpretation of data mining methods 
and signal detection(Stephenson & Hauben, 2007). Therefore, currently, in post-
marketing surveillance systems, the traditional methods of signal detection, including 
literature searching, case-by-case analysis, and denominator-based analysis of 
incidence rates, should be integrated with the newly computer-enhanced 
DPAs(Almenoff et al., 2005). Though the DPA methods were first used in SDR 
detection in drug pharmacovigilance, they were gradually introduced into vaccine 
pharmacovigilance as well(Almenoff et al., 2005). In US VAERS, DPAs were already 
introduced for signal detection(Banks et al., 2005; Leroy et al., 2012b; Moro et al., 
2015; Manette T Niu, Erwin, & Braun, 2001; Slade et al., 2009). We have applied 
them to the CNAEFIS data as complementary techniques to assess vaccine safety.  
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3 OBJECTIVES OF THE STUDY 
The overall aim of this thesis was to a) describe and evaluate the performance of the 
national adverse events following the immunization surveillance system in China 
during 2008–2015, to identify parts of vaccine safety concerns and ways to 
strengthen vaccine safety surveillance in China; b) to assess specific issues associated 
with vaccine safety by using this surveillance data. 
Specific objectives: 
I. To describe the characteristics and evaluate the performance of the National 
Adverse Events Following Immunization (AEFI) surveillance system in China. 
1.1 To provide an overview of the passive surveillance system for AEFIs in China 
(Study I) 
1.2 To summarize routine analyses of data collected in the Chinese Online 
National AEFI Information System (CNAEFIS), 2008–2013 (Supplemental 
published reports 1st-6th) 
1.3 To assess the performance attributes of CNAEFIS according to standard 
guidelines for evaluating public health surveillance systems. 
II. To assess specific issues associated with vaccine safety by using the following 
Chinese national surveillance data: 
2.1 Case characteristics and occurrence of cases of recipient vaccine-associated 
paralytic poliomyelitis (VAPP) during 2010–2015 (Study II) 
2.2 Causality assessment of reported associations of fatalities with vaccinations 
during 2010–2015. (Study III) 
2.3 Monitoring the post-licensure vaccine safety of JE vaccines. (Study IV) 
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4 MATERIALS AND METHODS 
4.1 Study settings 
Mainland China has 32 provinces (including Xinjiang Corps), with an estimated 
population of 1.3 billion and more than 16 million births every year. China initiated 
the National EPI in 1978. Currently, there are about 14 vaccines targeting 15 VPDs 
in the NIP. The vaccines included are funded by the central government and 
administered to target children free of charge. There are still vaccines used outside 
the national immunization schedule in the private market, produced by 
manufacturers based on market demand, and these can be purchased by consumers 
on a voluntary basis. All vaccines are to be administered in vaccination clinics 
approved by the local government and supervised by the local CDC. The nationwide 
AEFI surveillance covers all vaccines marketed in the mainland of China.  
4.2 Data resources 
All AEFI data were extracted from the online CNAEFIS database.  
AEFI surveillance covers all vaccines marketed in Mainland China, with the scope 
of reporting shown in Table 8. Healthcare facilities, vaccination clinics, CDCs at all 
four administrative levels (i.e. National-, provincial-, prefecture-, and county- level), 
ADR monitoring agencies, and vaccine manufacturers’ executive staff are all 
responsible reporting units and reporters of AEFIs. The reporting of AEFIs is 
implemented in line with the principle of localized management. The public or the 
guardians (parents) can notify any of these authorized reporters about an AEFI. 
Cases are gathered by local, county-level CDCs, which are responsible for 
completing AEFI Case Reporting Cards (Appendix 1) and submitting the data to 
CNAEFIS. Duplicate reports are identified and de-duplicated centrally in 
CNAEFIS. Once the case information is entered, it can be viewed by staff at all 
administrative levels of the CDCs and ADRs.  
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Table 8 Scope of reporting* (Paper I) 
AEFI onset time since 
vaccination 
Specific AEFI 
Within 24 hours Anaphylactic shock, allergic reactions without shock (hives, rash, laryngeal edema, 
etc.), toxic shock syndrome, syncope, hysteria 
Within 5 days Fever (axillary temperature ≥ 38.6°C), angioedema, systemic purulent infection 
(toxemia, septicemia, sepsis), redness and swelling at the injection site (diameter 
> 2.5cm), induration (diameter > 2.5cm), localized purulent infection (localized 
abscess, lymphangitis, lymphadenitis, or cellulitis) 
Within 15 days Measles-like or scarlet-fever-like rash, Henoch Schonlein purpura, localized 
allergic necrotic reaction (Arthus reaction), febrile convulsion, epilepsy, 
polyneuritis, encephalopathy, encephalitis, and meningitis 
Within 6 weeks Thrombocytopenic purpura, Guillain-Barré Syndrome, vaccine-associated 
paralytic poliomyelitis 
Within 3 months Brachial neuritis, sterile abscess at the injection site 
1–12 months after BCG 
vaccination 
Lymphadenitis or lymphangitis, osteomyelitis, systemic disseminated BCG 
infection 
Unspecified time frame Other serious AEFIs suspected to be related to vaccination 
* From National AEFI surveillance guideline (2010) 
All AEFIs are to be investigated, except for common adverse reactions which 
have a clear diagnosis (e.g., fever, redness and swelling at the injection site, or 
induration). County CDCs start their investigation by collecting the relevant data and 
completing an AEFI Case Investigation Form (Appendix 2), which is subsequently 
entered CNAEFIS. For deaths, serious AEFIs, AEFI clusters, and AEFIs of 
significant public concern that are suspected to be related to immunization, upon 
receiving the CNAEFIS reports, the prefectural or provincial CDCs must 
immediately organize an AEFI expert panel for investigation. 
As a key part of an investigation, county CDCs organize a group of relevant 
experts in clinical medicine, epidemiology, laboratory practices, pharmacy, 
vaccinology, vaccine regulation, and other fields relevant to the case. This group of 
experts is responsible for making a diagnosis and assessing the causality of the AEFI. 
For deaths, serious AEFIs, AEFI clusters, and AEFIs of significant public concern, 
the higher-level prefectural or provincial CDCs organize an AEFI Investigation and 
Diagnosis Expert Panel to conduct a diagnostic and causality assessment. The flows 
of reporting and investigation are shown diagrammatically in Figure 7.  
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Figure 7 AEFI reporting, investigation, and causality assessment flow* (Paper I) 
*I&D: investigation and Diagnosis 
4.3 Case definitions 
Case definition of AEFI 
In CNAEFIS, an AEFI case is defined as a reaction or an event occurring after 
vaccine administration that is suspected to be related to the vaccination. 
Serious AEFIs are defined as rare adverse reactions, including death and long-
term disabilities. Those diseases include allergic shock, allergic laryngeal edema, 
allergic purpura, thrombocytopenic purpura, localized allergic necrosis reaction 
(Arthus reaction), febrile convulsion, epilepsy, brachial plexus neuritis, polyneuritis, 
Guillain-Barré syndrome (GBS), encephalopathy, encephalitis and meningitis, 
vaccine-related paralytic polio (VAPP), BCG osteomyelitis, systemic disseminated 
BCG infection, etc. 
Following investigation and causality assessment, AEFI cases are classified into 
one of five categories (Table 9). AEFIs are classified as serious if they are any of the 
following: death, life-threatening condition, permanent or significant disability, or 
damage to organs or bodily functions. Serious AEFIs include but are not limited to 
allergic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, 
63 
 
localized allergic necrotic reaction (Arthus reaction), febrile convulsion, epilepsy, 
brachial neuritis, polyneuritis, Guillain-Barré Syndrome, encephalopathy, 
encephalitis and meningitis, VAPP, BCG osteomyelitis, systemic disseminated BCG 
infection, syncope, toxic shock syndrome, and systemic purulent infection.  
Table 9 Cause-specific classification of AEFIs (Paper I) 
Category Definition 
vaccine reaction 
 following immunization 
 
 
Unexpected harmful reactions or reactions unrelated to the expected 
purpose of the vaccination that occur after standard vaccination with a 
vaccine product, including common adverse reactions and rare adverse 
reactions. 
Common adverse reactions or common vaccine reactions are reactions 
caused by the inherent character of the vaccine after vaccination and 
that only impair body functions transiently. They mainly include fever and 
localized redness and swelling that may be accompanied by discomfort, 
fatigue, poor appetite, tiredness, etc. 
Rare adverse reactions or rare vaccine reactions are drug adverse 
reactions occurring during the process of or after a standard vaccination 
with a qualified vaccine that has caused damage to the tissues or organs 
or damage to the functioning of the vaccine recipient when all parties 
involved have made no medical errors. Included are reactions caused 
by the inherent character of the vaccine that might be related to the 
strain, purity, production technology, or added substances of the vaccine 
such as antiseptics, stabilizers, and adjuvants.  
 
Vaccine quality event Damage to tissues or organs and damage to functions of the vaccinated 
person due to substandard quality of the vaccine. Substandard quality 
refers to problems with the strain and purity of the vaccine, production 
technology, or added substances in the vaccine (excipients), exogenous 
factors. Also, if inspection and control of the vaccine were not consistent 
with national protocols or standards for vaccine production. 
 
Program error Damage to tissues or organs and damage to functions of the vaccine 
recipient due to violation of standard operational practices, vaccination 
procedures, guidelines for using the vaccine. 
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Category Definition 
Coincidental event The vaccine recipient was in the incubation stage or preclinical stage of 
a certain condition, and the onset of the disease coincides with the 
vaccination by chance. Coincidental events are not caused by the 
inherent character of the vaccine.  
 
Psychogenic reaction 
 or injection reaction 
Individual reactions or reactions of groups of individuals that occur during 
or after a vaccination due to the psychological responses of the vaccine 
recipients. Psychogenic reactions are not caused by the inherent 
character of the vaccine. 
Vaccine schedules of JE vaccines in China 
As JEV-L was the first Chinese produced vaccine product to be prequalified by 
WHO, and JEV-L and JEV-I were used simultaneously in the country, this vaccine 
was chosen to be studied. In Mainland China, both JEV-I and JEV-L have been 
included in the NIP since 2007. The JEV-L has a two-dose schedule and is 
administered at ages 8 months and 24 months, with an interval of at least 3 months. 
The JEV-I has a four-dose schedule and is administered as follows: 2 doses at 8 
months with at least 7–10 days intervals, and subsequent doses at ages 2 years and 6 
years. 
Case definition of VAPP 
In 2008, the MoH of the People’s Republic of China issued two regulations on the 
diagnosis and verification of VAPP: “Instruction advice on diagnosis and treatment 
of vaccine associated paralytic poliomyelitis” (Wei Ban Yi Fa [2008] No. 17), and 
“Instruction advice on verification of VAPP and handling of remaining problems” 
(Wei Ban Fa [2008] No. 40). These regulations describe two types of VAPP: recipient 
and contact. Although contact VAPP is not included in CNAEFIS, recipient VAPP 
is defined as a case of i) fever occurring 4–35 days after vaccination, acute flaccid 
paralysis (AFP) occurring 6–40 days after vaccination, and a clinical diagnosis 
compatible with paralytic poliomyelitis; or ii) the isolation of vaccine-related 
poliovirus from stool samples, which are considered as supplementary conditions. 
Like other AEFI cases, VAPP is also now investigated by a panel of experts and 
receives a causality assessment based on the clinical and epidemiological 
characteristics of each case. 
Case definition of AEFI-associated deaths 
Included in this study are deaths reported in CNAEFIS that are suspected to be 
related to vaccinations. Neonatal deaths were cases who died within 28 days after 
birth. 
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4.4 Study designs 
To evaluate the system performance of CNAEFIS and vaccine safety in China, we 
conducted descriptive epidemiological studies. In addition, we also conducted a 
signal detection for JE vaccines using both denominator-based methods and DPA.  
4.4.1 Descriptive analysis  
To study the system performance and safety of JE vaccines, we analyzed the national 
AEFI database from 2008–2013. For VAPP and reported in CNAEFIS, we 
conducted descriptive analyses on database from 2010–2015. Deaths which were 
suspected to be related to the vaccinations, with dates of death from 1st January 
2010 to 31st December 2015, were extracted from CNAEFIS and included in the 
study. 
In the descriptive analysis of the national AEFI database, the variables used 
included demographic variables (i.e., year of onset of AEFI, district, age, and gender), 
seriousness of AEFIs, classification (i.e., causality assessment), vaccine, and 
outcomes of AEFIs (Table 10).  
Table 10 Variables of the quantitative analysis 
Variables Definitions or category 
Year The onset year of AEFIs in the database 
Gender Female, Male, Unknown 
Age groups ≤1 year; 2–6 years; ≥7 years  
Districts Eastern area includes Beijing, Tianjin, Liaoning, Shanghai, Jiangsu, Zhejiang, Fujian, 
Shandong and Guangdong. Middle area includes Hebei, Shanxi, Jilin, Heilongjiang, 
Anhui, Jiangxi, Henan, Hubei, Hunan and Hainan. Western area includes Inner 
Mongolia, Guangxi, Chongqing, Sichuan, Guizhou, Yunnan, Tibet, Shaanxi, Gansu, 
Qinghai, Ningxia, Xinjiang, and Xinjiang Corps. 
Seriousness  According to the national guidelines, since 2011, AEFI cases are classified into serious 
and non-serious. 
Classification After investigation and causality assessment by CDCs and expert panel of causality 
assessment, AEFI cases are classified into five groups: 
Vaccine reactions (includes common and rare vaccine reactions); Vaccine quality 
event; Program error; Coincidental event; Psychogenic reaction or injection reaction. 
Vaccine In every AEFI case, the maximum number of suspected vaccines is three; however, in 
this analysis, the first and most suspected vaccine will be included. 
Outcome of 
 AEFI cases 
The outcomes of AEFI cases are classified as recovered or bettered, death, sequela, 
unknown. 
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In addition, for VAPP, we also analyzed the OPV vaccination history and 
serotype of the vaccine strains of each case. For AEFI-associated deaths, we also 
included other variables such as time interval from vaccination to onset of symptoms 
and concurrent vaccines administered.  
Since there are two types of JE vaccines used in China, for its safety assessment, 
we analyzed AEFI reports submitted from 2008–2013 for subjects vaccinated with 
JEV-L or JEV-I. In CNAEFIS, a maximum of three suspected vaccines can be 
reported at a time in a single report. JE vaccines listed as the first, second, or third 
suspected vaccine were all included. When more than one symptom was reported 
for a case, only the main symptom or the most serious diagnosis was recorded in 
CNAEFIS. 
4.4.2 Performance attributes 
According to the literature review on the system attributes of surveillance systems, 
several attributes could be analyzed using only the AEFIs database in CNAEFIS and 
no external information. Since we did not have cost information on establishing and 
maintaining this surveillance system, the utility and cost evaluation of this 
surveillance was not included in this analysis. These attributes could reflect the 
following indicators or analyses: 
Sensitivity & PVP  
Reporting sensitivity is calculated as the proportion of events in a specific 
population that are actually reported. PVP is the proportion of reported cases that 
actually have the health-related event under surveillance. The calculation of 
sensitivity and PVP can be seen in Table 11. 
Table 11 Calculation of sensitivity and PVP in CNAEFIS 
Detected by AEFI surveillance Condition present  
Yes No 
Yes True positive A False positive B A + B 
No False negative C True negative D C + D 
 A + C B + D Total 
Sensitivity = Number of vaccine reactions (after causality assessment) (A) / 
Number of Expected Reports (A + C) *100% 
PVP = Number of vaccine reactions (after causality assessment) (A)/Number of 
all AEFIs detected by CNAEFIS (A + B) *100% 
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Nine pairs of vaccine-diseases events were selected: BCG-Suppurative 
lymphadenitis; BCG-Disseminated BCG infections; HepB-Anaphylaxis; OPV-
VAPP; measles containing vaccines (MCV)-Febrile seizures; MCV-
Thrombocytopenia; Varicella live attenuated Vaccine (VarV)-Febrile seizures; 
seasonal influenza inactive Vaccine (InfV)-Guillain-Barré Syndrome (GBS); InfV-
Anaphylaxis. 
The number of vaccine reactions (A) and total number of AEFIs detected by 
CNAEFIS (A + B) were extracted from the CNAEFIS database. The number of 
expected reports (A + C) were estimated by calculating incidence rate of events in 
the literature × administered doses of certain vaccines.  
In China, BCG, HepB, OPV, and parts of MCV, which includes MV, measles-
mumps attenuated live vaccine (MM), measles-rubella combined vaccine (MR), and 
MMR belong to Group I, which is covered by the government, which means parents 
can freely and easily give their children these vaccines. VarV and InfV were common 
vaccines in Group II, which is not free, and parents therefore have to pay for these 
vaccinations. Since administration doses of vaccines in Group II were not collect 
before 2010, we only included data from 2010–2013 for MCV, VarV, and InfV. 
Incidence rates for selected vaccine reactions following vaccination were estimated 
based on a review of the WHO guidelines: i) Immunization Safety Surveillance—
Guidelines for Immunization Program Managers on the Surveillance of Adverse 
Events Following Immunization (Second Edition)(WHO/WPRO, 2013); and ii) 
Supplementary Information on Vaccine Safety: Part 2—Background Rates of 
Adverse Events following Immunization(WHO, 2000). 
Timeliness 
The variables were used, and the time intervals were calculated according to the 
flowchart. Table 12 presents the definitions of the different variables. 
Table 12 Definition of different time variable in CNAEFIS 
Variables Definition 
Onset date The onset date of the disease or first symptom will be enquired about when AEFI 
patients contact the responsible nurses or physicians. 
Reporting date The date of the AEFI patients or guardian reporting the case to the responsible nurses 
or physicians. 
Investigation date The date when investigation started, if the cases needed to be investigated by the 
CDCs. 
The time interval analysis includes the reporting time interval and the 
investigation time interval. 
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Reporting time interval = Reporting date – Onset date; 
Investigate time interval = Investigate date – Reporting date. 
Time lag: If the time interval was more than 2 days, the case will be identified as 
a time lag case.  
The range and median days of time interval will be calculated, and the proportion 
of time lag will be analyzed.  
Proportion of unknowns or errors in the variables  
The variables and criteria of errors or unknowns are displayed in Table 13. The 
proportion of errors or unknown cases was analyzed.  
Table 13 Indicators in the analysis and criteria of unknowns or errors 
Indicators Related key variables Criteria of unknowns or errors 
Age Vaccination date; 
Birth date 
If the age is unknown (either 
vaccination date or onset date is 
missing), or >120 years old, or <0 year, 
the case will be marked as an error 
case.  
Time interval between 
 vaccination date and 
 onset date 
Vaccination date; 
Onset date 
Time interval between vaccination and 
onset = Onset data – vaccination date 
If this time interval < 0, the case will be 
marked as an error case. 
Vaccine dose Vaccine dose (the first 
suspected vaccine) 
If the vaccine dose >30, the case will 
be marked as an error case. 
Classification after 
 causality assessment 
Classification If the classification of causality 
assessment is unknown, the case will 
be marked as an error case. 
Outcome Outcome If the outcome of the case was 
unknown, the case will be marked as 
an error case. 
Representativeness 
At least one AEFI is reported into the CNAEFIS within one year by county, this 
county will be the county reported cases. The proportion of reported cases in 2008–
2013 will be considered as geographic representativeness. The 32 provinces 
(including Xinjiang Corps) will be divided into three categories according to their 
location: i) Eastern (including Beijing, Tianjin, Liaoning, Shanghai, Jiangsu, Zhejiang, 
Fujian, Shandong, and Guangdong); ii) Middle (including Hebei, Shanxi, Jilin, 
Heilongjiang, Anhui, Jiangxi, Henan, Hubei, Hunan, and Hainan); iii) Western 
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(including Inner Mongolia, Guangxi, Chongqing, Sichuan, Guizhou, Yunnan, Tibet, 
Shaanxi, Gansu, Qinghai, Ningxia, Xinjiang, and Xinjiang Corps). 
4.4.3 Denominators for incidence estimation 
Denominators for performance evaluation 
According to the WHO GACVS(WHO, 2015a), the ratio of AEFI reports per 
100,000 surviving infants per year is used as a general AEFI indicator to assess the 
progress in the development of AEFI surveillance systems. The surviving infants per 
year were calculated by total population × birth rate × (1-infant mortality rates). The 
total population, birth rate and infant mortality rates were downloaded from the 
website of Chinese National Bureau of Statistics.  
Denominators for risk estimation 
Vaccination doctors or nurses collect information on vaccination doses and send 
monthly reports to the national CDCs. The CDCs then report the data to the 
municipal CDCs who in turn report to provincial CDCs. China CDC collects 
administered vaccination data from all provincial CDCs(Zuo et al., 2010; Landaverde 
et al., 2014). Before 2010, only doses of vaccines provided by the government for 
free were reported. Since 2010, however, the vaccination information system has 
been collecting all vaccination doses administered in the vaccination clinics, enabling 
the analysis of the reporting rates. As the denominator information only included 
the number of vaccine doses, without information on age or sex, the rates of AEFI 
for specific population groups by age or gender could not be calculated.  
For VAPP risk calculations, two methods were used(Platt, Estivariz, & Sutter, 
2014): VAPP per million administered OPV doses, and VAPP per million births. 
The risk of recipient VAPP per administered OPV doses was calculated using the 
number of recipients VAPP cases reported during the study period divided by the 
total number of OPV doses administered during the same period. The OPV-
administered doses were collected from a Chinese immunization information 
system, which collects immunization doses of all vaccines in the national 
immunization schedules, including OPV. However, the immunization doses of OPV 
in supplementary immunization activities launched at the provincial level are not 
collected in this system. VAPP per million births is calculated using the number of 
recipients VAPP cases divided by the number of estimated births during the same 
period. The estimated births are calculated by multiplying the total population by the 
birth rate. Both total population and birth rate were secured from the website of 
Chinese National Bureau of Statistics (http://data.stats.gov.cn/easyquary.htm?cn=C01, 
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accessed: 2016.10.15). The data from 2010 were census data, while data from other 
years were from annual sampling surveys. 
We used the following denominators to estimate the risk of AEFI-associated 
deaths: 1) administered doses collected from vaccination clinics during the study 
period, 2) population data from the National Bureau of Statistics of the People’s 
Republic of China, and 3) neonatal death rates after vaccination. For denominator 1 
and 2, the numerator was AEFI-associated deaths reported to CNAEFIS during the 
same period. The rates were calculated per million administered vaccination doses 
or per million population. For denominator 3, we used administered doses for first 
dose of Hepatitis B vaccines (HepB) which administered within 24h after birth and 
vaccination coverage to estimate the number of live births. The numerator was cases 
who died within 28 days after birth. 
4.4.4 Disproportionality analysis of JE vaccines 
For the detection of SDRs, we used PRR, BCPNN, and GPS. The threshold of PRR 
was LB95 (PRR) ≥1 & a >3; for BCPNN it was the lower limit of 95% CI of IC >1 
& a>3; for GPS it was EB05>2 & n>3.  
Since DPAs require pairs consisting of a vaccine and a diagnosis, we excluded 
cases without enough clinical diagnoses. For cases diagnosed as common and minor 
adverse reactions, with mixed symptoms of fever, local redness, local swelling, and 
other minor local or systematic symptoms, we used the common reaction as one 
diagnosis. We also excluded cases of concurrent vaccines.  
4.5 Statistical analysis  
All calculations were performed using R software, version i386 3.2.3, and the epitools 
package was used to calculate CIs. 95% CIs were obtained using Wilson’s formula, 
which approximates the exact method for Poisson rates (study II, III and IV). With 
the package PhVID, SDRs were calculated by R (version i386 3.0.3; accessed: 
http://www.r-project.org/). 
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4.6 Ethical considerations  
The study protocol was reviewed and approved by the China CDC. Informed 
consent is routinely obtained from all vaccine recipients in China. When vaccine 
recipients visit vaccination clinics, nurses will do a general health screening and 
provide an informed consent to the individual or caregiver before vaccine 
administration. Like VAERS in US, CNAEFIS is considered part of a public health 
activity, and MoH and CDC are public health authorities collecting this data, thus 
informed consent was not required in case of the passive reporting of AEFIs. The 
identities of all individuals and establishments in CNAEFIS were kept confidential.  
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5 RESULTS 
5.1 Overview of CNAEFIS 
Since the establishment of CNAEFIS, AEFI data have been used extensively by the 
Chinese national vaccine regulatory authorities (primarily, CFDA and MOH) to 
study the safety of vaccines used in China. For example, using AEFI data from 
CNAEFIS, NIP and ADR analyzed safety data for the novel 2009 A(H1N1) 
influenza vaccine and the JEV-L vaccine, both of which were manufactured in 
China. An important purpose of passive AEFI surveillance is to detect emerging 
vaccine safety signals. With the development of CNAEFIS, NIP scientists detected 
an increased incidence of anaphylactic shock after the administering of a 
manufacturer’s HepA live attenuated vaccine in 2011 and 2012 (unpublished data). 
Although there was not enough evidence to show that this vaccine did cause an 
increased incidence of anaphylaxis shock, following discussions between the CFDA 
and the manufacturer, the manufacturer decided to withdraw its product from the 
market pending further investigation.  
The identification of vaccination medical practice errors and related adverse 
reactions is of great importance, because these errors are preventable and have the 
potential to derail the benefits of the immunization program. Between 2008 and 
2013, about 1% of AEFI cases in CNAEFIS were identified as program errors, 
primarily related to the MMR and BCG vaccinations.  
5.1.1 Descriptive analysis of CNAEFIS database, 2008–2013  
5.1.1.1 Reporting over time 
From 2008 and 2013, CNAEFIS received 439,693 AEFIs reports, with an average 
of 457 reports per 100,000 surviving infants per year. The number of AEFIs has 
increased by more than 30% every year since 2009. The AEFI general program 
indicator—the ratio of AEFIs per 100,000 surviving infants per year— increased 
about six-fold from 2008–2013 (Figure 8). 
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Figure 8 AEFI/ serious AEFI and ratio of AEFIs/serious AEFI per 100,000 surviving infants 
per year, 2008–2013 
Since 2010, AEFI cases have been divided into serious and non-serious. An 
average of 973 (range of 892–1152) AEFIs were identified as serious per year during 
2011–2013, with no significant difference among the annual ratios of serious AEFIs 
per 100,000 surviving infants (χ2 = 0.2751; P= 0.8715).  
5.1.1.2 Age and gender distribution 
Since most immunizations are administrated to infants and young children, more 
than 60% of AEFIs were reported among ≤1-year-olds. Age distribution by year was 
similar, except in 2009 when the A(H1N1) influenza vaccination campaign also 
targeted adults. The proportion of AEFIs among ≥7-year-old was higher than other 
years (Figure 9). The ratio of male to female was 1.4:1 (range 1.4:1–1.3:1).  
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Figure 9 AEFIs by age group, 2008–2013 
5.1.1.3 Vaccine distribution 
Due to the Chinese national immunization schedule and total of two to four doses 
of some vaccines, the most frequent AEFI were reported after DTP (including 
Diphtheria, Tetanus, and Acellular Pertussis combined vaccine [DTaP] and DTwP) 
vaccination. Routine MCV immunization schedule is 2 doses for children. However, 
in September 2010, China launched a national MCV SIA and vaccinated more than 
100 million children during the 10-day campaign. Also, with the development of the 
measles elimination program in China, MCV SIAs were conducted at the subnational 
levels from 2011–2013. These events led to MCV being listed on the vaccine with 
second most frequent AEFI reports (Figure 10). 
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Figure 10 AEFIs by vaccine, 2008–2013 
DTP: Diphtheria Tetanus and Pertussis Combined Vaccine; MCV: Measles Containing Vaccine; MenV: 
Meningococcal Vaccine; DT: Diphtheria and Tetanus combined vaccine; JE: Japanese Encephalitis vaccine; Hib: 
Haemophilus Influenza Type B Polysaccharide Conjugate Vaccine; HepB: Hepatitis B vaccine; InfV: Influenza Vaccine 
(including 2009 A(H1N1) influenza vaccine); PenV23: 23-valent Pneumococcal Polysaccharide Vaccine; PV: Poliomyelitis 
Vaccine; HepA: Hepatitis A vaccine; VarV: Varicella Vaccine; BCG: Bacilli Calmette-Guérin Vaccine; RabV: Rabies 
Vaccine for human use; RotV: Rotavirus Vaccine.  
5.1.1.4 Classification of causality assessment distribution 
Most of the AEFIs reported were common vaccine reactions, such as fever, local 
redness, and local duration (Figure 11). An average of 8.8% (range: 6.5%–13.5%) of 
AEFIs were classified as rare vaccine reactions following an investigation and a 
causality assessment. No vaccine quality events were reported. 
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Figure 11 AEFIs by classification, 2008–2013 
A total of 155 program error-related AEFIs were reported over 6 years from 
2008–2013. In 155 of the program error cases, 102 (65.8%) AEFIs were related to 
the BCG vaccination. 
5.1.1.5 Outcomes of AEFI cases 
Of all AEFIs, 98.4% (432,645) recovered or improved without sequale. 0.1% (304) 
AEFIs were with sequele. 0.1% (614) cases died, and 1.4% (6130) cases were 
unknown or lost to follow-up.  
The annual number of AEFI-associated deaths ranged from 30 in 2008 to 166 in 
2013, on average of 102 deaths per year. In all fatal cases, 17 different vaccines were 
involved, with the most frequent vaccines being HepB, BCG, DTP, OPV, and MCV 
(Figure 12). 
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Figure 12 Number of AEFI-associated deaths by vaccine, 2008–2013 
5.1.2 System attributes of CNAEFIS 
5.1.2.1 Simplicity 
The surveillance flowchart is shown in Figure 7. The vaccine recipients or their 
guardians are advised to report AEFIs by calling or visiting the vaccination clinic or 
local county CDC where they received the vaccine. The physicians in vaccination 
clinics or county CDCs will gather information according to the AEFI reporting 
form (Appendix 1) and give their professional advice to the patients. The trained 
staff in county CDCs, usually in the immunization department, will verify the 
information and enter it into the CNAEFIS database. There are also built-in quality 
control mechanisms when the data is entered into the online system. If there is a 
need to start an investigation, the online system will generate the investigation form 
accordingly and send reminders to the county CDC to start investigating. If the cases 
are investigated, the members of the investigation panel must follow the national 
guidelines, and all the information in the AEFI investigation form (Appendix 2) is 
to be entered into the database. For serious cases, the trained staff in prefectural and 
provincial CDCs must recheck the case information. 
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The reporters are expected to gather all information related to the reporting and 
investigation in accordance with the reporting and investigation forms. The quality 
check is to be done by the online system and the higher-level CDCs. The use of this 
online system is easy; however, the investigation and causality assessment are 
difficult. For serious cases, this process is done by an expert panel. Sometimes, 
several meetings of the panel will be organized, and more complex clinical materials 
and examinations will be collected so as to generate the final result.  
5.1.2.2 Flexibility 
There are restrictions on how many vaccines can be included in one CNAEFIS 
report. The maximum number of suspected vaccines for one case is 3 concurrent 
vaccines. There are no restrictions on which events should be included in a report. 
In the analysis, the most serious events will be chosen. When new vaccines are 
introduced, the NIP’s administrator will simply add it to the database, and this would 
then become available to all levels of CDCs.  
Flexibility can be evaluated by retrospectively observing how a system has 
responded to a new demand. In the initial development period, CNAEFIS served as 
the AEFI surveillance system for the pandemic A(H1N1) influenza vaccination in 
2009 and the measles SIAs in 2010. During the 2009 pandemic influenza vaccination 
campaign, the CNAEFIS collected information on 8067 AEFIs from 89.6 million 
doses of vaccine from September 21, 2009, through March 21, 2010(Liang et al., 
2011). In September 2010, over 10 days of measles SIA, there were 15,330 reported 
cases of AEFIs(Wu et al., 2012). The CNAEFIS experienced these two 
immunization campaigns after its establishment, which could demonstrate its 
flexibility. Currently, the data linkage between CNAEFIS and the immunization 
registry is under consideration. 
5.1.2.3 Sensitivity and PVP 
In CNAEFIS, true vaccine reactions can be derived through a causality 
assessment(China MoH & China FDA, 2010). Nine pairs of vaccine-adverse 
reactions were studied. The administered doses varied by vaccine from 8 million per 
year (VarV) to 72.2 million per year (OPV). A total of 3835 AEFI cases were 
included in this study from reports submitted in 2008–2013, of which 3727 were 
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judged to be vaccine reactions. Most of the reports were related to BCG suppurative 
lymphadenitis (Table 14).  
Table 14 Administered doses, expected incidence rates, and frequency of selected 
AEFIs and vaccine adverse events in China, 2008–2013 
Vaccines Events 
Administered 
doses # 
Expected 
incidence * AEFIs  Rare vaccine reactions 
(millions) (/doses) 2008–2009 2010–2013 2008–2009 2010–2013 
BCG 
Suppurative lymphadenitis 
101 
10/104 685 2634  671 2610 
Disseminated BCG infections 1.56/106 3 34  3 34 
HepB Anaphylaxis 343 1.1/106 8 19  5 18 
OPV VAPP 433 2-4/106 25 88  25 88 
MCV 
Febrile seizures 
263 
3/103 - 165  - 134 
Thrombocytopenia 3/104 - 130  - 105 
VarV Febrile seizures 32 4-9/104 - 33  - 25 
InfV 
GBS 
46 
1-2/106 - 5  - 3 
Anaphylaxis 0.7/106 - 6  - 6 
# For BCG, HepB, and OPV, the administered doses were calculated from 2008–2013. For other vaccines, the 
administered doses were calculated from 2010–2013. 
*WHO guidelines(WHO/WPRO, 2013),(WHO, 2000) 
Reporting sensitivity varied with the vaccine and the related reactions (Table 15). 
From 2008–2013, the sensitivity increased for all. Among all the reactions studied, 
disseminated BCG infections and VAPP were specific reactions related to BCG and 
OPV. Therefore, the AEFI cases of disseminated BCG infections and VAPP were 
all classified as vaccine reactions after a causality assessment, and the PVP was 100% 
from 2008–2013 (Table 15). There were no statistical differences among all the nine 
pairs in both periods of 2008–2013 and 2010–2013. 
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Table 15  Reporting sensitivity (%) and PVP (%) of selected outcomes in CNAEFIS, 
2008–2013 
Vaccines Events 
2008  2009  2010  2011  2012  2013 
S P S P S P S P S P S P 
BCG 
Suppurative lymphadenitis 1.6 99.6  2.5 96.9  3.0 98.2  4.5 99.1  4.4 99.4  3.2 99.4 
Disseminated BCG infections 4.0 100  7.8 100  15.3 100  41.4 100  24.6 100  44.9 100 
HepB Anaphylaxis 3.8 100  5.5 50.0  6.1 100  6.0 100  7.2 100  7.3 83.3 
OPV VAPP 4.4 100  5.5 100  5.3 100  9.3 100  4.8 100  8.7 100 
MCV 
Febrile seizures - -  - -  0.02 79.0  0.02 80.8  0.01 88.2  0.01 86.4 
Thrombocytopenia - -  - -  0.1 79.6  0.1 89.5  0.2 73.3  0.2 84.4 
VarV Febrile seizures - -  - -  0.04 100  0.1 88.9  0.1 60.0  0.1 75.0 
InfV 
GBS - -  - -  5.2 100  8.1 100  0 0  0 0 
Anaphylaxis - -  - -  0 0  23.0 100  25.2 100  23.4 100 
#S:Sensitivity; P: PVP. 
5.1.2.4 Timeliness 
CNAEFIS adopted an online reporting scheme to timely captured all AEFIs.  
Besides the online scheme, the time interval between reporting and event onset, 
reporting and investigation, could also show the timeliness of CNAEFIS. All reports 
were submitted within 2 years of the event onset by reporters, with the range of 
reporting time intervals in 2008–2013 being 0–730 days (Table 16). The median of 
all reporting time intervals in 6 years was 1 day. The timeliness of reporting has 
certainly improved, and the proportion of time lags (reported more than 2 days after 
event onset) was decreased from 25.7% in 2008 to 16.7% in 2013. 
Table 16 Reporting time intervals in CNAEFIS, 2008–2013 
Reporting time interval (days) 2008 2009 2010 2011 2012 2013 
Range 0-420 0-323 0-618 0-671 0-481 0-537 
Median 1 1 1 1 1 1 
Mean 5.9 5.2 4.7 4.2 3.6 3.3 
Proportion of time lags 25.7 25.9 21.8 20.4 18.3 16.6 
The national guidelines lay out certain requirements regarding the timeliness of 
investigations: Any AEFIs except common adverse reactions with a clear diagnosis 
(e.g., fever, redness and swelling at the injection site, scleroma) should be 
investigated. For AEFIs that need to be investigated, the county CDC should start 
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the investigation and collect the relevant data within 48 hours of receiving the report. 
The surveillance indicators in the national guidelines require that the rate of AEFIs 
that need investigation within 48 hours after reporting ≥ 90% (at the provincial level 
in 1 year). 
All cases needing investigation were investigated within almost 1 year, with the 
longest time interval being 367 days in 2012 (Table 17). 99.9% of the investigations 
were started with 100 days after reported into the CNAEFIS. The median of the 
investigation time interval in 3 years was 0 days, and the proportion of time lags also 
decreased with time from 1.1% in 2011 to 0.5% in 2013.  
Table 17 Investigation time intervals in CNAEFIS, 2011–2013 
Investigation time interval (days) 2011 2012 2013 
Range 0–206 0–367 0–179 
Median 0 0 0 
Mean 0.3 0.3 0.4 
Proportion of time lags 1.1 0.9 0.5 
5.1.2.5 Data quality  
Proportions of unknowns or errors in key variables 
In CNAEFIS, there are several key variables in the reporting and investigation 
forms; therefore, the proportion of missing/unknown/error values of key variables 
could be proxy indicators for an indirect measure of data quality. This analysis 
included 6 key variables: date of vaccination, birth date, onset date, dose of suspected 
vaccine, classification, and outcome. As the CNAEFIS developed, several quality 
controls were added to it, such as the time interval checked when entering the 
information online. For the age check, there was no error or unknown (missing) 
value. The proportions of other indicators, such as vaccination doses and time 
intervals between vaccination date and onset date, decreased from 2008–2013 (Table 
18).  
To improve the data quality of the AEFI surveillance, during the annual national 
AEFI surveillance meetings or workshops, a key session was conducted on data 
quality recheck. Also, follow-ups of serious cases were required by the provincial 
CDCs. The proportions of unknowns or errors in the causality assessment 
classification and outcomes also decreased over 6 years (Table 18). 
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Table 18  Percentage of unknowns or errors of key variables in CNAEFIS, 2008–2013 
Unknowns or errors 2008 2009 2010 2011 2012 2013 
Time interval between vaccination date and onset date 0.4 0 0.01 0.01 0 0 
Vaccination doses 0.4 0.01 0.02 0.01 0.004 0.004 
Causality assessment classification 3.1 0.9 0.3 0.1 0.03 0.04 
Outcome 9.1 1.9 1.6 0.8 0.8 0.7 
5.1.2.6 Representativeness 
In CNAEFIS, the proportion of countries reporting AEFI cases could be an 
indicator of geographic representativeness. The proportion of counties that reported 
AEFIs in 2008 was 34.3%, which increased to 94.6% in 2013. In the eastern and 
middle areas, the proportions of cases reported by counties were over 90% since 
2010 and steadily increasing to 100%. The proportion of reports from the western 
area also increased over 6 years, reaching 87.5% in 2013 (Figure 13). 
In CNAEFIS, the agency responsible for reporting was the county CDC. Usually, 
only one CDC institute is set up in each county to perform all disease control and 
prevention work. Therefore, the proportion of counties reporting cases of AEFIs is 
also the county’s CDC participation rate, which reflects acceptability among CDCs.  
 
Figure 13 Proportion of counties with at least one AEFI report by year and geographic 
areas, 2008–2013 
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5.2 Recipient VAPP in CNAEFIS, 2010–2015 (Study II) 
5.2.1 Characteristics of VAPP cases 
A total of 157 recipient VAPP cases were reported in CNAEFIS during 2010–2015. 
The male to female ratio was 8.2:1, and 151 cases (96.2%) were of children less than 
6 months of age. 24 of the 31 provinces and the Xinjiang Production and 
Construction Crops in China reported recipient VAPP; 51.6% (81 cases) were 
reported from eastern regions, 38.9% (61 cases) from middle regions, and 9.6% (15 
cases) from western regions. The number of recipients VAPP cases by year, gender, 
and age are summarized in Table 20. Perianal abscess was reported in 24.8% (39) of 
the 157 recipient VAPP cases, all of which were male infants.  
Table 19 Number of recipients VAPP cases by gender and age, 2010–2015, China 
  
2010 2011 2012 2013 2014 2015 Total 
N % N % N % N % N % N % N % 
Gender               
Male 23 100 30 93.8 17 77.3 35 87.5 21 87.5 14 87.5 140 89.2 
Female 0 0 2 6.2 5 22.7 5 12.5 3 12.5 2 12.5 17 10.8 
AgeͧMonthͨ               
1–3 months 17 73.9 24 75.0 17 77.3 29 72.5 21 87.5 14 87.5 122 77.7 
4–6 months 5 21.7 7 21.9 4 18.2 8 20.0 3 12.5 2 12.5 29 18.5 
>6 months 1 4.4 1 3.1 1 4.5 3 7.5 0 0 0 0 6 3.8 
Total 23   32   22   40   24   16   157   
The vaccine associated with all recipient VAPP cases in CNAEFIS from 2010–
2015 was tOPV, which was recommended in the national immunization schedule 
during the study period. Among all 157 recipient VAPP cases, 89.8% (141) of the 
cases occurred after the infants received their first dose of OPV; 7.6% (12) cases 
occurred after the second dose; and 2.6% (4) cases occurred after the third or more 
doses. None of the recipient VAPP cases had a history of IPV vaccination. 
Information on the serotype of poliovirus isolation was reported in 139 cases 
(88.5%). The type II poliovirus vaccine strain was isolated from 27 cases; type III 
was isolated from 25 cases; type I was isolated from 16 cases; and multiple serotypes 
were isolated from 25 cases. Three recipient VAPP cases reported vaccine strain 
isolation but did not report any of the specific serotypes. 15 cases did not report 
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results of vaccine strain isolation. The results of serotype isolation from 46 cases 
(29.3%) were negative (Table 20).  
Table 20 Number of recipients VAPP cases by OPV vaccination history and serotype 
of vaccine strains, 2010–2015, China 
  
2010 2011 2012 2013 2014 2015 Total 
N % N % N % N % N % N % N % 
OPV vaccination history 
1st dose 22 95.6 29 90.6 20 90.9 34 85.0 21 87.5 15 93.8 141 89.8 
2nd dose 0 0.0 3 9.4 2 9.1 3 7.5 3 12.5 1 6.2 12 7.6 
≥ 3 doses 1 4.4 0 0.0 0 0.0 3 7.5 0 0.0 0 0.0 4 2.6 
Serotype of vaccine strains  
II 4 17.4 6 18.7 2 9.1 5 12.5 6 25.0 4 25.0 27 17.2 
III 2 8.7 9 28.1 1 4.5 6 15.0 4 16.7 3 18.8 25 15.9 
I 4 17.4 3 9.4 2 9.1 4 10.0 1 4.2 2 12.5 16 10.2 
II + III 3 13.0 2 6.3 3 13.6 3 7.5 1 4.2 2 12.5 14 8.9 
I + III 1 4.4 0 0.0 1 4.5 2 5.0 1 4.2 0 0.0 5 3.2 
I + II + III 0 0.0 0 0.0 1 4.5 1 2.5 2 8.3 0 0.0 4 2.6 
I + II 0 0.0 0 0.0 0 0.0 1 2.5 0 0.0 1 6.2 2 1.3 
Negative 6 26.1 7 21.9 8 36.4 14 35.0 7 29.2 4 25.0 46 29.3 
Unclassified* 0 0.0 1 3.1 2 9.1 0 0.0 0 0.0 0 0.0 3 1.9 
Unreported 3 13.0 4 12.5 2 9.1 4 10.0 2 8.3 0 0.0 15 9.6 
Total 23   32   22   40   24   16   157   
*Unclassified: These cases reported positive results but not specific serotypes. 
Of the 157 cases, 118 (75%) reported fever between 3–35 days following the 
vaccination, while the others did not provide enough temperature information to 
assess fever. One recipient VAPP case died and another recovered; the remaining 
155 cases experienced physical disabilities—107 cases reported residual paralysis on 
the 60-day follow-up visit, of which 55.1% (59) cases involved a single limb.  
5.2.2 Rate calculation 
Using the administered OPV vaccination doses as the denominators, the incidence 
of recipient VAPP in the study period was 0.4 per million OPV doses with a range 
of 0.2 per million OPV doses–0.6 per million OPV doses in 2013. If we use the total 
population and birth rates to approximate the number of births, the recipient VAPP 
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per million births can be estimated; accordingly, the recipient VAPP per million 
births ranged from 1.0–2.4 in 2010–2015 (Table 21).  
Table 21 Risk of recipient VAPP in China by year, 2010–2015 
 
Recipient 
VAPP 
Million 
OPV 
doses 
Recipient 
VAPP per 
million OPV 
doses 95% CI  
Total 
population 
(million) 
Birth 
rates 
(%) 
Estimated 
births (in 
millions) 
Recipient 
VAPP per 
million 
births 95% CI 
2010 23 66.6 0.3 0.2–0.5  1340.9 11.9 16.0 1.4 0.9–2.2 
2011 32 69.6 0.5 0.3–0.6  1347.4 11.9 16.1 2. 0 1.4–2.8 
2012 22 73.1 0.3 0.2–0.5  1354.0 12.1 16.4 1.3 0.8–2.0 
2013 40 72.5 0.6 0.4–0. 8  1360.7 12.1 16.4 2.4 1.7–3.3 
2014 24 71.9 0.3 0.2–0.5  1367.8 12.4 16.9 1.4 0.9–2.1 
2015 16 70.1 0.2 0.1–0.4  1374.6 12.1 16.6 1.0 0.6–1.6 
Total 157 423.8 0.4 0.3–0.4  - - 98.4 1.6 1.4–1.9 
 After the first dose, 141 recipient VAPP cases occurred, with an incidence of 1.3 
per million doses, which is 1 in 764,107 vaccinations. The risk after the first dose 
was substantially higher than after the second and third doses (Table 22). For the 
second dose, the risk was about 1 in 9 million doses, while it was 1 in 27 million 
doses for the third dose or more. 
Table 22 Risk of recipient VAPP cases in China by dose, 2010–2015 
  No. of cases Vaccination doses Incidence rates (per million doses) 95% CI 
1st dose 141 107.7 1.3 1.1–1.5 
2nd dose 12 108.1 0.1 0.1–0.2 
≥ 3rd dose 4 107.7 0.04 0.01–0.1 
5.3 AEFI-associated deaths in CNAEFIS, 2010–2015 (Study III) 
5.3.1 Demographic distribution of deaths following vaccination 
A total of 753 AEFI-associated deaths were reported during 2010–2015. AEFI-
related deaths peaked in 2013–2014 (Figure 14). The proportion of neonatal deaths 
varied from 5.0% (2010, 2011) to 16.5% (2013). In 2012–2014, the proportion 
exceeded 10.0%. All deaths were reported from locations within mainland of China.  
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Figure 14 Reports of AEFI-associated deaths by year, 2010-2015 
During the first quarter of the year (January to March), there were 249 (33.1%) 
AEFI-associated deaths, followed by 234 (31.1%) during the fourth quarter, 140 
(18.6%) and 130 (17.3%) during the third and second quarters, respectively. Fifty-
one AEFI-associated deaths were reported in December 2013, and 34 (66.7%) of 
these were related to HepB vaccine, administered alone or with other vaccines 
(Figure 15). 
 
Figure 15 Seasonal distribution of AEFI-associated deaths, 2010-2015 
Of AEFI-associated death reports, 293 (38.9%) were females, 635 (84.3%) were 
aged <1 year, and 82 (10.9%) cases were aged 1–4 years (Table 23). The median age 
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in the group aged <1 year was 68 days, and the median age in the group aged 1–4 
years was 1 year old.  
Table 23 AEFI-associated deaths by year of death, age and gender, 2010-2015 
 
<1 1–4 5–9 10–17 18–64 ≥65 Total 
N Female % N 
Female 
% N 
Female 
% N 
Female 
% N 
Female 
% N 
Female 
% N 
Female 
% 
2010 84 44.05 20 50.00 3 0 2 50.00 9 44.44 1 0 119 43.70 
2011 90 44.44 8 37.50 1 0   1 100 1 100 101 44.55 
2012 79 27.85 12 25.00 2 50.00   1 0.00 1 0 95 27.37 
2013 139 36.69 13 38.46   2 0 2 50.00 2 50.00 158 36.71 
2014 141 39.01 15 40.00 3 0     1 100 160 38.75 
2015 102 42.16 14 42.86 1 100   2 0.00 1 0 120 41.67 
Total 635 39.06 82 40.24 10 20.00 4 25.00 15 40.00 7 42.86 753 38.91 
Sixty-Nine different vaccines or vaccine combinations were associated with 
reported deaths. The most common vaccines or vaccine combinations were 1) HepB 
(alone) (182, 24.2%), 2) Bacillus Calmette Guerin (BCG) and HepB (116, 15.4%), 3) 
oral poliomyelitis vaccine (OPV) and diphtheria, tetanus and acellular pertussis 
combined vaccine (DTaP) (84, 11.2%), 4) BCG (alone) (61, 8.1%), and 5) DTaP 
(alone) (31, 4.1%) (Table 24).  
Table 24 AEFI-associated deaths by vaccine and vaccine combination, and the 
causality assessment classification, 2010-2015 
Vaccines and  
vaccine combinations Vaccine reaction Immunization error Coincidental events Indeterminate Total 
HepB 13  163 6 182 
BCG + HepB 16 1 92 7 116 
OPV + DTaP 13  65 6 84 
BCG 34  24 3 61 
DTaP 7  22 2 31 
OPV   26 1 27 
HepB + OPV 2  17  19 
RabV 7  8 3 18 
JEV-L 4  12 1 17 
OPV + DTaP + Hib 1  12  13 
61 other vaccines  
and vaccine combinations 23  153 9 185 
Total 120 1 594 38 753 
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5.3.2 Results of the causality assessments  
Autopsies were conducted in 257 (34.1%) cases. According to the causality 
assessment, 120 (15.9%) deaths were classified as vaccine reactions, 594 (78.9%) 
deaths were due to coincidental events, 38 (5.1%) deaths were classified as 
indeterminate, and 1 (0.1%) death was due to an immunization error-related reaction. 
No deaths were classified as due to vaccine quality defect-related reactions or 
immunization anxiety-related reactions during the study period (Table 24). 
5.3.2.1 Vaccine reactions and deaths 
One hundred-twenty deaths were classified as vaccine-related reactions, with an 
estimated rate of 0.04 per million doses, using the all vaccination doses as the 
denominator. Anaphylactic reactions accounted for 55 cases, in which 53 cases 
occurred within 1 day after vaccination. Anaphylactic reactions take 45.8% of 
vaccine-related reactions, with estimated rates of 0.02 per million vaccination doses. 
Nineteen vaccines or vaccine combinations were related to anaphylactic reactions. 
The average numbers of deaths per year due to anaphylactic reactions post-
vaccination was about 9 (range: 6–13 cases). The most common vaccine and vaccine 
combinations associated with vaccine reactions were HepB (by itself) (12 cases), 
OPV and DTaP (10 cases), BCG and HepB (9 cases).  
There were 39 BCG-related deaths (estimated rate: 0.37 per million BCG 
vaccination doses, including 34 BCG-alone cases and 7 BCG+HepB concurrently 
vaccinated cases). Thirty BCG-related deaths were classified as the result of 
disseminated BCG infections, and nine cases were due to BCG lymphadenitis or 
other infections (recurring). One death due to vaccine associated Vaccine-Associated 
Paralytic Poliomyelitis (VAPP) was reported. One case of hemorrhagic measles was 
reported in which the autopsy and laboratory findings confirmed that this was related 
to the vaccine virus.  
Thirteen deaths were attributed to neurological, illness, of which six cases were 
meningitis (aseptic or viral), four cases were acute disseminated encephalomyelitis, 
two cases were encephalopathy, and one case was epilepsy. Seven vaccines and 
vaccine combinations were administered in these cases, of which the rabies vaccine 
was the most common vaccine, accounting for five deaths. The average number of 
deaths per year was three, with a range of two to four in the study period. 
Nine deaths were confirmed as status thymicolymphaticus (STL) after autopsies. 
Other two cases were diagnosed as malaise and vomiting post vaccination, and both 
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died of aspiration asphyxia. In all above 11 cases, vaccination was not the direct cause 
of death. However, in the causality assessment, the expert committee concluded that 
vaccination contributed to these deaths and classified the deaths as vaccine-related 
reactions. 
5.3.2.2 Immunization errors 
Only one death was classified as immunization error-related reaction. In this case, 
the baby had been diagnosed with severe malnutrition prior to immunization, and 
the immunization nurse had failed to perform a physical examination when the 
parents requested that the infant be vaccinated. The direct cause of death was severe 
malnutrition, respiratory failure, and cardiac failure, not vaccine related. 
5.3.2.3 Coincidental events 
After causality assessment, 594 deaths were classified as coincidental events. The 
most common causes of death were asphyxia, sudden infant death syndrome (SIDS), 
pneumonia (neonatal and infant), congenital heart diseases, and vitamin K deficiency 
(which could lead to internal bleeding). In these cases, 577 (97.1%) deaths occurred 
within 15 days after vaccination. Sixty vaccines and vaccine combinations were 
administered, the most common were HepB (alone) (163 cases), BCG and HepB (92 
cases), OPV and DTaP (65 cases), OPV (alone) (26 cases), and BCG (alone) (24 
cases). In 574 (96.6%) cases, the patients aged < 5 years.  
5.3.2.4 Indeterminate cause of death 
During 2010–2015, 38 deaths were classified as due to indeterminate causes. There 
was no clear clinical diagnosis in 25 (65.8%) cases, and for the rest cases there was 
insufficient evidence available to conduct the causality assessment. All 38 deaths 
occurred within one-week post-vaccination, and 34 (89.5%) cases aged < 5 years.  
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5.3.3 Risk estimation of deaths after vaccination 
Using all administered doses as the denominator, the average rate of AEFI-
associated death was 0.26 per million vaccination doses (range: 0.20-0.32) during the 
study years. Using population data as the denominator, the average rate was 0.09 per 
million population (range: 0.07-0.12) (Table 25). 
Table 25 Estimated overall AEFI-associated death rates using different denominators, 
2010-2015 
Year No. of deaths 
All 
vaccination 
doses 
(in millions) 
Estimated rate by vaccination dose 
 
Total 
population 
(in millions) 
Estimated rates by total population 
Death rate 
(per million 
vaccination doses) 
95% CI 
Death rate 
(per million 
population) 
95% CI 
2010 119 427.88 0.28 0.23–0.33  1340.91 0.09 0.07–0.11 
2011 101 461.44 0.22 0.18–0.27  1347.35 0.07 0.06–0.09 
2012 95 478.97 0.20 0.16–0.24  1354.04 0.07 0.06–0.09 
2013 158 489.21 0.32 0.27–0.38  1360.72 0.12 0.10–0.14 
2014 160 495.74 0.32 0.27–0.38  1367.82 0.12 0.10–0.14 
2015 120 504.23 0.24 0.20–0.28  1374.62 0.09 0.07–0.10 
Total 753 2857.49 0.26 0.25–0.28  8145.46 0.09 0.09–0.10 
Neonatal deaths accounted for 10.4% (78 cases) of all reported AEFI-associated 
deaths. The highest rate of reported neonatal deaths after vaccination occurred in 
2013 (1.48 per million live births). The rate of neonatal deaths after vaccination in 
2010–2011 was significantly different from 2013–2014(Table 26).  
Table 26 Estimated neonatal deaths rates after vaccination, 2010-2015 
Year 
No. of 
Neonatal 
death 
Vaccination 
dose of 1st 
dose of 
HepB (in 
millions) 
Vaccination 
coverage % 
Estimation 
of live 
births (in 
millions) 
Neonatal 
death rates 
(per million 
births) 
95% CI 
2010 6 17.16 99.81 17.19 0.35 0.13–0.76 
2011 5 17.5 99.86 17.53 0.29 0.09–0.67 
2012 10 18.68 99.87 18.71 0.53 0.26–0.98 
2013 26 17.48 99.77 17.52 1.48 0.97–2.17 
2014 21 15.18 99.84 15.2 1.38 0.86–2.11 
2015 10 15.75 99.87 15.77 0.63 0.30–1.17 
Total 78 101.75 - 101.91 0.77 0.61–0.96 
During 2013–2014, 47 neonatal deaths were reported and 44 (93.6%) of those 
were related to HepB (with concurrent vaccines). In the causality assessment 
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however, only one of the reported deaths was considered causally related to 
vaccination. During 2010-2015, we identified 182 reports of AEFI-associated deaths 
after vaccination with HepB was the only vaccine used. Of these, 13 were causally 
related to vaccination in the causality assessment. The annual numbers of causally 
related deaths during the period were 2,3,2,1,3,2, respectively. 
5.4 Post-marketing vaccine safety of JE vaccines (Study IV) 
5.4.1 AEFIs following JEV-L and JEV-I 
A total of 34,879 AEFI cases associated with JE vaccines were collected by 
CNAEFIS, 2008–2013; 95.2% (33,186) cases were related to JEV-L. JE vaccines 
were administered concurrently with one or more other vaccines in 13,592 (39.0%) 
of cases (39.9% for JEV-L and 19.9% for JEV-I, respectively). Both for JEV-L and 
JEV-I, the most common concurrently administered vaccine was measles containing 
vaccines, with a proportion of 24.8% for JEV-L (8226 cases in 33,186 JEV-L-related 
cases) and 17.5% for JEV-I (297 cases in 1693 JEV-I-related cases).  
JEV-L was listed as the first suspected vaccine in 23,627 (71.2% of the JEV-L-
associated AEFI cases). JEV-I was the first suspected vaccine in 1357 (80.2% of 
JEV-I-associated cases) (p < 0.05). There were more cases in males than in females, 
with a sex ratio of 1.3:1. More cases occurred in 1 years of age, with 66.4% of JEV-
L and 60.8% of JEV-I (Table 27). Of all 34,879 AEFI cases, 361 (1.0%) AEFI cases 
were defined as serious. There were 146.7 million vaccination doses collected of JE 
vaccines from 2010 to 2013, in which 95.1% (139.5 million doses) was JEV-L. Since 
both JEV-L and JEV-I could be used as NIP vaccines and voluntary vaccines, among 
all JE vaccination doses, 91.5% (134.3 million doses) were used as NIP vaccines, 
including 133.1 million of JEV-L and 1.2 million of JEV-I. Using the doses 
administered from 2010 to 2013 as denominators, the overall reporting rates of 
AEFIs per million were 214.4 for JEV-L and 176.9 for JEV-I (RR: 1.2, 95% CI: 1.1–
1.3). the annual reporting rates increased substantially from 2010 to 2013 (Table 28). 
During 2010–2013, 271 serious AEFIs were reported. The overall reporting rates of 
serious AEFIs were 1.8 per million doses for JEV-L and 2.8 per million doses for 
JEV-I (RR: 0.7, 95% CI: 0.4–1.0).  
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Table 27 Characteristics of AEFIs after JEV-L and JEV-I vaccination, China, 2008-
2013 
 
JEV-L  JEV-I 
As most suspected* 
N=23627 (%) 
others 
N=9559(%)  
As most suspected 
N=1357(%) 
Others 
N=336(%) 
Serious Serious 244 1.03 66 0.69  51 3.76 0 0.00 
 Non-serious 23383 98.97 9493 99.31  1306 96.24 336 100.00 
           
Gender Male 13444 56.90 5358 56.05  768 56.60 190 56.55 
 Female 10183 43.10 4201 43.95  589 43.40 146 43.45 
           
Age group ≤1yr 13306 56.32 8712 91.14  710 52.32 320 95.24 
 2-6yrs 10036 42.48 825 8.63  511 37.66 14 4.17 
 ≥7yrs 285 1.21 22 0.23  136 10.02 2 0.60 
* There were at most three suspected vaccines were reported in one AEFI cases, the reporters will put one vaccine 
as the most suspected vaccines. JE as most suspected means JE was most suspected related to adverse events 
in the reports. 
Table 28 Number and estimated AEFI reporting rates of after JEV-L and JEV-I by 
severity* of AEFI, China, 2010-2013 
AEFI 
JEV-L  JEV-I Rate ratios 
Non-serious Serious  Non-serious Serious Non-serious Serious 
No. of 
cases 
Reporting 
rates** 
No. of 
cases 
Reporting 
rates 
No. of 
cases 
Reporting 
rates 
No. of 
cases 
Reporting 
rates 
(95% CI) 
2010 2428 75.97 43 1.35  96 33.99 5 1.77 
2.23 
(1.83-2.76) 
0.74 
(0.32-2.17) 
2011 5816 168.51 41 1.19  102 124.86 1 1.22 
1.35 
(1.12-1.65) 
0.85 
(0.19-19.85) 
2012 8495 240.25 69 1.95  756 294.80 13 5.07 
0.82 
(0.76-0.88) 
0.38 
(0.22-0.72) 
2013 12908 343.11 98 2.60  308 295.79 1 0.96 
1.16 
(1.04-1.30) 
2.37 
(0.54-54.72) 
2010-
2013 
29647 212.60 251 1.80  1262 174.15 20 2.76 
1.22 
(1.15-1.29) 
0.65 
(0.42-1.05) 
*The severity of AEFI were classified according to national AEFI guidelines. Serious AEFIs include, but are not 
limited to, allergic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, localized allergic 
necrotic reaction (Arthus reaction), febrile convulsion, epilepsy, brachial neuritis, polyneuritis, Guillain–Barre 
syndrome, encephalopathy, encephalitis and meningitis, syncope, toxic shock syndrome, and systemic purulent 
infection. 
**Reporting rates: per million vaccination doses given 
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5.4.2 Clinical diagnosis of AEFIs 
Of the 29,831 non-serious AEFIs, (86.4%) were diagnosed as common and minor 
adverse reactions, such as fever, local redness, and swelling. Among serious AEFIs, 
the most frequently reported clinical diagnosis were febrile convulsion (132, 36.6%), 
thrombocytopenic purpura (39, 10.8%), encephalitis and meningitis (29, 8.0%), 
Henoch-Schönlein purpura (28, 7.8%), and anaphylactic shock (25, 6.9%)  (Table 
29). 22 death cases were reported during the study period, only 4 cases were classified 
as related to vaccination due to anaphylactic shock.  
Table 29 Clinical Diagnosis of serious AEFI after the immunization of JEV-L and JEV-
I, China, 2008-2013 
Clinical diagnosis 
JEV-L 
 
JEV-I* 
First suspected,  
N=244 (%) 
Not first suspected,  
N=66(%) 
First suspected,  
N=51 (%) 
Febrile Convulsion 83 34.02 16 24.24  33 64.71 
Thrombocytopenic Purpura 22 9.02 15 22.73  2 3.92 
Encephalitis and Meningitis 23 9.43 5 7.58  1 1.96 
Henoch-Schönlein Purpura 18 7.38 6 9.09  4 7.84 
Anaphylactic Shock 21 8.61 1 1.52  3 5.88 
Apsychia 11 4.51 4 6.06  5 9.80 
Seizure 16 6.56 1 1.52  1 1.96 
Laryngeal Edema 4 1.64 1 1.52  1 1.96 
Acute disseminated encephalomyelitis (ADEM) 5 2.05 0 0.00  0 0.00 
Arthus Reaction 3 1.23 1 1.52  0 0.00 
Guillain Barre Syndrome (GBS) 1 0.41 1 1.52  0 0.00 
Others 37 15.16 15 22.73  1 1.96 
*For JEV-I, there was no cases coded as serious AEFIs when administered in combination with other vaccines. 
5.4.3 SDR detection of JEV-L and JEV-I 
A total of 20,988 AEFIs with complete information on vaccine and diagnosis were 
included in the disproportionality analysis. All three methods, PRR, EB, and 
BCPNN, suggested JEV-I and febrile convulsion as the suspected SDRs (Table 29). 
For JEV-L, there was no diagnosis with disproportionally higher reporting. Based 
on the results of Table 30, using the administered doses from 2010 to 2013 as the 
denominator, the estimated reporting rates of febrile convulsion after JEV-L (as the 
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only vaccine suspected) and JEV-I (as the only vaccine suspected) were calculated: 
0.3 per million doses for JEV-L and 0.4 per million doses for JEV-I (p = 0.5). 
Table 30 Suspected SDR of JE vaccines using 3 DPA methods, China, 2008-2013* 
Methods (Criteria) Results 
PRR (Lower limit of 95% CI of PRR >1 & n >3) JEV-I- Febrile Convulsion 
PRR=7.44, Lower limit of 95% CI =1.59 
 
EB (EB05>2 & n>3) JEV-I- Febrile Convulsion  
EB05=3.27 
 
BCPNN (Lower limit of 95% CI of IC >1 & n>3) JEV-I- Febrile Convulsion 
 Lower limit of 95% CI of IC=1.64 
*PRR: Proportional Reporting Ratios  
EB05: single sided 5% Empirical Bayesian Geometric Mean (EBGM)  
BCONN: Bayesian Confidence Propagation Neural Network  
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6 DISCUSSION 
National AEFI surveillance is a key component of vaccine safety evaluation. China 
CDC developed CNAEFIS, which has served as the national passive surveillance 
system since 2005. So far, it has successfully captured more than 300,000 AEFI cases, 
providing a robust database for vaccine safety evaluation in the Mainland of China. 
Experience and evidence drawn from CNAEFIS has been a vital resource for 
decision-making by Chinese Vaccine Regulatory Agency and related stakeholders. 
6.1 Study strengths and limitations 
National AEFI surveillance is a key part of public health surveillance and it could 
provide evidence for vaccine safety evaluations. CNAEFIS covers all the vaccines 
used in Mainland China, whether manufactured in China or abroad, whether used in 
NIP or in the free market (purchased and used by parents or adults). China is one of 
the most populous countries in the world, with vaccines being used and 
manufactured by the billion every year. Thus, the massive amounts of AEFI data in 
CNAEFIS could provide valuable information on vaccine safety in Mainland China, 
India and some African counties which also used Chinese manufactured vaccines. 
Based on national laws and national AEFI guidelines issued by MoH and CFDA, 
CNAEFIS is the primary tool to collect AEFI cases nationally. The case verification 
from county, prefectural and provincial CDCs and experts committee of causality 
assessment strength the data quality, especially for rare and serious cases. The 
analysis of reporting over time and epidemiological distribution illustrates the 
progress made with vaccine safety monitoring during study years in China.  
To evaluation the vaccine safety in China, three examples were chosen in our 
analysis with various reasons. VAPP is the rare and most serious vaccine reactions 
following Oral polio vaccines, which is used in China for more than 30 years, and 
risk estimation showed that the incidence of recipient VAPP in China was consistent 
with international studies, and with the polio vaccine switch program started in 2016, 
would diminish the VAPP further. Fatalities is also a serious event following 
immunization, especially among neonatal. The widely publicity of Hepatitis B 
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vaccines in the end of 2013, bring public concern on vaccine safety situation in 
China, and our analysis providing reassured information on vaccine safety and the 
peak of fatalities during the media reports was pure reporting boost. The two 
examples will be the important evidence to document how safe immunization risks 
in China. 
Since JEV-L is the first vaccine to be prequalified by the WHO, which is 
produced by domestic vaccine manufactures in China, the safety evaluation of this 
vaccine could benefit not only inside China, but also internationally, especially India, 
Thailand and some Africa counties that imported this vaccine.   
Limitations 
An important limitation of this analysis is that CNAEFIS is a passive surveillance 
system with low sensitivity and the potential underreporting of AEFI cases, which 
could result in reporting bias(Singleton et al., 1999). Reporting of adverse events 
might be influenced by a number of factors, such as clinical seriousness, temporal 
proximity to vaccination and vaccination providers’ awareness and obligation to 
report(Rosenthal & Chen, 1995).  More serious the cases are, and shorter time 
interval between vaccination and occurrence, more likely vaccines could be 
suspected by parents and health providers. Also, the increase of reporting AEFI 
cases might be related to vaccination campaigns during which more vaccination 
doses were used, or after media reports and rose public’s attention on vaccinations. 
Therefore, the vaccine safety signal detected by passive surveillance should be 
considered with caution and used a clue for further studies.  
National AEFI surveillance data is different with researcher-collected data, with 
all vaccination doses were covered and there are no statistical analyses focusing on 
sampling errors. According to experts’ analysis and conclusion(Thygesen & Ersboll, 
2014), validity of epidemiological studies with inclusion of all persons in a population 
followed for decades, should be characterized as completeness and validity of 
variables included. The completeness is whether all individuals (with vaccinations in 
our study) are included. The validity of the variables include is whether the 
information on vaccinated persons are collected and whether the information 
collected is correct.  
In Study I, the only available data on AEFIs in China is currently the CNAEFIS, 
and no another surveillance system dataset is available for comparison. Continuous 
improvement and investigation are needed for more detailed information and 
assessment of the surveillance system. In the future, data completeness could be 
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evaluated by comparing the AEFI database with another data source at local level, 
by capture-recapture method or, by comprehensive medical chart review. However, 
these would be very resource-intensive methods.   
The demand for completeness and validity depends on the research questions. 
Usually, the population-based surveillance data has high completeness, however, the 
analytical studies to address specific vaccination safety question, such as vaccination 
as the exposure and diseases as the outcome, needs high validity(Thygesen & Ersboll, 
2014).   
In Study II, since only cases of recipient VAPP were reported, no contact cases 
were included in our analysis: This could lower the estimated risk for VAPP. Another 
limitation is that since some laboratory data were unavailable in CNAEFIS, cases 
were categorized as VAPP without serotype information, which influence the 
validity of the outcome assessment. In addition, since VAPP cases stand to receive 
government compensation, some cases were classified as VAPP even when the 
laboratory results of the serotypes were negative. Compensation is also given for 
vaccine-related reactions in Mainland China. When an expert panel finds no other 
cause of death in its causality assessment, it might conclude that the vaccine or 
vaccination was a trigger or contributor to the death. In such cases, the families of 
the deceased can apply for compensation. This policy might have increased the 
number of reports of vaccine-related reactions in the present VAPP and deaths 
study. 
Also, one should be cautious when comparing related rates across countries by 
using the incidence estimates in our study. The limitation of denominator-based risk 
estimation includes different resources to identify the vaccine-administered doses 
and unknown background information, which make it difficult to compare the 
observed to the expected, as well as among different settings(Hauben & Zhou, 
2003). In our study, the denominators used were estimated from different data 
resources and one should be cautious about comparing the estimated rates with 
immunization related death rates in other countries.  In Study II, to eliminate wild 
poliovirus, many complementary polio vaccine campaigns were launched in 
Mainland China. Yet, information regarding these campaigns, including vaccination 
doses, was not completely reported during the study period. This could lead to 
underestimate denominators (administered doses will be underreported), thereupon 
lead to an overestimation of overall risk. 
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6.2 Methods considerations  
The evaluation of a surveillance system could be divided into two: 1) utility and cost, 
2) system attributes(US CDC, 2001). The completeness is closely related to 
sensitivity and positive predictive value(Thygesen & Ersboll, 2014). Completeness 
could be evaluated by different methods, such as comparing with another data 
source believed to be complete, or alternatively to calculate the expected number of 
cases by applying rates of similar populations or “gold standard”. In our study, 
according to the review of attributes in the evaluation guidelines(US CDC, 2001), 
the sensitivity and positive predictive value are used for evaluated the completeness. 
Validity of the variables include is another dimension of population-based 
surveillances. Important measures for validity are sensitivity, specificity and 
predicative value (both positive and negative)(Thygesen & Ersboll, 2014). 
Commonly, the validity of a register is performed by case to case evaluation. In 
CNAEFIS, all serious cases, including death, serve disabilities, clusters, and cases 
with public concerns, would be investigated and causally assessed by prefectural level 
or provincial level expert committee. 
Besides of sensitivity and PVP, we also use the demographic representativeness 
to show that how the CNAEFIS covered whole China. Based on the national AEFI 
surveillance guidelines, the events following immunization suspected should be 
reported, however, the nature of voluntary reporting makes underreporting more 
likely in this system. Through with several years of training, there were still some 
counties with no cases reported every year. The demographic representativeness 
could be a proxy indicator for reporting sensitives.     
To evaluate vaccine safety, we conducted two levels of analysis: a descriptive 
analysis of AEFIs (Studies II–IV) and a disproportionate reporting analysis (Study 
IV). We calculated AEFI incidence rates using different denominators. Through 
comparison with historic data and published studies, emerging vaccine safety signals 
were detected. As serious AEFIs are very rare and it is difficult to know the 
background incidence rates, DPAs in the SDR detection could be used. Since both 
JEV-L and JEV-I are used in China, we mainly compared the vaccine safety of JEV-
L and JEV-I instead of comparing them with all other vaccines in the DPAs. Since 
there are no DPA gold standard methods, we applied both Bayesian and non-
Bayesian DPAs to screen SDRs. 
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6.3 Performance of National AEFI system 
Study I comprise three parts: i) a review of the national AEFI surveillance system in 
Mainland China; ii) a descriptive analysis of AEFI surveillance data during 2008–
2013; iii) an analysis of the system attributes of CNAEFIS. The descriptive analysis 
of CNAEFIS during 2008–2013 showed that about 440,000 AEFI cases were 
reported, with an average rate of 454 per 100,000 surviving infants per year. The 
number of annually reported cases increased by 30%, and the ratio of AEFI cases 
per 100,000 surviving infants per year also increased six-fold. However, the ratio of 
serious cases per 100,000 surviving infants per year remained steady for the 6 years. 
Consistent with NIP target population, the majority of reported AEFI cases were in 
children and occurred after administration of NIP vaccines. Most of the AEFIs were 
common vaccine reactions, and the proportion of rare vaccine reactions remained 
at about 8% every year. Program errors in CNAEFIS decreased, and most of them 
were related to the BCG vaccination. More than 98% of AEFI cases recovered or 
improved. About 0.1% of cases resulted in death and various vaccines were involved. 
As a public health surveillance system, CNAEFIS is simple to use and adaptable 
to new situations and requirements. Much like other SRSs, the sensitivity of 
CNAEFIS is relatively low and varies by vaccine and event type. However, its level 
of specificity is quite high. Cases were reported and investigated in a timely manner, 
and timeliness increased every year. Though the estimated incidence rates of certain 
vaccines in CNAEFIS were still lower than when enhanced or active reporting was 
implemented(Yue et al., 2012), its completeness increased each year. With the 
development of quality control mechanisms, unknown, missing, or errors in key 
information decreased and were adjusted to some extent. The geographic 
representativeness of CNAEFIS has also increased in each of the 6 years. 
Our analysis shows that CNAEFIS has the capability to continuously collect 
AEFI information in China since its establishment. It also makes it simple to report 
and generate valuable post-marketing information. However, conclusive evaluation 
of vaccine safety is difficult, as the investigation and causality assessment are labor 
intensive and require collection of clinical information in most cases. The flexibility 
of CNAEFIS is good and it could adapt to mass immunization campaigns and new 
conditions such as the launch of new vaccines. We thus can conclude that CNAEFIS 
is a low-sensitivity and high-specificity surveillance system. Despite this low 
sensitivity, it is a useful system as long as the sensitivity remains reasonably consistent 
over time(Rosenthal & Chen, 1995). As a national passive surveillance system in a 
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country with limited resources, the high PVP of the CNAEFIS reports seems 
reasonable, although it varied by vaccine.  
The reporting time interval from onset date to reporting of cases to county CDCs 
or the responsible reporters not only reveals the timeliness of reporting but also 
illustrates the reporting behavior of vaccine recipients or their guardians. The 
reporting time lag has decreased from 2008–2013, suggesting that the public is 
paying more and more attention to vaccine safety. The investigation time interval 
has also decreased, and this is solely due to the work of the CDCs and the expert 
panels. An indicator for data quality is the key variable check: With built-in quality 
control mechanisms, training sessions, and error checks every year, the missing, 
unknown, or incorrect key variables have decreased. Also, for causality and outcome 
assessment, follow-up by the CDCs is important to reduce unknown or missing 
values.  
At its grassroots, the CDC in China functions at the county level, playing an 
important role in AEFI surveillance. The county CDCs are responsible for receiving 
reports and entering the data into the database, performing case verification, and 
starting the initial investigation. The proportion of cases reported by county CDCs 
could thus be an indirect indicator of the representativeness of CNAEFIS. With the 
unequal development of CDCs in the eastern, middle, and western areas, the 
proportions of cases reported by county CDCs are also unequal. From 2010, the 
proportion of reported cases by county CDCs from the eastern and middle areas 
was over 90%; however, the proportion from the western area was lower than 90% 
in 2013, suggesting that that there are geographic differences in CDC’s investigation 
capacities. 
Although AEFI surveillance in China is passive, it does have several 
advantageous characteristics. CNAEFIS is supported by national vaccination and 
immunization laws and regulations, and China CDC’s national AEFI surveillance 
guidelines are the official standards for conducting AEFI surveillance. The reporting 
of AEFIs is mandatory for all health professionals and vaccine providers. CNAEFIS 
is the primary tool to collect AEFI data so that these data can be used rapidly, 
efficiently, effectively, and conveniently. The system is online and is designed to 
ensure data quality through data verification at all levels of CDCs, especially for rare 
and serious cases.  
China also has a mechanism to arrange for panels of AEFI experts to participate 
in investigations and conduct causality assessments. The immunization program in 
China is unified and vertically integrated, and all provinces, prefectures, and counties 
have CDCs that participate in the vaccine safety surveillance system. The AEFI 
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Surveillance and Management Division was established in January 2009 in China 
CDC NIP, and, by 2014, several province-level CDCs had also established AEFI 
surveillance divisions. China CDC NIP has an ongoing training plan for AEFI 
surveillance staff and physicians to build and sustain their capacity of AEFI 
surveillance. Since 2005, training workshops and conferences on AEFI surveillance 
have been conducted at least annually. Such programs will continue to help ensure 
that there is no dearth of highly qualified staff for AEFI surveillance in China. 
An analysis of the national AEFI surveillance is published monthly in the NIP 
Bulletin, which is distributed to all the CDCs and shared with ADRs. Analyses of 
AEFI surveillance data are published annually in the Chinese Journal of Vaccine and 
Immunization. Analyses of AEFI data reported during special immunization 
campaigns, such as measles SIAs and the A(H1N1) influenza response vaccination 
campaign, have also been published in Chinese and other international scientific 
journals. For example, an early paper on a post-marketing safety surveillance of the 
2009 A(H1N1) influenza vaccine was published shortly after the vaccination 
campaign in China.  
In addition to information shared among CDCs and other vaccination 
stakeholders, vaccine safety information is released to the public through press 
releases and news announcements by MOH. Since 2013, annual national AEFI 
surveillance information has been released jointly by MOH and CFDA to the public 
through their websites, providing AEFI surveillance summary and safety evaluation 
on vaccines given to children.  
The personal identification information, including names, telephone numbers, 
address were blocked and could not be viewed by prefectural level, provincial level 
and national level CDCs and all levels of ADRs to protect database. Since AEFI 
reporting forms and investigation forms were collected and entered the online 
CNAEFIS by staff in points of vaccination and county level CDCs, those users could 
only view the personal data they entered and for purpose of following-ups. 
6.4 Recipient VAPP in China  
In Study II, using data from the national passive AEFI surveillance system in China, 
we estimated that the risk of recipient VAPP was 0.4 per million administered OPV 
doses. The NIP began in 1978, and tOPV has been used for more than 35 
years(Zheng et al., 2010). VAPP data reported in CNAEFIS complements routine 
Acute Flaccid Paralysis surveillance and provides an estimate of the baseline risk of 
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VAPP before China switches to the bivalent polio vaccine. In previous studies, 
VAPP cases were more frequently reported in males and in children under 5 years 
of age(Landaverde et al., 2014). However, in our study, the gender imbalance in 
VAPP reports was striking (8:1) for unclear reasons. This could be related to several 
issues, including surveillance or reporting artifact—in the whole passive AEFI 
surveillance, more AEFIs were reported for males than females, with a ratio of 
1.4:1(Wu et al., 2012; Wu et al., 2014; Jiakai Ye et al., 2016). Also, as immunity to 
poliovirus is largely antibody-mediated, persons with antibody deficiencies are much 
more susceptible to VAPP than immune-competent individuals(MacLennan et al., 
2004). However, considering that only part of the reported VAPP cases were 
immune deficient, and not all relevant immune deficiency syndromes are x-linked, 
immune deficiency may only explain part of the gender difference. One study in a 
children’s hospital in Beijing(J. Zhang, et al., 2013) found that among patients 
suffering from primary immunodeficiency diseases (PID), the ratio of boys to girls 
was 4.4:1. The same study found that in 174 patients with PID over 11 years, the 
median age of onset of antibody deficiency was 12 months(J. Zhang et al., 2013). 
Therefore, it is difficult to assess immune-competency in young infants as they are 
only 2 months old at the time of OPV vaccination. We also found that about 25% 
of VAPP cases had perianal abscesses and they were all male. The possible 
relationship between gender, perianal abscesses, and VAPP requires further study.  
The age distribution of VAPP cases is obviously associated with the OPV vaccine 
schedule, with the recommended age for OPV doses being 2, 3, and 4 months of 
age. The majority of recipient VAPP cases occurred after the first dose. A literature 
review of the VAPP burden indicated that in low-income countries, the number of 
VAPP cases is highest among children aged 1–4 years, whereas in middle- and high-
income countries, the risk of VAPP is highest among children under 1 year of 
age(Landaverde et al., 2014). The reason for this was assumed to be related to the 
prevalence of protective maternal antibodies and the high coverage provided by the 
first dose of OPV; accordingly, VAPP was high in the under 1-year age group. In 
high-income countries, high OPV immunogenicity and the delivery of the first dose 
of OPV after 2 months (when maternal antibody levels have decreased) might have 
been associated with the risk of VAPP following the first dose. Because of oral 
administration, the coverage of OPV is generally higher than that of other vaccines, 
and it has been reported to be as high as 99% in China according to national 
immunization coverage surveillance data(Cui et al., 2016).  
Improved reporting capacity for AEFIs might have affected the geographic 
distribution of VAPP cases. Since CNAEFIS developed rapidly after national AEFI 
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guidelines were issued in 2010, AEFI surveillance in different regions in China might 
have been implemented unevenly. Like all reported AEFI cases, most cases of 
recipient VAPP were from the eastern regions, followed by the middle and western 
regions. In addition to the capability of AEFI surveillance, differential reporting 
might also be related to economic status and population distribution. After 2012, the 
central government issued financial support for AEFI investigation and causality 
assessment, which could enhance the number of recipients VAPP cases reported in 
CNAEFIS. The decline in recipient VAPP in 2015 might be related to the policy 
change in July 2015 in which six pilot provinces in China introduced IPV to replace 
tOPV as the first dose. Also, the domestically manufactured IPV-Sabin strains were 
introduced in the market in 2015. In the vaccine serotype analysis, type II accounted 
for about one-third (27/93) of all cases, as seen in other studies(Landaverde et al., 
2014).  
Our study suggested that the incidence of VAPP in China was similar to that of 
other countries. In studies from different countries, the estimated incidence of 
recipient VAPP has ranged from 0.33 to 19.08 cases per million births(Minor, 2009). 
Using the total population and birth rates from the National Bureau of Statistics to 
estimate the number of live births, the approximate recipient VAPP per million 
births during 2010–2015 was 1.34–2.34; similar to that of the US (1.91; 1961–1972), 
Cuba (2.91; 1963–2006), and England/Wales (1.68; 1985–1991)(Landaverde et al., 
2014; Platt et al., 2014). In our analysis, using vaccines administered doses as the 
denominator, the recipient VAPP per million vaccination doses was 0.4 per million 
OPV doses or about 1 case per 2.67 million vaccines administered doses. This is 
similar to countries such as Japan (1 recipient VAPP case per 2.3 million doses in 
1971–2000), India (1 recipient VAPP case per 2.8 million doses in 1999), and Brazil 
(1 recipient VAPP case per 2.39 million doses in 1989–1995)(Landaverde et al., 
2014). In contrast, the VAPP risk was estimated as 1 case per 750,000 vaccine 
recipients in the U.S., and 1 per 400,000 in Norway, England, and Wales(Zuo et al., 
2010); however, these rates include both recipient and contact VAPP. Without data 
on contact VAPP, the rates estimated from CNAEFIS could not be compared with 
these countries. Based on the vaccine doses, we could estimate the incidence of 
recipient VAPP after 3 doses. In our analysis, the risk after the first dose was highest 
(1.31 per million vaccine doses), which was about one in 760,000 vaccine doses, 
similar to international studies (one in 750,000 doses)(WHO, 2016). The risk after 
the second and third doses was significantly lower than after the first dose—about 1 
in 9 million for the second dose and 1 in 26 million for the third dose, consistent 
with the WHO estimate(WHO, 2016). 
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6.5 Deaths reported in CNAEFIS 
During six years of AEFI surveillance in mainland China, more than three quarters 
of reported AEFI-associated deaths were due to coincidental events, and only 16% 
could be attributed to vaccination by causality assessment. Most of those determined 
to be causally related to vaccination were related to anaphylactic reactions and 
disseminated BCG diseases. Although the reporting rates of neonatal deaths 
increased during 2013-2014, deaths that causally related to HepB were very rare 
during the study years.  
Overall, our study provides reassuring information about the small risk of deaths 
following immunization. Although 5% AEFI-associated deaths were indeterminate 
cause, the AEFI investigation and causality assessment process provided valuable 
information to evaluate vaccine safety in China. The reporting peak of AEFI-
associated deaths in late 2013 to early 2014, illustrates the sensitivity of passive 
reporting of serious AEFI to public information and the caution that should be 
exercised in interpreting peaks in serious AEFI reporting. Our analysis also illustrates 
progress made with vaccine safety monitoring during recent years in China.  
Regarding the seasonal distribution of deaths during the study period, except for 
2013, deaths were more common in winter than in summer months, consistent with 
findings of similar studies elsewhere(McGarthy et al., 2013). The results showed that 
children aged <5 years accounted for 95% of AEFI-associated death, which is 
consistent with Vaccine Adverse Event Reporting System (VAERS) data in the 
U.S(Moro et al., 2015) and the National Immunization Schedule in China. There 
were also more male than female deaths. This finding is consistent with data reported 
in the All Cause of Death Surveillance System in China (Chinese Center for Diseases 
Control and Prevention, 2013). Of the AEFI-associated deaths, 78.9% were 
classified as coincidental events. The reported causes of death were consistent with 
common causes of mortality nationally (Jianli Ye et al., 2012; Ren & Pang, 2016). 
According to the National Bureau of Statistics of the People’s Republic of China, 
all-cause neonatal death rates during 2010-2014 were 5.9–8.3‰. The estimated 
neonatal death rates in this study were lower than all-cause neonatal death rates in 
the general population, suggesting no association of vaccinations with an increased 
risk of death at the population level. 
Generally, parents have their children vaccinated when they are in relatively good 
health. In situations where the infant dies shortly after immunization, parents and 
even health providers may blame vaccine(Moro et al., 2015). Although vaccines play 
a vital role in preventing diseases in children, vaccine hesitancy has become an issue 
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in many counties, including China(W. Yu et al., 2016; Larson et al., 2013). Events in 
December 2013 in Hunan province of mainland China provide an example of how 
such concerns was arise (China Ministry of Health website.). Media reports of 17 
infant deaths, including one case of anaphylactic shock following HepB vaccination, 
raised widespread public concern in China (W. Yu et al., 2016; M.-N. Li et al., 2014). 
After investigation, The China Food and Drug Administration reported that the 
deaths were not related to the vaccine, but instead with a variety of problems, 
including severe pneumonia, suffocation, kidney failure, severe diarrhea and 
congenital heart disease(W. Yu et al., 2016; M.-N. Li et al., 2014; Yan et al., 2015). In 
passive surveillance systems, the behavior of parents and vaccine providers behavior 
may influence the number of reports. This publicity may have increased public 
awareness and led to a tendency to report deaths after immunization during 2013-
2014. Our analysis showed a reporting peak during 2013-2014, in which 94% of the 
neonatal deaths were reported to be related with HepB. However, vaccine reactions 
determined to be causally related to HepB were rare during the study years. Although 
the overall number of all AEFI reports in CNAEFIS increased from 2010 to 2015, 
the number of serious AEFIs (events causing a potential risk to the health/life of a 
recipient leading to prolonged hospitalization, disability/incapacity, congenital 
abnormalities/birth defects or death) has remained constant(Wu et al., 2012; Wu et 
al., 2013; Wu et al., 2014; Jiakai Ye et al., 2015; Jiakai Ye et al., 2016). 
Causality assessments in China are performed in accordance to WHO guidelines 
(China MoH & China FDA, 2010; M. S. Gold et al., 2016). The documented causes 
of death that could possibly occur due to the inherent properties of a vaccine are 
limited and include anaphylaxis, viscerotrophic disease following yellow fever 
vaccine, disseminated attenuated live vaccine agent infection in severely immune-
compromised individuals and death from intussusception following RotV (M. S. 
Gold et al., 2016). In China, yellow fever vaccine is not recommended, and RotV 
differ from those used internationally. In our study, the most common causes of 
vaccine-related reactions and deaths were anaphylaxis and disseminated BCG 
infections. BCG is recommended at birth, without screening to determine the status 
of the immune system at that time. In our study, several deaths were due to 
neurological diseases. There was no solid evidence that these neurological diseases 
were caused by the vaccines or vaccination, although some studies reported temporal 
associations of such diseases with various immunizations(Sejvar et al., 2007; 
Tapiainen et al., 2007). When no etiologic agent is identified, and the person was 
healthy prior to immunization, a suspicion may arise in the causality assessment that 
the vaccine contributed to the death. Several cases with STL was also assessed to be 
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causally related to vaccination during surveillance. STL is associated with immune 
system dysfunction, which occurs mostly in young children and young people. It is 
characterized by thymus hypertrophy, systemic lymphoid tissue proliferation (lymph 
nodes, respiratory and digestive tract lymphoid tissue and splenic lymph follicles), 
small heart, narrow circumference of aorta origin, adrenal and gonadal dysplasia, pale 
skin, rich subcutaneous fat, and late development of secondary sexual characteristics. 
Such a person may die suddenly when subjected to a mild stimulus, such as minor 
trauma, argument, sudden fright, anesthesia or injection. This kind of clinical state is 
difficult to recognize during one’s lifetime and usually diagnosed by autopsy after 
death. As reported previously, mild immune stimulation, such as that produced by 
minor trauma or immunizations, could give rise to sudden death among individuals 
with STL (X. Zhang et al., 2011). The expert committee concluded that it triggered 
these deaths, even when neither the vaccine nor the vaccination was the direct cause. 
Case causality assessments are extremely difficult. Strengthening the capacity of 
AEFI investigation and causality assessment is very important in the field of vaccine 
safety surveillance and evaluation in China. In 2018, WHO issued revised 
classification for causality assessment(WHO, 2018a) which could be adopted and 
modified for the Chinese setting in future. 
6.6 Evaluation of JE vaccines 
In Study IV, although the number and reporting rates of AEFIs following live 
attenuated and inactivated JE vaccines increased during the study period, there was 
no statistical difference between the two vaccines overall, or for serious AEFIs. 
Serious AEFIs only account for 1% of all AEFIs. The increased trend in AEFI 
reporting rates following JE vaccines might be related to the development of 
improved reporting. The increasing trends were similar for reporting rates of all 
AEFIs during the same period.  
Study IV included two JE vaccines used internationally: JEV-L and JEV-I. 
Different JE vaccines have been used in other countries. For example, the US used 
an inactivated mouse brain-derived JE vaccine (JEV-I) for travelers (most of whom 
were adults) from 1992–2009, while Japan used JEV-I for children. 
Takahashi(Takahashi et al., 2000) reviewed the post-marketing surveillance of JEV-
I in Japan and the US and found that the adverse event rate was 2.8 per 100,000 
doses in Japan and 15 per 100,000 doses in the US. Although the surveillance system, 
reporting scope, and denominators used were slightly different in China and other 
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countries, our reported AEFI rate for JEV-I was 17.6 per 100,000 vaccination doses, 
not substantially different from the US. JEV-L was widely used in WPR and Asia 
(China, Korea, and India), but very little systematic data are available on the adverse 
effects of JEV-L in these countries. An analysis of a post-marketing surveillance of 
JEV-L from 2009–2012 by the Chinese National Centre for Adverse Drug Reaction 
(ADR) Monitoring(WHO, 2015b) showed that of the 6024 AEFIs, only 70 were 
considered severe. The WHO advisory committee (GACVS) reviewed these data 
and noted that although no safety signals were identified, the number of events 
recorded in the AEFI reporting system was low given that >70 million doses of 
vaccines had been administered (WHO, 2015b).  
Following WHO’s positive assessment of Chinese Vaccine National Regulatory 
Authority in 2011 and with the rise of vaccine manufacturing in China, JEV-L was 
the first vaccine in China to be prequalified by WHO. Through ongoing surveillance 
and data mining analysis, we were able to monitor the vaccine safety of JEV-L 
produced and used in China. 
In a previous analysis of CNAEFIS data, only JE vaccines alone, listed as the 
most suspected vaccine, were included in the study(D. Liu et al., 2008). However, in 
our study, at least one-third of AEFIs occurred when vaccines were administered 
concurrently. Furthermore, in the ≤1-year age group, the target group of NIP. more 
than half the AEFIs related to JEV-L were related to JEV-L in combination with 
other vaccines. In these situations, it was not possible to determine the vaccine 
responsible for some adverse events such as allergic reactions. Therefore, we 
included in the analysis all AEFIs related to JE in the CNAEFIS database. 
The gender distribution of AEFIs related to JEV-L and JEV-I was similar to that 
of  other vaccines(Wu et al., 2013)—the male to female sex ratio was>1. Most of the 
cases occurred among ≤1-year-olds, consistent with the Chinese immunization 
schedule for EPI vaccines. Most AEFIs were relatively mild and self-limiting, with a 
diagnosis of common and minor adverse reactions, including fever, local redness and 
swelling, and local induration.  
The three measures of disproportionality analysis, including Proportional 
Reporting Ratios (PRR), Gamma-Poisson Shrinker algorithm (GPS), and Bayesian 
Confidence Propagation Neural Network (BCPNN) analyses, detected no SDR for 
JEV-L compared with JEV-I. Combined with the comparison of incidence rates 
between JEV-L and JEV-I, suggests no vaccine safety concern regarding JEV-L.  
Febrile convulsions are the most common type of seizure in children, affecting 
2–5% of children in North America and Europe and 6–9% of children in 
Japan(Daoud, 2004; Jones & Jacobsen, 2007). It usually occurs between 3 months 
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and 5 years of age, with a peak incidence at 18 months.(Waruiru & Appleton, 2004) 
This is also the target age  for vaccinations, including JEV-L and JEV-I. Through 
some risk factors, such as family history and exposure to infectious illnesses, were 
found to be related to febrile convulsions in children, in general, about 50% of 
children who presented with febrile convulsion will have  no identified risk 
factors(Waruiru & Appleton, 2004). Elevated body temperature is frequently 
observed following immunization, and febrile seizures are the most common type 
of non-epileptic seizure observed following immunization(Sun et al., 2012). Signals 
for  possible association of febrile convulsion with vaccination were found following 
MMR, DTP, and InfV in the US and Australia(Leroy et al., 2012a;  Cendes & Sankar, 
2011; Jacobsen et al., 2009; Sun et al., 2012). In our study, by using the three data-
mining methods, disproportionate reporting was detected for JEV-I and febrile 
convulsion compared with JEV-L, suggests that there were disproportionate reports 
of febrile convulsion after JEV-I compared to JEV-L.  
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7 CONCLUSIONS AND RECOMMENDATIONS 
Although clinical trials and various regulatory processes assess safety and efficacy of 
vaccines, rare vaccine adverse events among large populations can only be captured 
through post-licensure monitoring of AEFIs. National passive AEFI surveillance is 
an important part of the public health surveillance system in Mainland China. Having 
undergone several years of development, CNAEFIS, the national AEFI surveillance 
system, has functioned well in accordance with the national AEFI guidelines issued 
in 2010. CNAEFIS as a public health surveillance system is simple to use and can 
adapt to new situations and requirements. Like other spontaneous reporting systems, 
the sensitivity of CNAEFIS is relatively low and varies by type of vaccine and event; 
however, its specificity is high. The geographic representativeness has also increased 
in the past 6 years. All three vaccine safety evaluation studies in this thesis provide a 
snapshot of the vaccine safety situation in Mainland China. Study II showed that 
recipient VAPP in China was a rare adverse consequence of receiving OPV, similar 
to that found in studies in other countries, and that the risk of recipient VAPP 
calculated using either estimated births or vaccination doses was also comparable to 
that reported in studies from the US and Japan. As polio’s global eradication 
approaches, VAPP will become increasingly unacceptable. After the introduction of 
IPV and the replacement of tOPV, the burden of VAPP should diminish further. 
The AEFI-associated deaths study showed that the risk of deaths following 
vaccination was extremely small and did not identify specific safety concerns with 
vaccines used in China. The JE vaccine safety study did not show any apparent safety 
concerns regarding JE vaccines in Mainland China.  
The epidemiology distribution of national AEFI surveillance during recent years 
and the three examples of VAPP, deaths and JE vaccines safety, illustrated that the 
progress of vaccine safety surveillance made nationally, and provide important 
evidence to document how safe immunization risks in mainland of China. 
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7.1 Strengthening vaccine safety surveillance and evaluation in 
China 
Vaccines are among the safest medical products in use. However, parents will 
naturally become concerned when serious adverse events occur after vaccination, 
even though the event may only be temporally related to immunization(E. R. Miller 
et al., 2015). A functional vaccine safety surveillance system and thorough AEFI 
investigation for causality assessment can provide valuable information for both 
national regulatory authorities and the public (M. S. Gold et al., 2016).  Based on the 
systems of the CDC/NIP and through fruitful collaborations with Chinese NRA, 
CNAEFIS has operated smoothly in the sphere of AEFI surveillance since 2010. 
The AEFI surveillance system was a project of cooperation with standard national 
guidelines and support from Chinese MoH; the national immunization technical 
expert committee; and the operation of national, provincial, prefectural, and county 
CDCs and physicians in vaccination clinics. Based on the national AEFI surveillance 
guidelines, all information gathered from AEFI reporting, investigation, and 
causality assessment have been compiled in this online system. Post marketing 
vaccine safety surveillance and evaluation is an important function of vaccines 
National Regulatory Authority (NRA. Based on the guideline, AEFI data analysis is 
a collaborative work of the China CDC and the China adverse drug reaction 
surveillance center (CDR), which oversees national adverse drug reaction 
surveillance. All the stakeholders, including CDC, CDR, MoH, CFDA and related 
administrative bodies, would share safety evaluation information and communicate 
routinely based on surveillance data.  Through this close collaboration, the 
CNAEFIS can run smoothly and gather the database for post marketing vaccine 
evaluation in China. Since the national guidelines of AEFI surveillance were issued 
over 5 years ago, with the development of AEFI surveillance and vaccine safety 
research, along with advice from the WHO NRA reassessment in 2014, Chinese 
MoH and FDA are considering revisions to the guideline.  
Our evaluation shows that several issues should be considered when revising the 
national guidelines to improve the CNAEFIS: First, the definition/scope of 
reportable cases should clearer and related to different vaccines. The scope of 
reporting in CNAEFIS could follow the structure of reporting events in the US 
VAERS which is more precise and related to vaccines. Therefore, it would also be 
easier to operate for local physicians and nurses. Second, For CNAEFIS itself, a 
combination of test-based and coded medication conditions in the database makes 
it hard to analyze the data, and it is not as precise as the standard coding system, for 
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instance, MedDRA, which is used by VAERS. It is extremely labor-intensive to 
analyze test-based information, and the unstandardized coding system could also 
influence the results of the data-mining of safety signals. MedDRA is used 
internationally to standardize diagnoses and symptoms. This should also be adopted 
in data analysis in CNAEFIS. Third, standardized case definitions have also not been 
used in CNAEFIS, and this has affected AEFI classification, which is based on 
causality assessment. There are more than 30 globally accepted case definitions by 
the Brighton Collaboration with WHO that provide clear criteria for degrees of 
diagnostic certainty.(Bonhoeffer et al., 2004) These could also be introduced in the 
CNAEFIS, as appropriate. Fourth, since reporting from different areas of China has 
been uneven, further quality improvement work, such as training, education and 
supervision, should be offered to the weaker areas. 
For case investigation and causality assessment, consistency among different 
levels of the expert panels in charge of causality assessment should be evaluated and 
improved. Through Case causality assessments are extremely difficult, all the serious 
cases should be assessment by experts committee(China MoH & China FDA, 2010). 
Although the process of gathering information for investigation and causality 
assessment has been described in the national guidelines, the level of consistency in 
the workings of different levels of expert panels is not known. In our studies on 
recipient VAPP and fatalities in CNAEFIS, the clinical diagnosis the diseases and 
causality assessment which linked disease to vaccination, could influence the validity 
of the study. Since China has a large population, and there is 32 provincial level- and 
more than 400 prefectural level- AEFI experts committees, the causality assessment 
quality of expert committees is varied, even based on the same national principle. 
Also, the national compensation policy(China MoH & China FDA, 2010), which the 
victims related to vaccine-related reaction, could apply the economic compensation 
form the government or the manufactures, also affected the impartiality of causality 
assessment. Strength the capacity of AEFI investigation and causality assessment is 
an important work in field of vaccine safety surveillance and evaluation in China. 
The WHO had issued AEFI causality assessment: user manual for the revised WHO 
classification in 2018(WHO, 2018b) which could be adopted and modified for 
Chinese setting for future.  
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7.2 Implications for future studies on vaccine safety 
The vaccine safety evaluation of recipient VAPP, fatalities, and JE vaccines indicate 
that AEFI surveillance data could provide valuable information on vaccine safety 
and generate evidence for policy making and immunization program development. 
As a passive surveillance system is aimed for vaccine safety signal detection and 
generating hypotheses, the analytic method could be further developed in 
CNAEFIS. Based on Study IV’s JE vaccines analysis, besides traditional risk 
estimation using different denominators, a disproportionality reporting analysis is 
also recommended for signal detection using passive AEFI surveillance data, 
especially since this method needs no external data. Although we should be cautious 
about the signals it generates, it could be introduced as a compensatory method of 
analysis when using AEFI surveillance data to evaluate vaccine safety.  
The AEFI surveillance data however can only provide information on cases after 
vaccination, whereas we need external information on controls, i.e., patients who 
have not been vaccinated.  Various epidemiological methods, such as self-control 
case series, case control studies and cohort studies, could be implemented and 
applied to assess vaccine safety. We recommend further studies aimed at determining 
the effects of concurrent vaccination with JE vaccines and adopting more sensitive 
methods to detect signals. 
Since live attenuated polio vaccines continue to be used in Mainland China, 
recipient VAPP is certainly a concern of the public and the immunization programs. 
This concern must continue to be addressed and investigated in the future. The JE 
vaccines safety analysis shows that there is a rise in JEV-I and febrile seizure cases 
compared to JEV-L, which might be a safety signal for future studies.  
The CNAEFIS covers all vaccines used in Mainland China, but we only illustrated 
three examples, which were key concern during the study years. With the 
development immunization program, new vaccines might be introduced into 
immunization schedules that will be paid for by the government, such as a second 
dose of inactivated polio vaccines, varicella live attenuated vaccines, and seasonal 
influenza vaccines. Evaluating the safety of these vaccines will be done by using 
passive AEFI surveillance systems. 
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10 APPENDIXS 
Appendix 1 AEFI Case Reporting Form 
Code □□□□□□□□□□□□□□ 
Name*                             
Sex* 1. Male  2. Female 
DOB* □□□□/□□/□□ 
Occupation                             
Present address                             
Tel                             
Guardian                              
Suspicious vaccine and vaccination (start from the most suspicious vaccine)  
 
Vaccine 
name 
* 
specifications 
(dose/vial or 
pill) 
Manufacturer 
* 
Vaccine 
batch 
No.* 
Date of 
vaccination* 
Vaccination 
format* 
Vaccination 
dose* 
Vaccination 
dosage 
(ml or pill)* 
Vaccination 
route* 
Vaccination 
site* 
1           
2           
3           
 
Onset date* □□□□/□□/□□ 
Detection date* □□□□/□□/□□ 
Where to seek medical care                              
Clinical process*                             
Fever (axillary temperature ºC)* 1. 37.1-37.5  2. 37.6-38.5  3. ≥38.6  4. none 
Localized redness and swelling 
 (diameter in cm)* 
1. ≤2.5    2. 2.6-5.0     3. ͽ5.0   4. none 
Localized scleroma (diameter in cm)* 1. ≤2.5    2. 2.6-5.0     3. ͽ5.0   4. none 
Primary clinical diagnosis                             
Hospitalized* 1. yes    2. no 
Patient outcome* 1. cured 2. improved 3. sequelae 4. death 5. unknown 
Primary classification* 1. common adverse reactions 2. to be defined 
Identified by: 1. passive surveillance 2 .active surveillance 
Reporting date* □□□□/□□/□□ 
Reporting unit *                             
Reporter                             
Tel                              
Note:  * key items.  
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Appendix 2 AEFI Case Investigation Form  
A. Basic information  
Code □□□□□□□□□□□□□□ 
Name*                             
Sex* 1. Male  2. Female 
DOB* □□□□/□□/□□ 
Occupation                             
Present address                             
Tel                             
Guardian                              
B. Past history 
Any disease in the past before vaccination? 1. yes   2. no   3. unknown 
If yes, disease name                                 
Any allergies in the past before the vaccination? 1. yes   2. no  3. unknown 
If yes, name of allergic                                  
Family history 1. yes  2. no  3. unknown 
If yes, name of disease                                
Past history of adverse reactions 1. yes   2. no  3. unknown 
If yes, onset date □□□□/□□/□□ 
Vaccine name                                 
Clinical diagnosis                                
C. The suspicious vaccine (start from the most suspicious vaccine)  
  vaccine 1 vaccine 2 vaccine 3 
Vaccine name*                                        
Specifications (dose/vial or pill)                                        
Manufacturer*                                        
Vaccine batch number*                                        
Valid until                                        
Having batch release certificate?                                        
Appearance of vaccine normal?                                         
Storage container                                        
Storage temperature (ºC)                                        
Delivery date for testing                                        
Having passed the inspection and control?                                        
D. The diluent 
 vaccine 1 vaccine 2 vaccine 3 
Name of diluent                                        
Specifications (ml/vial)                                        
Manufacturer                                        
 129 
Batch number                                         
Valid until                                        
Appearance of diluent normal?                                         
Storage container                                        
Storage temperature (ºC)                                         
Delivery date for testing                                        
Having passed the inspection and control?                                        
E. Syringe 
 vaccine 1 vaccine 2 vaccine 3 
Syringe name                                         
Syringe type                                        
Specifications (ml/vial)                                        
Manufacturer                                        
Syringe batch number                                        
Valid until                                        
Delivery date for testing                                        
Having passed the inspection and control?                                        
F. vaccination 
 vaccine 1 vaccine 2 vaccine 3 
Vaccination date*                                        
Vaccination format*                                        
Vaccination dose*                                        
Vaccination dosage (ml or pill)*                                        
Vaccination route*                                        
Vaccination site*                                        
Vaccinating unit                                         
Vaccination address                                        
Vaccinator                                        
Having vaccination training certificate?                                        
Vaccination performed correctly?                                        
G. Clinical information 
Onset date* □□□□/□□/□□ 
Detection date/date seeing medical care* □□□□/□□/□□ 
Where to seek medical care                                 
Clinical process*                                
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fever (axillary temperature ºC) * 1. 37.1-37.5 2. 37.6-38.5 3. ≥38.6 4. none□ 
Localized redness and swelling  
(diameter in cm)* 
1. ≤2.5  2. 2.6-5.0  3. ͽ5.0  4. none 
Localized scleroma (diameter in cm)* 1. ≤2.5  2. 2.6-5.0  3. ͽ5.0  4. none 
Primary clinical diagnosis                                
Hospitalized* 1. yes   2. no 
If yes, name of hospital                                
Medical record number                                
Admission date □□□□/□□/□□ 
Discharge date □□□□/□□/□□ 
Patient outcome* 1. cured  2 .improved  3. sequelae 
4. death  5. unknown 
If death, date of death □□□□/□□/□□ 
Autopsy done?  1. yes   2. no 
Conclusion from the autopsy                                
H. Other information  
Vaccine distribution and vaccination implementation process                                
Vaccine doses of the same type and same batch  that have been 
vaccinated and occurrence of adverse reactions                                
Local incidence of similar disease                                 
I. Reporting and investigation  
Identified by 1. passive surveillance 2. active surveillance□ 
Reporting date* □□□□/□□/□□ 
Reporting unit *                                
Reporter                                
Tel                                 
Investigation date* □□□□/□□/□□ 
Investigation unit                                 
Investigator                                 
J. Conclusion  
Conclusion made by* 1. medical association   
2. Investigation and Diagnosis Expert Panel   
3. CDC   
4. healthcare facility  
Level* 1. provincial   2. prefectural   3. county  
Type of reactions* 1. common adverse reactions   
2. rare adverse reactions    
3. vaccine Quality Event   
4. Program Error   
5. Coincidental event   
6. psychogenic reaction  
7. to be defined 
If it is an adverse reaction, severity of 
damage to the body 
_________________________ 
(refer to the "Criteria for Classifying Medical Accidents")  
Final clinical diagnosis*                                
 131 
Whether a serious AEFI? 1. yes   2. no 
Whether a AEFI cluster? 1. yes   2. no 
If yes, code of the AEFI cluster? □□□□□□□□□□□□ 
Notes:  * key items.  
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Surveillance  for  adverse  events  following  immunization (AEFI) is an important component of any  national
immunization  program.  In the  People’s  Republic of China  (China),  a populous,  middle-income  country,
development  of  an  AEFI  surveillance  system began  in  2005.  In 2008, the AEFI  surveillance system was
implemented  as a nationwide,  online system  and called  the  Chinese  National  AEFI Information  Sys-
tem  (CNAEFIS). Since  then,  CNAEFIS  has  provided  useful, national-level  data on  vaccine  safety.  National
AEFI  surveillance  guidelines  were issued  jointly  by  the  Ministry  of Health and the China Food and Drug
Administration  in 2010.  This article  reviews  the development,  status, and key  aspects of  the Chinese  AEFI
surveillance system, and describes  challenges  and future plans  for  vaccine  safety assessment in  China.
©  2015 Published by Elsevier  Ltd.
1. Introduction
Vaccines are considered one of the most effective interventions
to improve global public health [1]. However, due to successes of
vaccines, vaccine-preventable diseases (VPDs) have become less
frequent, or even rare, and public attention often shifts from VPDs
to the safety of vaccines and adverse events associated with vac-
cines. Widespread concern about the occurrence of adverse events
following immunization may  lead to a loss of conﬁdence in  the
safety of vaccines, low vaccination coverage, and even a resurgence
of VPDs [2]. The safety of vaccines is evaluated extensively through
pre-licensure animal studies and human clinical trials, and through
post-licensure surveillance [3]. Safety monitoring in post-licensure
surveillance has relied primarily on passive reporting systems and
epidemiological studies [3,4].
China is one of the most populous, rapidly-developing countries
in the world, with an annual birth cohort of  over 16 million; China
uses an average of more than 500 million vaccine doses annually
[5]. China’s National Expanded Program on  Immunization started
in 1978 and provides government-purchased vaccine at no  cost to
parents for all children under 7 years of age, regardless of socioeco-
nomic status [6]. Since 2008, the  National Immunization Program
∗ Corresponding authors. Tel.: +86 10 63171892.
E-mail addresses: Huaqingwang@vip.sina.com,  wuwendi01@126.com
(H. Wang).
1 W. Wu and D. Liu contributed equally to this work.
(NIP) has included 14 types of vaccines targeting 15 VPDs (Table 1)
[6]. China’s large demand for vaccines is fulﬁlled by more than 60
vaccine presentations that are licensed for the Chinese market;
more than 80% of these vaccines are made domestically and are
administered through NIP [7]. Conducting adequate pharmacovig-
ilance for this large number of vaccines and the hundreds of millions
of vaccine doses administered requires a credible system to monitor
adverse reactions, detect and respond to emerging vaccine safety
signals, and  address concerns of the public and the  media [7]. The
purpose of  this  article is to review the development and status of
the Chinese AEFI surveillance system, and to discuss challenges and
future plans for vaccine safety assessment in China.
2. History of AEFI surveillance in China
Although the  China Ministry of Health (MOH), issued guidance
for handling vaccine adverse reactions in 1980 [8],  nationwide AEFI
surveillance was  not implemented until 2005. In March, 2005, with
the technical support of the World Health Origination (WHO), the
Chinese Center for Disease Control and Prevention (CDC) launched
a pilot study of  passive surveillance for AEFI in 10 of China’s 31
provinces [9]. These 10  provinces used a uniﬁed set of  guidelines,
which were based on the WHO  AEFI surveillance guidelines [10].
Following development of the AEFI surveillance guidelines
and with technical support from China CDC, several additional
provinces joined the safety system pilot. By 2006, the 10 original
pilot provinces and  6 additional provinces reported AEFI cases to
the surveillance system [11]. To further enhance surveillance, in
http://dx.doi.org/10.1016/j.vaccine.2015.04.060
0264-410X/© 2015 Published by Elsevier Ltd.
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Table 1
National Immunization Program vaccines and targeted VPDs.
Vaccine VPD
Hepatitis B vaccine (HepB)# Hepatitis B
Bacilli  Calmette-Guérin vaccine (BCG)# Tuberculosis
Oral poliomyelitis attenuated live
vaccine (OPV)#
Polio
Diphtheria tetanus and acellular
pertussis combined vaccine (DTP)#
Diphtheria, tetanus, and
pertussis
Diphtheria and tetanus combined
vaccine (DT)
Diphtheria and tetanus
Measles attenuated live vaccine (MV)# Measles, mumps, and rubella
Measles mumps and rubella combined
attenuated live vaccine (MMR)
(including measles and rubella
combined attenuated live vaccine
and measles and mumps  attenuated
live  vaccine)
Japanese encephalitis attenuated live
vaccine (JE-live)
Japanese encephalitis
Group A meningococcal polysaccharide
vaccine (MPV-A)
Meningococcal meningitis
Group A and C meningococcal
polysaccharide vaccine (MPV-AC)
Hepatitis A attenuated live vaccine Haptitis A
Hemorrhagic fever with renal
syndrome vaccine (HFV)*
Hemorrhagic fever with renal
syndrome
Anthrax vaccine* Anthrax
Leptospira vaccine* Leptospira
# Included in the original National Immunization Program.
* High risk individuals only.
2007 and 2008 China CDC supported 5 counties to conduct inten-
sive AEFI surveillance using an online AEFI information system [12].
During this time, China CDC launched a series of  AEFI surveillance
training workshops to promote AEFI reporting. In 2008, the online
China National AEFI Information System (CNAEFIS) was expanded
to cover all 31 provinces in China [13].
CNAEFIS played a key role in the collection of  AEFI reports dur-
ing the large inﬂuenza vaccination campaign response to the  2009
A(H1N1) inﬂuenza pandemic [14], leading to further improvement
of AEFI surveillance in China. In June 2010, MOH  and China Food and
Drug Administration (CFDA) jointly issued national AEFI guidance
[15]. According to this guidance, CNAEFIS (http://219.141.175.204/)
became the ofﬁcial AEFI information system, and was to be  owned
and maintained by China CDC. In order to support vaccine regu-
latory oversight, AEFI data collected through CNAEFIS are shared
routinely with Adverse Drug Reaction monitoring centers (ADR) in
China.
Since 2005, the number of AEFI cases reported to the  surveil-
lance system has increased by approximately 30% year by year. By
2013, CNAEFIS had over 300,000 AEFI reports, and more than 90% of
China’s 3100 counties were reporting AEFI cases to CNAEFIS (Fig. 1).
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Fig. 1. Number of AEFI cases and percentage of reporting counties in China,
2005–2013
Table 2
Scope of  reporting.
AEFI onset  time
since vaccination
Speciﬁc AEFI
Within 24 h Anaphylactic shock, allergic reactions without
shock  (hives, rash, laryngeal edema, etc.), toxic
shock  syndrome, syncope, hysteria
Within 5  days Fever (axillary temperature ≥38.6 ◦C), angioedema,
systemic purulent infection (toxemia, septicemia,
sepsis), redness and swelling at  the  injection site
(diameter >2.5 cm), induration (diameter >2.5 cm),
localized  purulent infection (localized abscess,
lymphangitis, lymphadenitis, or  cellulitis)
Within 15 days  Measles-like or scarlet-fever-like rash,  Henoch
Schonlein purpura, localized allergic necrotic
reaction (Arthus reaction), febrile convulsion,
epilepsy,  polyneuritis, encephalopathy,
encephalitis, and  meningitis
Within 6  weeks  Thrombocytopenic purpura, Guillain-Barre
syndrome, vaccine-associated paralytic
poliomyelitis.
Within 3  months Brachial neuritis, sterile abscess in  the injection
site
1–12  months after
BCG vaccination
Lymphadenitis or lymphangitis, osteomyelitis,
systemic disseminated BCG infection
Unspeciﬁed time
frame
Other serious AEFI suspected to be related to a
vaccination
3. Description of AEFI surveillance in China
CNAEFIS is  operated in accordance with China’s national AEFI
guidelines [15]. These guidelines are, in  turn, supported by the
Law on the Prevention and Treatment of Infectious Diseases of the
People’s Republic of China [16],  the Pharmaceutical Administra-
tion Law  of the People’s Republic of China [17], the Administrative
Regulation on the Circulation of Vaccines and Vaccination [18],  the
Regulations on  Preparedness for and Responses to Public Health
Emergencies [19], and other laws and regulations, with reference
to  WHO’s guidelines on AEFIs [10], and with the intent to improve
vaccine safety  and immunization service quality.
An AEFI case  is deﬁned as a reaction or an event following vac-
cination that is suspected to be related to the vaccination. AEFI
surveillance covers all  vaccines marketed in mainland China, with
a scope of reporting as shown in  Table 2. Healthcare facilities, vac-
cination clinics, Centers for  Disease Control and Prevention at all
4 administrative levels, adverse drug reaction (ADR) monitoring
agencies, and vaccine manufacturers executive staff are all respon-
sible reporting units and reporters of AEFIs. The reporting of AEFIs is
implemented in line with the principle of localized management.
The public  or the  guardian (parents) can notify any of  the above
authorized reporters to report an AEFI. Cases are  gathered by local,
county-level CDCs, which are  responsible for completing AEFI Case
Reporting Cards and submitting data to CNAEFIS. Duplicate reports
are identiﬁed and de-duplicated centrally in  CNAEFIS. Once case
information is entered, it  can be viewed by all administrative levels
of CDCs and ADRs.
All AEFIs  are to be investigated, with the exception of common
adverse reactions that have a clear diagnosis (e.g., fever, redness,
and swelling on the injection site; induration). County CDCs start
investigations by collecting relevant data and  completing an AEFI
Case Investigation Form, which is  subsequently entered into CNAE-
FIS. For deaths, serious AEFIs, AEFI clusters, and AEFIs of signiﬁcant
public concerns that are  suspected to be related to immunization,
upon receiving CNAEFIS reports, prefectural or  provincial CDC must
immediately organize an AEFI expert panel for investigation.
As a key part of an investigation, county CDCs organize a set
of  relevant experts in  clinical medicine, epidemiology, laboratory
practices, pharmacy, vaccinology, vaccine regulation, and other
ﬁelds relevant to the case. This set of experts is charged with making
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Fig. 2. AEFI reporting, investigation, and  causality assessment ﬂow chart
a diagnosis and assessing causality of the AEFI. For deaths, seri-
ous AEFIs, AEFI clusters, and AEFIs of signiﬁcant public concern,
the higher-level prefectural or  provincial CDCs organize an AEFI
Investigation and Diagnosis Expert Panel to conduct diagnostic and
causality assessment. Reporting and investigation ﬂow charts are
shown diagrammatically in Fig. 2.
Following investigation and causality assessment, AEFI cases
are classiﬁed into 1 of 5 categories (Table 3).  AEFIs are clas-
siﬁed as serious if they are any of  the  following: death,
life-threatening condition, permanent or signiﬁcant disability,
or damage to organs or body functions. Serious AEFIs include,
but are not limited to, allergic shock, allergic laryngeal edema,
allergic purpura, thrombocytopenic purpura, localized allergic
necrotic reaction (Arthus reaction), febrile convulsion, epilepsy,
brachial neuritis, polyneuritis, Guillain–Barre syndrome, encepha-
lopathy, encephalitis and meningitis, vaccine-associated paralytic
poliomyelitis, BCG osteomyelitis, systemic disseminated BCG infec-
tion, syncope, toxic shock syndrome, and  systemic purulent
infection.
Analysis of national AEFI surveillance is published monthly in
the National Immunization Program Bulletin, which is distributed
to CDCs and shared with ADRs. Analyses of AEFI surveillance data
are published annually in the  Chinese Journal of Vaccine and
Immunization [11,13,20–23]. Analyses of AEFI data reported during
special immunization campaigns, such as measles supplementary
immunization activities (SIAs) [24]  and the A(H1N1) inﬂuenza
response vaccination campaign [14], have also been published in
Chinese and international scientiﬁc journals. For example, an early
paper on post-marketing safety surveillance of the 2009 A(H1N1)
inﬂuenza vaccine was published shortly after the vaccination cam-
paign in China [14].
In addition to information shared among CDCs and  other vacci-
nation stakeholders, vaccine safety information is released to  the
public through press releases and news announcements by MOH.
Beginning in 2013, annual national AEFI surveillance information
is released jointly by MOH  and CFDA to the general pub-
lic through websites (http://www.chinacdc.cn/jkzt/ymyjz/ymyjjz
6758/201412/t20141230 108607.htm), providing information on
the safety of vaccines given to children.
Since the establishment of CNAEFIS, AEFI data have been used
extensively by the Chinese national vaccine regulatory authorities
(primarily CFDA and MOH) to study the safety of vaccines used
in China. For example, using AEFI data in CNAEFIS, NIP and ADR
analyzed safety data for the novel 2009 A(H1N1) inﬂuenza vac-
cine [14] and  the JE live-attenuated vaccine, both of which were
manufactured in  China [25]. An important purpose of passive AEFI
surveillance is to detect emerging vaccine safety signals. With
the development of CNAEFIS, NIP scientists detected an increased
incidence of  anaphylactic shock after vaccination with a manu-
facturer’s hepatitis A live attenuated vaccine in 2011 and 2012
(unpublished data). Although there was  not enough evidence to
show that an increased incidence of  anaphylaxis shock was caused
by this particular hepatitis A vaccine (still under investigation),
following discussions between CFDA and the manufacture, the
manufacture decided to withdraw their product from the market
pending further investigation.
The identiﬁcation of vaccination medical practice errors and
related adverse reactions is  of  great importance because these
errors are  preventable and have potential to derail the beneﬁt of
the immunization program. Between 2008 and 2013, about 1% AEFI
cases in  CNAEFIS have been identiﬁed as program errors, primarily
related to MMR  and BCG vaccination.
Although AEFI surveillance in China is passive, it  does have sev-
eral advantageous characteristics. CNAEFIS is  supported by national
vaccination and immunization laws and regulations, and China
CDC’s national AEFI surveillance guidelines are the  ofﬁcial stan-
dards for conducting AEFI surveillance. The reporting of  AEFIs
is mandatory for all health professionals and vaccine providers.
CNAEFIS is the  primary tool to collect AEFI data so that these data
can be  used  rapidly, efﬁciently, effectively and conveniently. The
system is an online system that is  designed to ensure data quality
through data veriﬁcation at all  levels of CDCs, especially for rare
and serious cases.
China has a mechanism to arrange for panels of AEFI experts
to participate in investigations and conduct causality assessments.
The immunization program in China is  a uniﬁed, vertically inte-
grated immunization program, and all provinces, prefectures,
and  counties have CDCs that participate in the vaccine safety
surveillance system. In China CDC NIP, the  AEFI Surveillance and
Management Division was established in January of 2009, and by
2014, several province-level CDCs also established AEFI surveil-
lance divisions. China CDC NIP has an ongoing training plan for AEFI
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Table 3
Cause-speciﬁc classiﬁcation of AEFIs.
Category Deﬁnition
Adverse reaction following
immunization or vaccine
reaction following
immunization
Unexpected harmful reactions or reactions unrelated to the expected purpose of  the vaccination that occur after standard
vaccination with a vaccine product, including common adverse reactions and rare adverse reactions
Common adverse reaction or common vaccine reaction: reactions caused by the inherent character of the vaccine after
vaccination, and that only impair body functions transiently. They mainly include fever and localized redness and swelling that
may  be accompanied by discomfort, fatigue, poor appetite, tiredness, etc.
Rare adverse reaction or rare vaccine reaction: Drug adverse reactions occurring during the process of, or after a  standard
vaccination with a qualiﬁed vaccine that caused damage to tissues or organs, or damage to functions of the vaccine recipient,
when  all parties involved have made no medical errors. Included are reactions caused by the  inherent character of  the vaccine
that  might be related to the strain, purity, production technology, or added substances of the vaccine such as  antiseptics,
stabilizers, and adjuvants
Vaccine quality event Damage to tissues or organs, and  damage to functions of the vaccinated person due to substandard quality of  the  vaccine.
Substandard quality refers to problems with the strain and purity of the vaccine, production technology, or with added substances
in  the vaccine (excipients), exogenous factors, and if  inspection and  control of the vaccine were not consistent with national
protocols  or standards for vaccine production
Program error Damage to tissues or organs, and  damage to functions of the vaccine recipient due to violation of  standard operational practices,
vaccination procedures, guidelines for  using  the vaccine
Coincidental event The vaccine recipient was  in  the incubation stage or preclinical stage of a  certain condition, and the  onset of  the disease coincides
with the vaccination by chance. Coincidental events are not  caused by the  inherent character of  the vaccine
Psychogenic reaction or
injection reaction
Individual reactions or reactions of  groups of individuals that occur during or after the vaccination due to the psychological
responses of  the vaccinees. Psychogenic reactions are  not  caused by the inherent character of the vaccine
surveillance staff and physicians to build and  sustain the capacity of
AEFI surveillance. Since 2005, training workshops or conferences on
AEFI surveillance have been conducted at  least annually. This AEFI
training program will be continued to help ensure highly qualiﬁed
staff for AEFI surveillance in China.
4.  Challenges and future work
Passive vaccine safety surveillance is cost-effective [3,4], and
CNAEFIS is able to collect timely national AEFI data and detect rare
and severe events. With a growing number of  years of experience
and data, CNAEFIS is providing a baseline of AEFI information in a
very populous country. Using vaccine doses administered data that
are available in China, CNAEFIS may  also be able to detect changes in
reporting rates of known adverse events to help determine whether
changes in established rates reﬂect uneven reporting.
A disadvantage of CNAEFIS’s passive surveillance, as with other
countries’ passive systems such as the national AEFI reporting
surveillance in Australia [26]  and the  Vaccine Adverse Event
Reporting System (VAERS) in the United States [27], is  under-
reporting and reporting bias. An evaluation of CNAEFIS as a public
health surveillance system is  being conducted, and involves the
assessment of 9 system attributes, including simplicity, ﬂexibil-
ity, data quality, acceptability, sensitivity, predictive value positive,
representativeness, timeliness, and stability, to ensure that AEFI are
being monitored efﬁciently and effectively. Although vaccine doses
administered data are also collected by NIP  [28],  calculations of the
incidence rates of AEFIs in passive surveillance system have inher-
ent biases [29], necessitating a cautious interpretation of rates. To
strengthen passive AEFI surveillance, China CDC launched an inten-
sive surveillance effort in 5 counties for  several vaccines, including
measles–mumps–rubella combined vaccine (MMR)  and hepatitis A
vaccine (HepA), from August 2007 to July 2009 [12]. Annual training
programs have been used to build reporting and analytic capacity of
AEFI staff, healthcare providers, and diagnostic AEFI expert panels,
in order to enhance AEFI surveillance development.
In  addition to the need to continually improve passive AEFI
surveillance, there are several qualitative changes to surveillance
that could be considered to better understand vaccine safety in
China. These qualitative changes include use of new data mining
methods for signal detection that are compatible with the  CNAE-
FIS database, active surveillance, and clinical data linkage for more
robust causality assessment.
For recording AEFI cases, CNAEFIS uses a combination of coded
diagnoses and text-based medical conditions. For example, medical
conditions, such as fever, local redness, swelling, local induration
and clinical diagnosis are symbol-coded events, while other clin-
ical information is  recorded as in  free text in CNAEFIS. Compared
with VAERS,  which adopted MedDRA (Medical Dictionary for Reg-
ulatory Activities) and with the WHO  Uppsala Monitoring Centre
(UMC), which adopted WHO-ART (Adverse Reaction Terminol-
ogy), CNAEFIS’s text-based information is  not as precise CNAEFIS’s
coded data. Without a standardized coding system, it is more chal-
lenging to conduct automated search for related cases [30]. As
a consequence, whenever new variables and codes are adopted,
web-based CNAEFIS text ﬁelds must be updated. Beginning in
2012, China CDC started to upgrade CNAEFIS, adding new informa-
tion from AEFI reports using coded medical symbols and clinical
diagnoses, and linking AEFI cases to immunization administration
registration data. The new CNAEFIS will be  used in 2015, with the
website of www.nipis.chinacdc.cn. Linkage between CNAEFIS and
immunization administration registration data will improve rate
determinations and causality assessments.
For the  purpose of vaccine injury compensation [31],  an expert
panel reviews AEFI case investigation information and conducts an
individual causality assessment–an explicit linkage that is differ-
ent from many other countries’ vaccine safety surveillance systems
and injury compensation programs. However, standardized case
deﬁnitions have not been used in CNAEFIS, and this  has affected
AEFI classiﬁcation, report reviews, and even causality assess-
ment. The Brighton Collaboration with WHO  (website: https://
brightoncollaboration.org/public) has developed more than 30
globally-accepted case deﬁnitions that provide criteria for degrees
of  diagnostic certainty [32]. Experts in China have attempted to
apply the Brighton Collaboration case deﬁnitions for AEFI surveil-
lance [33],  and China CDC is determining how to apply the Brighton
Collaboration case deﬁnitions in China’s system. With the support
of  WHO, China CDC is gradually developing its own case deﬁni-
tions as a  reference for AEFI investigation and causality assessment
that are  based on Brighton Collaboration case deﬁnitions. In 2013,
WHO updated its causality assessment methodology and its  guide-
lines for program managers for immunization safety surveillance
[34]. Following a China AEFI causality assessment training work-
shop supported by WHO  in  2012, China CDC is working to apply the
updated WHO  methodology for causality assessment [34], includ-
ing the  updated algorithms and classiﬁcations.
One of the primary goal of AEFI passive surveillance is to detect
vaccine safety signals and generate hypotheses for further stud-
ies  [35]. Vaccine safety signals provide data for action. Although
CDCs are only the  users of vaccines and  not responsible for the
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manufacturing quality of  vaccines, when abnormal vaccine safety
signals are detected, CDCs are the frontline guardians to pro-
tect vaccinated individuals and the public. Using vaccine doses
administered as a denominator, AEFI incidence rates are cal-
culated. Through comparison with historic data and published
studies, emerging vaccine safety signals are  detected. However,
since serious AEFIs are, fortunately, very rare – as examples, acute
disseminated encephalomyelitis (ADEM) and  Guillain–Barre syn-
drome (GBS) – it could be difﬁcult to detect emerging signals,
especially if vaccine lot information is not included in doses admin-
istered data. China CDC is learning new methods for vaccine safety
signal identiﬁcation for action. In the US CDC, a new data min-
ing method, Proportional Reporting Ratio (PRR), has been used to
screen VAERS data and generate signals, including signals from sea-
sonal inﬂuenza vaccines and from newly licensed vaccines [29,36].
WHO  UMC  has used a similar data mining method, Bayesian Con-
ﬁdence Propagation Neural Network (BCPNN) [37]. China CDC has
studied these new data mining methods, and plans to apply them in
CNAEFIS for signal screening and for triggering follow-up actions.
To overcome challenges of using passively-acquired surveil-
lance for validation of potential signals, some experts have advised
the inclusion of active surveillance into AEFI surveillance. Active
surveillance has potential to determine whether an adverse event
is causally linked to vaccination (population causality assessment),
and, if a causal relation is identiﬁed, the rate of the event or the  vac-
cine’s attribute risk [3,38] can be estimated. A recently-published
article reviewed active adverse event surveillance systems world-
wide [39]. Nine active systems were reviewed, including the US,
Canadian, some European countries, and Asian countries’ systems.
Due to differences in healthcare systems, these active surveillance
systems differed substantially from each other. Each had its  own
strengths and weakness, which indicated to us that we should
create our own active surveillance according to Chinese situation.
Following the positive reassessment by WHO  of China’s vaccine
National Regulatory Authority in 2014, China CDC has started to
determine how to build active vaccine safety surveillance that will
work effectively in the Chinese healthcare system.
To offset passive AEFI surveillance’s underreporting and inabil-
ity to establish a causal relationship between vaccination and
a speciﬁc adverse event, clinical data linkage has been used to
assess vaccine safety by some developed countries, such as US,
Australia and some parts of Vietnam [40–42]. In China, by 2007,
most national- and provincial-level hospitals owned a local Hos-
pital Information System (HIS), and about 38% of county-level
hospitals had various types of HISs, according to the  statistical data
of the Ministry of Health in  mainland of China [43]. Electronic Med-
ical Records (EMR), which are key components of an HIS, contain
information concerning patients’ hospitalizations. The presence of
these HISs, in conjunction with immunization information systems
in China’s CDCs, make it  possible in theory to develop a data linkage
system in China in the near future.
5. Conclusions
National AEFI surveillance is a key component of vaccine safety
evaluation. China CDC developed CNAEFIS, which has served as
the national passive surveillance system since 2005. So far, it
has successfully captured more than 300,000 AEFI cases, pro-
viding a fundamental database for vaccine safety evaluation in
mainland China. Experience and evidence drawn from CNAEFIS
has been a vital resource for  decision making by China’s vac-
cine National Regulatory Authority and related stakeholders. In
the future, strengthening the capacity and capabilities of  passive
surveillance, and developing new, active vaccine safety surveil-
lance and analytical methods will be priorities for the Chinese AEFI
surveillance program.
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Introduction: Vaccine-associated paralytic poliomyelitis (VAPP) is one of the most important adverse
effects of vaccines that are in current use globally. The Chinese national adverse event following immu-
nization information system (CNAEFIS) is a passive surveillance system which collects data on VAPP.
Aims: To describe the epidemiological characteristics of VAPP and estimate the risk of recipient VAPP in
China.
Methods: We retrieved information from reported cases of recipient VAPP from CNAEFIS from 2010 to
2015, examined the demographic characteristics of the cases, and used administrative data on vaccina-
tion doses and the estimated number of births as denominators to calculate VAPP incidence.
Results: During 2010–2015, 157 cases of recipient VAPP were reported to CNAEFIS (male-to-female ratio,
8.2:1); 151 cases (96.2%) were less than six months old. All cases were associated with trivalent OPV
(tOPV), and 89.8% occurred after the receipt of ﬁrst dose. Of the 157 recipient VAPP cases, type II, type
III, and type I poliovirus vaccine strains were isolated from 27 (17.2%) , 25 (15.9%) , and 16 (10.2%) cases,
respectively. One case died and one case recovered completely; the other 155 cases had various physical
disabilities, such as monolateral or bilateral limping. Using the administered doses of OPV as the denom-
inator, the incidence of recipient VAPP during the study period was estimated at 0.4 per million doses.
The estimated recipient VAPP per million births ranged from 1.0 to 2.4 during 2010–2015.
Conclusion: The epidemiological characteristics of recipient VAPP cases in China, such as age distribution,
were comparable to those in previous studies from other countries. The risk of recipient VAPP, using
either estimated births or vaccination doses, was comparable to that in the US and Japan. We recommend
using an inactive poliovirus vaccine to decrease the number of recipient VAPP cases in China.
 2018 Elsevier Ltd. All rights reserved.
1. Introduction
The oral poliovirus vaccine (OPV), which contains live, attenu-
ated poliovirus strains types I, II, and III, has served as the primary
tool for eradicating polio worldwide [1,2]. Poliovirus vaccines have
had a dramatic effect on the incidence of polio in developed coun-
tries since their introduction [2]. OPV was developed in 1959 and
manufacturing began in 1962 in China, as it was felt that an oral
vaccine would more closely imitate natural infections due to its
similar route of ingestion, and would thus potentially interrupt
transmission much more effectively [2].
China reported 20,000–43,000 polio cases each year in the early
1960s, making it a major affected area [3]. Chinese national immu-
nization program began in 1978, and China started to implement
the planned immunization schedule, in which OPV was recom-
mended to children in certain age brackets [4]; according to the
schedule, the recommended ages for OPV were two months, three
months, four months, and four years for each dose. Subsequently,
the number of polio cases declined dramatically, and in 2000, the
West Paciﬁc Regional Ofﬁce (WPRO) of the World Health Organiza-
tion (WHO) certiﬁed the nation to be polio-free. There have been
no reported indigenous wild poliovirus cases in China since 1994
[5]. In 2011, an outbreak of imported wild-type poliovirus occurred
in the Xinjiang Uygur Autonomous Region in northwest China.
https://doi.org/10.1016/j.vaccine.2018.01.019
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Supplementary immunization activity was launched and ﬁve
rounds of OPV vaccination were conducted among children and
adults; the outbreak ended 1.5 months after laboratory conﬁrma-
tion of the index case [6], and China was again certiﬁed by the
WHO as being polio-free [5].
Despite the great advantages of OPV in preventing wild polio-
virus, reversion of the attenuating mutations during OPV replica-
tion could lead to an increase in neurovirulence, thus triggering
abnormal reactions and even serious cases [2].
In polio eradication environments, such as China, vaccine-
associated paralytic poliomyelitis (VAPP), which is the only serious
adverse event associated with OPV [1], became a public health
problem. In the second half of 2005, parents from different pro-
vinces sought medical treatment in Beijing for their children,
who had developed abnormal limbs [3]. The Chinese government
issued several laws and policies aimed to compensate VAPP
patients. As neonatal immunodeﬁciency is a rare but natural part
of infancy, ‘‘one in a million” victims cannot be avoided when using
OPV.
VAPP is one of the most important vaccine-caused adverse
effects of vaccines that are in current use globally. With the
near-disappearance of wild-type polio, VAPP emerged as the lar-
gest cause of paralysis from polioviruses. One of the reasons for
the Global Polio Eradication Initiative’s Polio Endgame Strategic
Plan 2013–2018 is to reduce VAPP. TheWHO polio vaccine position
paper indicates that countries in which VAPP is a concern, a
sequential inactive poliovirus vaccine (IPV)/OPV schedule can be
adopted. In response to WHO’s planned global action of switching
from trivalent OPV (tOPV) to bivalent OPV (bOPV) in April 2016,
which was aimed at mitigating VAPP after conducting a pilot study
with IPV in 2015, the attenuated poliovirus vaccine has been
switched from tOPV to bOPV and IPV was included as the ﬁrst polio
vaccination dose across China as of May 1, 2016. Consequently, it
was expected that VAPP cases would decrease signiﬁcantly and
ultimately disappear in the near future. We reviewed data from
national AEFI surveillance to (1) describe the epidemiological char-
acteristics of recipient VAPP cases as adverse events following
immunization in China, and (2) estimate the risk of contracting
recipient VAPP during the study years.
2. Methods
2.1. Chinese national AEFI surveillance system (CNAEFIS) [7]
CNAEFIS is an online AEFI information reporting system. In
June 2010, the Chinese Ministry of Health (MoH) and Chinese
Food and Drug Administration (CFDA) jointly issued national
AEFI guidelines for reporting and management [8], making the
CNAEFIS the only and ofﬁcial vaccine safety surveillance system
in mainland China.
According to national AEFI guidelines, an AEFI case for
surveillance is deﬁned as a reaction or event after vaccination
that is suspected to be related to the vaccination. Healthcare
facilities, vaccination units, centers for disease control and pre-
vention (CDCs), adverse drug reaction (ADR) monitoring agencies,
vaccine manufacturers, and their executive staff are the respon-
sible reporting units for AEFI. The reporting of AEFI is imple-
mented in line with the principle of localized management,
although the public can also notify any of the reporters listed
above. Case reports are compiled by local county CDCs, which
can verify AEFI Case Reporting Cards and enter them into the
CNAEFIS; from there, duplicate reports can be detected and
deleted. Once cases are entered into the CNAEFIS, they can be
viewed by all levels of CDCs and ADRs.
Any AEFI with the exception of common adverse reactions with
a clear diagnosis (e.g., fever, redness and swelling at the injection
site, induration) should be investigated. For an AEFI in need of
investigation, county CDCs should begin by collecting relevant data
and then complete the AEFI Case Investigation Form; it can then be
reported to CNAEFIS.
2.2. Causality assessment in CNAEFIS
According to national AEFI guidelines [8], every level of the CDC,
including county, prefectural, and provincial, should organize an
AEFI Investigation and Diagnosis Expert Committee, which should
include relevant experts in clinical medicine, epidemiology, labora-
tory practices, pharmacy, vaccinology, vaccine regulation, and
related ﬁelds. This committee should be in charge of making diag-
noses and determining the cause of the AEFI when needed. For
deaths, severe disabilities, AEFI clusters, and an AEFI of signiﬁcant
public concern, prefectural or provincial CDCs should organize an
AEFI Investigation and Diagnosis Expert Panel, which should
include experts involved in the related committee, for diagnosis
and causality assessment.
Similar to WHO vaccine safety surveillance guidelines [9,10],
after the causality assessment, the AEFI should be classiﬁed into
the following categories [7,8]: (1) vaccine-related reaction or vac-
cine product-related reaction; (2) vaccine quality reaction or vac-
cine quality defect-related reaction; (3) program error or
immunization error-related reaction; (4) coincidental event; (5)
psychogenic reaction or immunization anxiety-related reaction.
2.3. Case deﬁnition of VAPP in CNAEFIS
In 2008, the Ministry of Health of the People’s Republic of China
issued two regulations on the diagnosis and veriﬁcation of VAPP:
‘‘Instruction advice on diagnosis and treatment of vaccine associ-
ated paralytic poliomyelitis” (Wei Ban Yi Fa [2008] No.17), and
‘‘Instruction advice on veriﬁcation of VAPP and handling of remain-
ing problems” (Wei Ban Fa [2008] No. 40).
In these regulations, there are two types of VAPP: recipient and
contact. In CNAEFIS, contact VAPP is not included. Recipient VAPP,
on the other hand, is deﬁned as a case of (1) fever occurring 4–35
days after vaccination, acute ﬂaccid paralysis (AFP) occurring 6–40
days after vaccination, and a clinical diagnosis compatible with
paralytic poliomyelitis, or (2) Isolation of vaccine-related polio-
virus from stool samples, which are used as supplementary condi-
tions. Similar to other AEFI cases, recipient VAPP is also
investigated by a panel of experts and receives a causality assess-
ment based on the clinical and epidemiological characteristics of
the cases.
2.4. Data analysis
For each case, we reviewed the date of occurrence, gender, age,
address, OPV vaccination history, and serotype of vaccine strains.
For risk calculations, two methods were used [11]: VAPP per
million administered OPV doses, and VAPP per million births. The
risk of recipient VAPP per administered OPV doses was calculated
by using the number of recipient VAPP cases reported during the
study period divided by the total number of OPV doses adminis-
tered during the same period. The OPV-administered doses were
collected from a Chinese immunization information system, which
collects immunization doses of all vaccines in national immuniza-
tion schedules, including OPV. However, the immunization doses
of OPV in supplementary immunization activities launched at the
provincial level are not collected in this system. VAPP per million
births was calculated by using the number of recipient VAPP cases
divided by the number of estimated births during the same period.
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The estimated births were calculated by multiplying the total pop-
ulation by birth rate. Both total population and birth rate were
determined from China’s National Bureau of Statistics website
[12]. The data from 2010 were census data, while data from other
years were from annual sampling surveys.
3. Results
3.1. Characteristics of VAPP cases
There were 157 recipient VAPP cases reported to CNAEFIS dur-
ing 2010–2015. The male to female ratio was 8.2:1; 151 cases
(96.2%) were children less than six months of age. Twenty-four
of 31 provinces and the Xinjiang Production and Construction
Crops in China reported recipient VAPP; 51.6% (81 cases) were
reported from eastern regions, 38.9% (61 cases) from middle
regions, and 9.6% (15 cases) from western regions. The number
of recipient VAPP cases by year, gender, and age are summarized
in Table 1. Perianal abscess was reported in 24.8% (39 cases) of
the 157 recipient VAPP cases, all of whom were male infants.
The vaccines associated with all recipient VAPP cases in CNAE-
FIS from 2010 to 2015 were trivalent OPV (tOPV), which was rec-
ommended in the national immunization schedule during the
study period. Among all 157 recipient VAPP cases, 89.8% (141
cases) occurred after the infants received their ﬁrst dose of OPV;
7.6% (12 cases) occurred after the second dose; and 2.6% (4 cases)
occurred after the third or more doses. None of the recipient VAPP
cases had a history of IPV vaccination.
Information on the serotype of poliovirus isolation was reported
in 139 cases (88.5%). The type II poliovirus vaccine strain was iso-
lated from 27 cases; type III was isolated from 25 cases; type I was
isolated from 16 cases; and multiple serotypes were isolated from
25 cases. Three recipient VAPP cases reported vaccine strain isola-
tion, but did not report the speciﬁc serotypes. Fifteen cases did not
report results of vaccine strain isolation. The results of serotype
isolation from 46 cases (29.3%) were negative (Table 2).
Of 157 cases, 118 (75%) reported fever between 3 and 35 days
after vaccination, while the others did not provide temperature
information to assess fever. One recipient VAPP died and another
recovered; the remaining 155 cases experienced physical disabili-
ties: 107 cases reported residual paralysis at the 60-day follow-up
visit, of which 55.1% (59 cases) involved a single limb.
3.2. Rate calculation
Using the administered OPV vaccination doses as the denomi-
nators, the incidence of recipient VAPP in the study period was
0.4 per million OPV doses with a range of 0.2 per million OPV
doses–0.6 per million OPV doses in 2013. If we use total population
and birth rates to approximate the number of births, the recipient
VAPP per million births can be estimated; accordingly, the
recipient VAPP per million births ranged from 1.0 to 2.4 in 2010–
2015 (Table 3).
After the ﬁrst dose, 141 recipient VAPP cases occurred, with an
incidence of 1.3 per million doses, which is one in 764,107 vaccina-
tions. The risk after the ﬁrst dose was substantially higher than
after the second and third doses (Table 4). For the second dose,
the risk was about one in 9 million doses, while it was one in 27
million doses for the third dose or more.
4. Discussion
By using data from the national passive AEFI surveillance sys-
tem in China, we estimated that the risk of recipient VAPP was
0.4 per million administered OPV doses. The Expanded Programme
on Immunization began in 1978, and tOPV has been used for more
than 35 years [4]. VAPP data reported in CNAEFIS complement rou-
tine AEFI surveillance and provide an estimate of the baseline risk
of VAPP before switching to the bivalent polio vaccine in China.
VAPP cases were more frequently reported in males and chil-
dren under ﬁve years of age in previous studies [13]. However, in
our study there was a striking gender imbalance in the VAPP
reports for which the reasons are unclear, but possibly related to
different aspects. One is the surveillance or reporting artefact. In
overall passive AEFI surveillance, there are slightly more AEFIs
reported for males than females, with a ratio of 1.4:1 [14–17]. Also
as immunity to poliovirus is largely antibody-mediated, persons
with antibody deﬁciencies are much more susceptible to VAPP
than immune-competent individuals [18]. However, considering
that only part of the reported VAPP cases were immune deﬁcient,
and not all relevant immune deﬁciency syndromes are x-linked,
immune deﬁciency may only explain part of the gender difference.
One study in a children’s hospital in Beijing [19] found that among
primary immunodeﬁciency diseases (PID)patients, the ratio of boys
to girls was 4.4: 1. The same study found that in 174 patients with
PID for 11 years, the median age of onset of antibody deﬁciency
was 12 months [19]. Therefore, it is difﬁcult to assess immune-
competency in a young infant as they are only two months old at
the time of OPV vaccination. We also found that about 25% of VAPP
cases had perianal abscess and they were all male. The possible
relations of gender, perianal abscess and VAPP require further
study.
The age distribution of VAPP cases is obviously associated with
the OPV vaccine schedule, in which the recommended age for OPV
doses are two, three, and four months of age. The majority of recip-
ient VAPP cases occurred after the ﬁrst dose. A literature review of
VAPP burden indicated that in low-income countries, VAPP was
highest in children 1–4 years of age; whereas in middle- and
high-income countries, the risk of VAPP was highest in infants
under one year old [13]. The reason for this was assumed to be
related to the prevalence of protective maternal antibodies and
the high coverage provided by the ﬁrst dose of OPV; accordingly,
Table 1
Number of recipient VAPP by gender and age, 2010–2015, China.
2010 2011 2012 2013 2014 2015 Total
N % N % N % N % N % N % N %
Gender
Male 23 100 30 93.8 17 77.3 35 87.5 21 87.5 14 87.5 140 89.2
Female 0 0 2 6.2 5 22.7 5 12.5 3 12.5 2 12.5 17 10.8
Age (Month)
1–3 month 17 73.9 24 75.0 17 77.3 29 72.5 21 87.5 14 87.5 122 77.7
4–6 month 5 21.7 7 21.9 4 18.2 8 20.0 3 12.5 2 12.5 29 18.5
>6 month 1 4.4 1 3.1 1 4.5 3 7.5 0 0 0 0 6 3.8
Total 23 32 22 40 24 16 157
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VAPP was high in the under one year age group. In high-income
countries, high OPV immunogenicity and delivery of the ﬁrst dose
of OPV after two months (when maternal antibodies are lower)
might increase the risk of VAPP following the ﬁrst dose. Because
of oral administration, the coverage of OPV is generally higher than
other vaccines, and has been reported to be as high as 99% in China,
according to national immunization coverage surveillance data
[20].
Improved capacity for reporting AEFI might affect the geo-
graphic distribution of VAPP cases. Since CNAEFIS developed
rapidly after national AEFI guidelines were issued in 2010, the
capability of AEFI surveillance in different regions in China might
have been implemented unevenly. Similar to all reported AEFI
cases, cases of recipient VAPP were highest in eastern regions, fol-
lowed by middle regions, and then western regions. In addition to
the capability of AEFI surveillance, this ﬁnding might also be
related to economic status and population distribution. After
2012, the central government issued ﬁnancial support for AEFI
investigation and causality assessment, which could enhance the
number of recipient VAPP cases reported to CNAEFIS. The decline
in recipient VAPP in 2015 might be related to the policy change
in July 2015 in which six pilot provinces in China introduced IPV
to replace tOPV as the ﬁrst dose. Also, the domestically manufac-
tured IPV-sabin strains were put into market for parents in 2015.
In the vaccine serotype analysis, type II accounted for about one-
third (27/93) of cases, similar to other studies [13]. Responding
to the WHO’s global recommendations, China withdrew tOPV,
and IPV was included as the ﬁrst polio vaccination dose, and bOPV
as the subsequent doses, across China in May 2016. This action is
expected to reduce VAPP cases by about 25–30% in the future.
The incidence of VAPP in China was similar to other countries.
In various studies, the incidence of recipient VAPP in different
countries has been estimated to range from 0.33 to 19.08 cases
per million births [2]. Using the total population and birth rates
from the National Bureau of Statistics to estimate the number of
births, the approximate recipient VAPP per million births was
1.0–2.4 from 2010 to 2015, which was similar to the US (1961–
1972) (1.91), Cuba (1963–2006) (2.91), and England/Wales
(1985–1991) (1.68) [11,13]. In our analysis, using vaccination
doses as the denominator, the recipient VAPP per million vaccina-
tion doses was 0.4 per million OPV doses, or about one case per 2.7
million vaccine doses. This is similar to countries such as Japan
(one recipient VAPP case per 2.3 million doses in 1971–2000), India
(one recipient VAPP case per 2.8 million doses in 1999), and Brazil
Table 2
Number of recipient VAPP by OPV vaccination history, serotype of vaccine strains, 2010–2015, China.
2010 2011 2012 2013 2014 2015 Total
N % N % N % N % N % N % N %
OPV vaccination history
1st dose 22 95.6 29 90.6 20 90.9 34 85.0 21 87.5 15 93.8 141 89.8
2nd dose 0 0.0 3 9.4 2 9.1 3 7.5 3 12.5 1 6.2 12 7.6
3 doses 1 4.4 0 0.0 0 0.0 3 7.5 0 0.0 0 0.0 4 2.6
Serotype of vaccine strains
II 4 17.4 6 18.7 2 9.1 5 12.5 6 25.0 4 25.0 27 17.2
III 2 8.7 9 28.1 1 4.5 6 15.0 4 16.7 3 18.8 25 15.9
I 4 17.4 3 9.4 2 9.1 4 10.0 1 4.2 2 12.5 16 10.2
II + III 3 13.0 2 6.3 3 13.6 3 7.5 1 4.2 2 12.5 14 8.9
I + III 1 4.4 0 0.0 1 4.5 2 5.0 1 4.2 0 0.0 5 3.2
I + II + III 0 0.0 0 0.0 1 4.5 1 2.5 2 8.3 0 0.0 4 2.6
I + II 0 0.0 0 0.0 0 0.0 1 2.5 0 0.0 1 6.2 2 1.3
Negative 6 26.1 7 21.9 8 36.4 14 35.0 7 29.2 4 25.0 46 29.3
Unclassiﬁeda 0 0.0 1 3.1 2 9.1 0 0.0 0 0.0 0 0.0 3 1.9
Unreported 3 13.0 4 12.5 2 9.1 4 10.0 2 8.3 0 0.0 15 9.6
Total 23 32 22 40 24 16 157
a Unclassiﬁed: They reported the positive results, but did not reported the speciﬁc serotypes.
Table 3
Risk of recipient VAPP in China by year, 2010–2015, China.
Recipient
VAPP
Million
OPV doses
Recipient VAPP
per million
OPV doses
95% CI Total population
(million)
Birth
rates (‰)
Estimated
births (million)
Recipient VAPP
per million births
95% CI
2010 23 66.6 0.3 0.2–0.5 1340.9 11.9 16.0 1.4 0.9–2.2
2011 32 69.6 0.5 0.3–0.6 1347.4 11.9 16.1 2. 0 1.4–2.8
2012 22 73.1 0.3 0.2–0.5 1354.0 12.1 16.4 1.3 0.8–2.0
2013 40 72.5 0.6 0.4–0. 8 1360.7 12.1 16.4 2.4 1.7–3.3
2014 24 71.9 0.3 0.2–0.5 1367.8 12.4 16.9 1.4 0.9–2.1
2015 16 70.1 0.2 0.1–0.4 1374.6 12.1 16.6 1.0 0.6–1.6
Total 157 423.8 0.4 0.3–0.4 – – 98.4 1.6 1.4–1.9
Table 4
Risk of recipient VAPP in China by dose, 2010–2015.
No. of cases Vaccination doses Incidence rates (per million doses) 95% CI
1st dose 141 107.7 1.3 1.1–1.5
2nd dose 12 108.1 0.1 0.1–0.2
3rd dose 4 107.7 0.04 0.01–0.1
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(one recipient case per 2.39 million doses in 1989–1995) [13]. In
contrast, the VAPP risk was estimated as one case per 750,000 vac-
cinees in the US, and one per 400,000 in Norway, England, and
Wales [2]; however, these rates included both recipient and con-
tact VAPP. However, without contact VAPP, the rates estimated
from CNAEFIS could not be compared with these countries. Based
on the vaccination doses, we could estimate the incidence of recip-
ient VAPP after three doses. In our analysis, the risk after the ﬁrst
dose was highest (1.3 per million vaccination doses), which was
about one in 760,000 vaccination doses, similar to international
studies (one in 750,000 doses) [9]. The risk after the second and
third dose was signiﬁcantly lower than after the ﬁrst dose, about
one in 9 million for the second dose and one in 26 million for the
third dose, consistent with the WHO estimate [1,9].
5. Limitations
An important limitation of this analysis it that CNAEFIS is a pas-
sive surveillance system with low sensitivity and could potentially
underreport recipient VAPP. As only recipient VAPP was reported,
no contact cases were included in our analysis, which could lower
the estimated risk of VAPP. Another limitation is that since some
laboratory data were unavailable in CNAEFIS, cases were catego-
rized as VAPP without serotype information. In addition, for com-
pensation reasons (VAPP cases could receive government
compensation), some cases were classiﬁed as VAPP even when
the laboratory results on serotypes were negative. To eliminate
wild poliovirus, many complementary polio vaccine campaigns
have been launched in China, yet information regarding these cam-
paigns, including vaccination dosage, was not completely reported
during the study period. This error could lead to an overestimation
of overall risk.
Despite these limitations, our analysis showed that the epi-
demiology of recipient VAPP in China, as a rare adverse conse-
quence of receiving OPV, was similar with other international
studies, and that the risk of recipient VAPP, using either estimated
births or vaccination doses, was comparable to that reported in US
and Japanese studies. As the global eradication of polio is
approaching, VAPP will become increasingly unacceptable. After
the introduction of IPV and the replacement of tOPV, the burden
of VAPP should diminish further.
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Background: The national Adverse Events Following Immunization (AEFI) surveillance system in China
(CNAEFIS) has collected AEFI reports -including deaths following all vaccines used in China since 2008.
Aims: To review reports of AEFI-associated death cases from 2010 to 2015 to assess potential vaccine
safety issues.
Methods: Descriptive analysis of epidemiologic characteristic of AEFI-associated death cases and stan-
dard causality assessment for reported causes of deaths. To estimate the risk of death after vaccination,
we used population data, administered doses and live births to calculate denominators.
Results: During 2010–2015, 753 deaths were reported to CNAEFIS from mainland China. Highest num-
bers were reported in 2013 and 2014 when reporting peak of AEFI-associated deaths occurred after
media reports concerning ‘‘death following Hepatitis B vaccination” in China. About 95% of deaths were
in children <5 years of age and males accounted for 60%. Most common vaccines associated with reports
of fatal AEFIs were vaccines in national immunization schedule. In causality assessment, 120 (16.0%)
deaths were classiﬁed as vaccine-associated reactions such as anaphylactic reactions and disseminated
BCG infections; 594 (78.9%) deaths were identiﬁed as coincidental events. The main causes of death were
asphyxia, and Sudden Infant Death Syndrome. The overall estimated AEFI-associated death rates were:
0.26 per million vaccination doses administered and 0.09 per million population. The neonatal AEFI death
rate was 0.77 per million live births.
Conclusions: These data provide reassuring information about the small risk of death following immu-
nization. They also illustrate sensitivity of passive reporting to public information and that peaks in seri-
ous AEFI reports should be interpreted with caution. Continuous monitoring and scientiﬁc causality
assessment for serious AEFIs, including AEFI-associated deaths is imperative to ensure public conﬁdence
in the immunization program.
 2019 Elsevier Ltd. All rights reserved.
1. Introduction
China initiated the National Expanded Program on Immuniza-
tion (EPI) in 1978 and expanded it to cover 14 types of vaccines
in National Immunization Schedule in late 2007 [1]. As part of
the EPI in China, about 22 vaccine doses are administered during
the ﬁrst year of life [2]. With its 1.3 billion inhabitants and over
17 million annual newborns, China is one of the largest market
and manufacturer for vaccines in the world [3]. On average, more
than 500 million vaccine doses are administered every year [2].
Deaths that occur after immunization, particularly neonatal or
infant deaths frequently attract media attention and cause public
concern. Recently, concerns were raised about adverse events fol-
lowing immunization (AEFI) and vaccine safety [4]. After media
reports of deaths following hepatitis B vaccine (HepB) administra-
tion in Hunan province of China in December 2013, concerns about
the vaccine safety increased among parents and the public [4].
However, vaccinations during childhood are common, and deter-
mining whether or not they are associated with pediatric deaths
is difﬁcult.
All vaccines administered in mainland China are monitored and
considered to be safe and effective by the National Regulatory
Authority [3]. Since 2008, Chinese Center for Disease Control and
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Prevention (CCDC) has monitored AEFI reports, which are recorded
using a passive AEFI nationwide surveillance program (Chinese
AEFI Information System [CNAEFIS]) [5]. Since its implementation,
the CNAEFIS has collected information on a large number of AEFI
cases associated with vaccines used in China.
To understand the epidemiological characteristics, causes of
death, and risk of death following vaccination in China, we
reviewed and analyzed reports of deaths after immunization from
2010 to 2015.
2. Materials and methods
2.1. Data sources
The CNAEFIS is a nationwide passive surveillance system for
AEFI [2,5]. In 2008, after 3 years of various pilot studies [6,7], the
CNAEFIS became an online system covering all provinces. The AEFI
surveillance of mass immunization campaigns, including the 2009
A(H1N1) inﬂuenza vaccine campaign during 2009–2010 inﬂuenza
season [8] and measles vaccines campaign, which included more
than 100 million children in 10 days in September 2010 [9] were
covered by CNAEFIS, strengthening the reporting capacity. In June
2010, Chinese Ministry of Health and the Food and Drug Adminis-
tration jointly issued a national AEFI guideline that made the
CNAEFIS the sole and ofﬁcial surveillance system in mainland
China [10].
According to the national AEFI guideline, an AEFI is deﬁned as a
reaction or an event after vaccination that is suspected to be
related to vaccination. Healthcare facilities, vaccination units, local
centers for disease control and prevention (CDCs), adverse drug
reaction monitoring agencies, vaccine manufacturers, and their
executive staff are responsible for reporting AEFIs. In addition,
the public can notify any of these bodies. The data are collated
by local county CDCs. These centers verify the AEFI Case Reporting
information, which is then entered the CNAEFIS. Duplicate reports
are detected and deleted by county-level, prefectural-level and
provincial-level CDCs. Once a case is reported in the CNAEFIS, it
can be viewed online by CDCs, and adverse drug reaction monitor-
ing agencies [10].
2.2. Causality assessment
According to national AEFI guidelines [10], all deaths reported
in the CNAEFIS must be investigated. County-level CDCs com-
mence an investigation by collecting relevant data and completing
the AEFI Case Investigation Form, which is entered in CNAEFIS. An
ad hoc AEFI Investigation and Diagnosis Expert Committee is then
established by the CDCs. The committee includes experts in clinical
medicine, epidemiology, laboratory practices, pharmacy, vaccinol-
ogy, vaccine regulation, and related ﬁelds, as needed. In cases of
deaths, prefectural or provincial CDCs establish the AEFI Investiga-
tion and Diagnosis Expert Committee, which includes experts and
committee members related to the case. This Committee then con-
ducts the causality assessment [5,10].
After the causality assessment, the AEFI (including reports of
deaths) is classiﬁed into one of the following categories [10]: (1)
vaccine reactions or vaccine-related reactions, (2) vaccine quality
reactions, (3) program errors or immunization errors, (4) coinci-
dental events, or (5) psychogenic reactions or immunization
anxiety-related reactions.
2.3. Data collection
Deaths which were suspected to be related to the vaccinations,
with dates of death from 1st January 2010 to 31st December 2015,
were extracted from CNAEFIS and included in the study. Informa-
tion collected included age and gender of the patients, vaccines
received, results and conclusions of the causality assessments, time
intervals from vaccinations to onset of symptoms, clinical diag-
noses, and concurrent vaccines administered.
2.4. Calculation of reporting rates
We used the following denominators to estimate the risk of
AEFI-associated deaths: (1) administered doses collected from vac-
cination clinics during the study period, (2) population data from
the National Bureau of Statistics of the People’s Republic of China,
and (3) neonatal death rates after vaccination. For denominator 1
and 2, the numerator was AEFI-associated deaths reported to
CNAEFIS during the same period. The rates were calculated per
million administered vaccination doses or per million population.
For denominator 3, we used administered doses for ﬁrst dose of
HepB vaccine which administered within 24 h after birth and vac-
cination coverage to estimate the number of live births. The
numerator was cases who died within 28 days after birth.
2.5. Statistical analysis
All calculations were performed by using R software, version
i386 3.2.3; the epitools package was used to calculate conﬁdence
intervals for Poisson rates.
3. Results
3.1. Characteristics of AEFI-associated deaths
A total of 753 AEFI-associated deaths were reported during
2010–2015. AEFI-related deaths peaked in 2013–2014 (Fig. 1).
The proportion of neonatal deaths varied from 5.0% (2010, 2011)
to 16.5% (2013). In 2012–2014, the proportion exceeded 10.0%.
All deaths were reported from locations within mainland of China.
During the ﬁrst quarter of the year (January to March), there
were 249 (33.1%) AEFI-associated deaths, followed by 234
(31.1%) during the fourth quarter, 140 (18.6%) and 130 (17.3%) dur-
ing the third and second quarters, respectively. Fifty-one AEFI-
associated deaths were reported in December 2013, and 34
(66.7%) of these were related to HepB vaccine, administered alone
or with other vaccines (Fig. 2).
Of AEFI-associated death reports, 293 (38.9%) were females, 635
(84.3%) were aged <1 year, and 82 (10.9%) cases were aged 1–
4 years (Table 1). The median age in the group aged <1 year was
68 days, and the median age in the group aged 1–4 years was
1 year old.
Fig. 1. Reports of AEFI-associated deaths by year, 2010–2015.
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Sixty-Nine different vaccines or vaccine combinations were
associated with reported deaths. The most common vaccines or
vaccine combinations were (1) HepB (alone) (182, 24.2%), (2) Bacil-
lus Calmette Guerin (BCG) and HepB (116, 15.4%), (3) oral
poliomyelitis vaccine (OPV) and diphtheria, tetanus and acellular
pertussis combined vaccine (DTaP) (84, 11.2%), (4) BCG (alone)
(61, 8.1%), and (5) DTaP (alone) (31, 4.1%) (Table 2).
3.2. Results of the causality assessments
Autopsies were conducted in 257 (34.1%) cases. According to
the causality assessment, 120 (15.9%) deaths were classiﬁed as
vaccine reactions, 594 (78.9%) deaths were due to coincidental
events, 38 (5.1%) deaths were classiﬁed as indeterminate, and 1
(0.1%) death was due to an immunization error-related reaction.
No deaths were classiﬁed as due to vaccine quality defect-related
reactions or immunization anxiety-related reactions during the
study period (Table 2)
3.2.1. Vaccine-related reactions
One hundred-twenty deaths were classiﬁed as vaccine-related
reactions, with an estimated rate of 0.04 per million doses, using
the all vaccination doses as the denominator. Anaphylactic reac-
tions accounted for 55 cases, in which 53 cases occurred within
1 day after vaccination. Anaphylactic reactions take 45.8% of
vaccine-related reactions, with estimated rates of 0.02 per million
vaccination doses. Nineteen vaccines or vaccine combinations
were related to anaphylactic reactions. The average numbers of
deaths per year due to anaphylactic reactions post-vaccination
was about 9 (range: 6–13 cases). The most common vaccine and
vaccine combinations associated with vaccine reactions were HepB
(alone) (12 cases), OPV and DTaP (10 cases), BCG and HepB (9
cases).
There were 39 BCG-related deaths (estimated rate: 0.37 per
million BCG vaccination doses). Thirty BCG-related deaths were
classiﬁed as the result of disseminated BCG infections, and nine
cases were due to BCG lymphadenitis or other infections (recur-
ring). One death due to vaccine associated Vaccine-Associated Par-
alytic Poliomyelitis (VAPP) was reported. One case of hemorrhagic
measles was reported in which the autopsy and laboratory ﬁndings
conﬁrmed that this was related to the vaccine virus.
Thirteen deaths were attributed to neurological, illness, of
which six cases were meningitis (aseptic or viral), four cases were
acute disseminated encephalomyelitis, two cases were
encephalopathy, and one case was epilepsy. Seven vaccines and
vaccine combinations were administered in these cases, of which
Fig. 2. Seasonal distribution of AEFI-associated deaths, 2010–2015.
Table1
AEFI-associated deaths by year of death, age and gender, 2010–2015.
<1 1–4 5–9 10–17 18–64 65 Total
N Female % N Female % N Female % N Female % N Female % N Female % N Female %
2010 84 44.05 20 50.00 3 0 2 50.00 9 44.44 1 0 119 43.70
2011 90 44.44 8 37.50 1 0 1 100 1 100 101 44.55
2012 79 27.85 12 25.00 2 50.00 1 0 1 0 95 27.37
2013 139 36.69 13 38.46 2 0 2 50.00 2 50.00 158 36.71
2014 141 39.01 15 40.00 3 0 1 100 160 38.75
2015 102 42.16 14 42.86 1 100 2 0 1 0 120 41.67
Total 635 39.06 82 40.24 10 20.00 4 25.00 15 40.00 7 42.86 753 38.91
Table 2
AEFI-associated deaths by vaccine and vaccine combination, and the causality
assessment classiﬁcation, 2010–2015.
Vaccines and
vaccine
combinations
Vaccine
reaction
Immunization
error
Coincidental
events
Indeterminate Total
HepB 13 163 6 182
BCG + HepB 16 1 92 7 116
OPV + DTaP 13 65 6 84
BCG 34 24 3 61
DTaP 7 22 2 31
OPV 26 1 27
HepB + OPV 2 17 19
RabV 7 8 3 18
JE-L 4 12 1 17
OPV + DTaP
+ Hib
1 12 13
Other 59
vaccines
and vaccine
combinations
23 153 9 185
Total 120 1 594 38 753
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the rabies vaccine was the most common vaccine, accounting for
ﬁve deaths. The average number of deaths per year was three, with
a range of two to four in the study period.
Nine deaths were conﬁrmed as status thymicolymphaticus
(STL) after autopsies. Other two cases were diagnosed as malaise
and vomiting post vaccination, and both died of aspiration asphyx-
ia. In all above 11 cases, vaccination was not the direct cause of
death. However, in the causality assessment, the expert committee
concluded that vaccination contributed to these deaths and classi-
ﬁed the deaths as vaccine-related reactions.
3.2.2. Immunization errors
Only one death was classiﬁed as immunization error-related
reaction. In this case, the baby had been diagnosed with severe
malnutrition prior to immunization, and the immunization nurse
had failed to perform a physical examination when the parents
requested that the infant be vaccinated. The direct cause of death
was severe malnutrition, respiratory failure, and cardiac failure,
not vaccine related.
3.2.3. Coincidental events
After causality assessment, 594 deaths were classiﬁed as coinci-
dental events. The most common causes of death were asphyxia,
sudden infant death syndrome (SIDS), pneumonia (neonatal and
infant), congenital heart diseases, and vitamin K deﬁciency (which
could lead to internal bleeding). In these cases, 577 (97.1%) deaths
occurred within 15 days after vaccination. Sixty vaccines and vac-
cine combinations were administered, the most common were
HepB (alone) (163 cases), BCG and HepB (92 cases), OPV and DTaP
(65 cases), OPV (alone) (26 cases), and BCG (alone) (24 cases). In
574 (96.6%) cases, the patients aged <5 years.
3.2.4. Indeterminate cause of death
During 2010–2015, 38 deaths were classiﬁed as due to indeter-
minate causes. There was no clear clinical diagnosis in 25 (65.8%)
cases, and for the rest cases there was insufﬁcient evidence avail-
able to conduct the causality assessment. All 38 deaths occurred
within one-week post-vaccination, and 34 (89.5%) cases aged
<5 years.
3.3. Risk estimation of AEFI-associated deaths
Using all administered doses as the denominator, the average
rate of AEFI-associated death was 0.26 per million vaccination
doses (range: 0.20–0.32) during the study years. Using population
data as the denominator, the average rate was 0.09 per million
population (range: 0.07–0.12) (Table 3).
Neonatal deaths accounted for 10.4% (78 cases) of all reported
AEFI-associated deaths. The highest rate of reported neonatal
deaths after vaccination occurred in 2013 (1.48 per million live
births) (Table 4). The rate of neonatal deaths after vaccination in
2010–2011 was signiﬁcally different from 2013 to 2014 (Table 4).
During 2013–2014, 47 neonatal deaths were reported and 44
(93.6%) of those were related to HepB (with concurrent vaccines).
In the causality assessment however, only one of the reported
deaths was considered causally related to vaccination.
During 2010–2015, we identiﬁed 182 reports of AEFI-associated
deaths after vaccination with HepB was the only vaccine used. Of
these, 13 were causally related to vaccination in the causality
assessment. The annual numbers of causally related deaths during
the period were 2,3,2,1,3,2, respectively.
4. Discussion
During six years of AEFI surveillance in mainland China, more
than three quarters of reported AEFI-associated deaths were due
to coincidental events, and only 16% could be attributed to vaccina-
tion by causality assessment. Most of those determined to be cau-
sally related to vaccination were related to anaphylactic reactions
and disseminated BCG diseases. Although the reporting rates of
neonatal deaths increased during 2013–2014, deaths that causally
related to HepB were very rare during the study years.
Overall, our study provides reassuring information about the
small risk of deaths following immunization. Although 5% AEFI-
associated deaths were indeterminate cause, the AEFI investigation
and causality assessment process provided valuable information to
evaluate vaccine safety in China. The reporting peak of AEFI-
associated deaths in late 2013 to early 2014, illustrates the sensi-
tivity of passive reporting of serious AEFI to public information
and the caution that should be exercised in interpreting peaks in
serious AEFI reporting. Our analysis also illustrates progress made
with vaccine safety monitoring during recent years in China.
Several limitations should be considered when interpreting the
study ﬁndings. As CNAEFIS is a passive surveillance, it has inherent
limitations, including reporting bias, and lack of control groups
[11]. The limitation of denominator-based risk estimation includes
different resources to identify the vaccine-administered doses and
unknown background information, which make it difﬁcult to com-
pare the observed to the expected, as well as among different set-
tings [12]. In our study, the denominators used were estimated
from different data resources and one should be cautious about
comparing the estimated rates with immunization related death
rates in other countries. In China, compensation is available for
reactions determined to be vaccine-related. When the expert panel
ﬁnds no other cause of death, it might be concluding that the vac-
cine or vaccination was a contributor to the death in the causality
assessment. In such cases, the families of the deceased are eligible
to apply for compensation. This policy might increase the number
of reports of vaccine-related reactions.
Regarding the seasonal distribution of deaths during the study
period, except for 2013, deaths were more common in winter than
in summer months, consistent with ﬁndings of similar studies else-
where [13]. The results showed that children aged <5 years
accounted for 95% of AEFI-associated death, which is consistent
Table 3
Estimated overall AEFI-associated death rates using different denominators, 2010–2015.
Year No. of deaths All vaccination
doses (millions)
Estimated rates by vaccination doses Total population
(millions)
Estimated rates by total population
Deaths rates (per million
vaccination doses)
95% CI Deaths rates (per million
population)
95% CI
2010 119 427.88 0.28 0.23–0.33 1340.91 0.09 0.07–0.11
2011 101 461.44 0.22 0.18–0.27 1347.35 0.07 0.06–0.09
2012 95 478.97 0.20 0.16–0.24 1354.04 0.07 0.06–0.09
2013 158 489.21 0.32 0.27–0.38 1360.72 0.12 0.10–0.14
2014 160 495.74 0.32 0.27–0.38 1367.82 0.12 0.10–0.14
2015 120 504.23 0.24 0.20–0.28 1374.62 0.09 0.07–0.10
Total 753 2857.49 0.26 0.25–0.28 8145.46 0.09 0.09–0.10
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with Vaccine Adverse Event Reporting System (VAERS) data in the
U.S. [14] and the National Immunization Schedule in China. There
were also more male than female deaths. This ﬁnding is consistent
with data reported in the All Cause of Death Surveillance System in
China [15]. Of the AEFI-associated deaths, 78.9% were classiﬁed as
coincidental events. The reported causes of death were consistent
with common causes of mortality nationally [16,17]. According
to the National Bureau of Statistics of the People’s Republic of
China (http://data.stats.gov.cn/easyquery.htm?cn=C01), all-cause
neonatal death rates during 2010–2014 were 5.9–8.3‰. The esti-
mated neonatal death rates in this study were lower than all-
cause neonatal death rates in the general population, suggesting
no association of vaccinations with an increased risk of death at
the population level.
Generally, parents have their children vaccinated when they are
in relatively good health. In situations where the infant dies shortly
after immunization, parents and even health providers may blame
vaccine [13]. Although vaccines play a vital role in preventing dis-
eases in children, vaccine hesitancy has become an issue in many
counties, including China [18,19]. Events in December 2013 in
Hunan province of mainland China provide an example of how
such concerns was arise [20]. Media reports of 17 infant deaths,
including one case of anaphylactic shock following HepB vaccina-
tion, raised widespread public concern in China [3,19]. After inves-
tigation, The China Food and Drug Administration reported that the
deaths were not related to the vaccine, but instead with a variety of
problems, including severe pneumonia, suffocation, kidney failure,
severe diarrhea and congenital heart disease [3,19,20,21]. In pas-
sive surveillance systems, the behavior of parents and vaccine pro-
viders behavior may inﬂuence the number of reports. This
publicity may have increased public awareness and led to a ten-
dency to report deaths after immunization during 2013–2014.
Our analysis showed a reporting peak during 2013–2014, in which
94% of the neonatal deaths were reported to be related with HepB.
However, vaccine reactions determined to be causally related to
HepB were rare during the study years. Although the overall num-
ber of all AEFI reports in CNAEFIS increased from 2010 to 2015, the
number of serious AEFIs (events causing a potential risk to the
health/life of a recipient leading to prolonged hospitalization, dis-
ability/incapacity, congenital abnormalities/birth defects or death)
has remained constant [9,22–25].
Causality assessments in China are performed in accordance to
WHO guidelines [10,26]. The documented causes of death that
could possibly occur due to the inherent properties of a vaccine
are limited and include anaphylaxis, viscerotrophic disease follow-
ing yellow fever vaccine, disseminated attenuated live vaccine
agent infection in severely immune-compromised individuals
and death from intussusception following rotavirusvaccine [27].
In China, yellow fever vaccine is not recommended, and rotavirus
vaccines differ from those used internationally. In our study, the
most common causes of vaccine-related reactions and deaths were
anaphylaxis and disseminated BCG infections. BCG is recom-
mended at birth, without screening to determine the status of
the immune system at that time. In our study, several deaths were
due to neurological diseases. There was no solid evidence that
these neurological diseases were caused by the vaccines or vacci-
nation, although some studies reported temporal associations of
such diseases with various immunizations [28,29]. When no etio-
logic agent is identiﬁed, and the person was healthy prior to immu-
nization, a suspicion may arise in the causality assessment that the
vaccine contributed to the death. Several cases with STL was also
assessed to be causally related to vaccination during surveillance.
STL is associated with immune system dysfunction. As reported
previously, mild immune stimulation, such as that produced by
minor trauma or immunizations, could give rise to sudden death
among individuals with STL [30]. The expert committee concluded
that it triggered these deaths, even when neither the vaccine nor
the vaccination was the direct cause. Case causality assessments
are extremely difﬁcult. Strengthening the capacity of AEFI investi-
gation and causality assessment is very important in the ﬁeld of
vaccine safety surveillance and evaluation in China. In 2018,
WHO issued revised classiﬁcation for causality assessment [31]
which could be adopted and modiﬁed for the Chinese setting in
future.
5. Conclusions
Vaccines are among the safest medical products in use. How-
ever, parents will naturally become concerned when serious
adverse events occur after vaccination, even though the event
may only be temporally related to immunization [32]. A functional
vaccine safety surveillance system and thorough AEFI investigation
for causality assessment can provide valuable information for both
national regulatory authorities and the public [27]. Our study
showed that the risk of death following vaccination was extremely
small and did not identify speciﬁc safety concerns with vaccines
used in China. Because passive surveillance might be stimulated
by media reports and public concerns, continuous monitoring
and scientiﬁc causality assessment of serious AEFI reports, includ-
ing AEFI-associated deaths, is imperative to ensure public conﬁ-
dence in the immunization program.
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Table 4
Estimated neonatal deaths rates after vaccination, 2010–2015.
Year No. of Neonatal death Vaccination doses of 1st
dose of Heptitis B (million doses)
Vaccination
coverage %
Estimation of live birth
(million live birth)
Neonatal death rates
(per million birth)
95% CI
2010 6 17.16 99.81 17.19 0.35 0.13–0.76
2011 5 17.5 99.86 17.53 0.29 0.09–0.67
2012 10 18.68 99.87 18.71 0.53 0.26–0.98
2013 26 17.48 99.77 17.52 1.48 0.97–2.17
2014 21 15.18 99.84 15.2 1.38 0.86–2.11
2015 10 15.75 99.87 15.77 0.63 0.30–1.17
Total 78 101.75 – 101.91 0.77 0.61–0.96
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Introduction: Two types of Japanese encephalitis (JE) vaccines, inactivated JE vaccine (JE-I) and live-
attenuated JE vaccine (JE-L), are available and used in China. In particular, one JE-L, produced by a domes-
tic manufacturer in China, was prequaliﬁed by WHO in 2013. We assessed the safety of JE vaccines in
China during 2008–2013 using the Chinese National Adverse Events Following Immunization
Information System (CNAEFIS) data.
Methods: We retrieved AEFI reporting data about JE vaccines from CNAEFIS, 2008–2013, examined demo-
graphic characteristics of AEFI cases, and used administrative data on vaccine doses as denominator to
calculate and compare crude reporting rates. We also used disproportionality reporting analysis between
JE-I and JE-L to assess potential safety signals.
Results: A total of 34,879 AEFIs related with JE-I and JE-L were reported, with a ratio of male to female as
1.3:1; 361 (1.0%) cases were classiﬁed as serious. JE vaccines were administered concurrently with one or
more other vaccines in 13,592 (39.0%) of cases. The overall AEFI reporting rates were 214.4 per million
vaccination doses for JE-L and 176.9 for JE-I (rate ratio [RR]: 1.2, 95% conﬁdence interval [CI]: 1.1–1.3)
in 2010–2013. Febrile convulsions (FC) following JE-I was found as a signal of disproportionate reporting
(SDR). However, there was no signiﬁcant difference between the reporting rates of FC of JE-I and JE-L (0.3
per million vaccination doses for JE-L, 0.4 for JE-I, p = 0.05).
Conclusions: While our analysis did not ﬁnd apparent safety concern of JE vaccines in China, further study
should consider JE-I vaccines and febrile convulsion, and taking more sensitive methods to detect signals.
 2017 Published by Elsevier Ltd.
1. Introduction
Japanese encephalitis (JE) is a mosquito-borne acute viral infec-
tion of the central nervous system caused by a ﬂavivirus [1]. JE is
the most important cause of vaccine-preventable viral encephalitis
in nearly all Asian countries, whether temperate, subtropical, or
tropical, and has expanded into new areas through the importation
of infected-mosquito vectors. Currently, an estimated 3 billion
people living in 24 countries, mainly in the South-East Asia and
Western Paciﬁc Regions are considered at risk of JE [2]. The inacti-
vated JE vaccine (JE-I) was developed in China and has been used
since the 1970 s and live-attenuated vaccine (JE-L) was in the
beginning of the 1990s [1]. Since 2007, JE vaccines were included
into the Expanded Program on Immunization (EPI) in the mainland
of China [1]. With the decline of number of JE disease in China, the
public became more concern about the adverse events following JE
vaccination currently. The safety of JE vaccines manufactured in
China and abroad was evaluated in previous clinical and post-
marketing studies [3–7]. The vaccine safety review of JE vaccines
by World Health organization (WHO) were found to have accept-
able safety proﬁles, and data frommultiple studies (including mul-
ticenter randomized controlled trail and randomized trials) had
shown the same conclusion [2,8,9]. However, The JE vaccine used
in China were mainly produced by domestic manufacturers, and
a JE-L product was prequaliﬁed by WHO in 2013, which was the
ﬁrst Chinese-produced vaccine to be prequaliﬁed by WHO. Limited
data are available on the safety of JE after its inclusion into the
Chinese EPI and consequently its large-scale use. Concurrently
with the inclusion of JE vaccines into EPI, the Chinese national
adverse event following immunization (AEFI) information system
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(CNAEFIS), a passive post-marketing vaccine safety surveillance
system, was also expanded to cover the entire country after a 3-
year pilot study [10,11]. With 6 years of information collection,
there were valuable AEFI data in the CNAEFIS which could provide
some evidence for evaluation of vaccine safety in China. Also, using
the passive surveillance data, the disproportionality analysis,
which was ﬁrst used in signal detection of drug safety, could also
be necessary to generate signals, especially when the causality of
the speciﬁc events and vaccination has not been well known. We
conducted a study to analyze AEFI data for both JE-I and JE-L vac-
cines in CNAEFIS from 2008 to 2013 to understand and compare
the vaccine safety proﬁles of these 2 vaccines.
2. Methods
2.1. Vaccination schedules of JE vaccines in China [10]
In the mainland of China, both JE-I and JE-L have been included
in National Immunization Program (NIP) vaccinations since 2007.
For JE-L, a 2-dose schedule is used: at 8 and 24 months of age, with
at least 3 months’ interval. For JE-I, a 4-dose schedule is used (2
doses at 8 months with at least 7–10 day intervals, and subsequent
doses at 2 and 6 years of age).
2.2. Vaccination doses of JE vaccines
All the vaccines should be used in Vaccination clinics, which
was approved by local government and supervised by local Center
for diseases control and prevention (CDC). Vaccination doctors or
nurses collected information of vaccination doses and reported to
the county CDCs monthly. The county CDCs report the data to
municipal CDCs who report to provincial CDCs. China CDC collects
administered vaccination data from all provincial CDCs [3,13].
Before 2010, only doses of vaccines provided by the government
for free were reported. Therefore, complete data on all JE vaccina-
tion doses given during 2008–2009 are not available. Since 2010,
however, the vaccination information system collected all vaccina-
tion doses administered in the vaccination clinics, enabling the
analysis of the reporting rates. As the denominator information
only included the number of vaccine doses, without information
on age or sex, the rates of AEFI for speciﬁc population groups by
age or gender could not be calculated.
2.3. CNAEFIS
The online CNAEFIS is administered by the Chinese Center for
Disease Control and Prevention (CCDC). After two pilot studies, it
was expanded to cover all 31 provinces in the mainland of China
in 2008 [10]. The pilot studies included a passive surveillance sys-
tem for AEFI in 10 provinces and an enhanced AEFI surveillance
system in 5 counties. CNAEFIS is operated in accordance with Chi-
na’s national AEFI guidelines [12]. According to this guidance,
CNAEFIS became the ofﬁcial AEFI information system and was to
be owned and maintained by China CDC [10].
An AEFI case is deﬁned as a reaction or an event occurring after
vaccine administration that is suspected to be related to the vacci-
nation. AEFI surveillance and reporting covers all vaccines mar-
keted in the mainland of China [10].
2.4. Reporting and investigation [10–13]
Healthcare facilities, vaccination clinics, Centers for Disease
Control and Prevention (CDCs) at all 4 administrative levels,
adverse drug reaction monitoring agencies (ADRs), and vaccine
manufacturers are required by law to report suspected AEFIs. The
public or the guardian (parents) can notify any of the above autho-
rized reporters to report an AEFI. Cases are investigated by local,
county-level CDCs, which are responsible for completing AEFI Case
Reporting Cards and submitting the data to online CNAEFIS. Once
the information is entered, it can be viewed by all administrative
levels of CDCs and ADRs. Based on the address, name and birthday
of the child, vaccines, and vaccination dates, duplicate reports are
identiﬁed and potential multiple reports are combined into one
case.
Investigation is required for all AEFIs, except common adverse
reactions with a clear diagnosis (e.g., fever; redness, swelling,
and induration on the injection site). For deaths, serious AEFIs, AEFI
clusters, and AEFIs of signiﬁcant public concern that are suspected
to be related to vaccination, prefectural or provincial CDCs must
immediately organize an AEFI expert panel for investigation upon
receiving CNAEFIS reports.
2.5. Serious and non-serious AEFIs [13]
Serious AEFI is deﬁned as an event that is causing a potential
risk to the health/life of a recipient leading to prolonged hospital-
ization, disability/incapacity, congenital abnormalities/birth
defects or death. In CNAEFIS, it include, but are not limited to, aller-
gic shock, allergic laryngeal edema, allergic purpura, thrombocy-
topenic purpura, localized allergic necrotic reaction (Arthus
reaction), febrile convulsion, epilepsy, brachial neuritis, polyneuri-
tis, Guillain–Barre syndrome, encephalopathy, encephalitis and
meningitis, syncope, toxic shock syndrome, and systemic purulent
infection.
2.6. Data analysis
We analyzed AEFI reports submitted during 2008–2013, for
subjects vaccinated with JE-L or JE-I. In CNAEFIS, a maximum 3
suspected vaccines can be reported at the same time in a single
report. JE vaccines listed as the ﬁrst, second, or third suspected vac-
cine were all included. When more than one symptom was
reported for a case, only the main symptom or the most serious
diagnosis was recorded in CNAEFIS.
The age and sex distribution and clinical diagnoses were
described, and crude AEFI reporting rates per million doses given
were calculated. Since there is no information on whether the vac-
cines were NIP vaccine or not in AEFI cases, the incidence of NIP
vaccine or voluntary vaccination could not be estimated during
the study year.
We used disproportionality analysis of data mining algorithms
to compare the frequency of reports for JE-L and JE-I to detect
any signal of disproportionate reporting (SDR) [14]. Disproportion-
ality analysis identiﬁes AEFIs that were more frequent than
expected and relies on the principle that when a SDR is identiﬁed
for a speciﬁc vaccine, this event (or diagnosis) is reported relatively
more frequently in association with this speciﬁc vaccine than all
the other vaccine in the database. Three disproportionality analysis
methods were applied: the proportional reporting ratio (PRR)
[15,16], Bayesian conﬁdence propagation neural network (BCPNN)
[17], and empirical Bayesian (EB) data mining [18–20]. Dispropor-
tionality analysis were based on a 2 ⁄ 2 contingency table similar
to a case-control study or cohort study [21]. Calculations were per-
formed using R (version i386 3.2.3), and the PhViD package were
used in analysis.
Since disproportionality analysis required ‘‘vaccine and diagno-
sis” as a pair, cases without conﬁrmed clinical diagnosis were
excluded. For the cases in which diagnosis included common
minor adverse reactions, with a mix of symptoms such as fever,
local redness, local swelling, and other minor local or systemic
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symptoms, ‘‘common reaction” was used as a single diagnosis.
Cases who had received concurrent vaccines were excluded.
3. Results
3.1. AEFI following JE-L and JE-I
A total of 34,879 AEFI cases associated with JE vaccines were
collected by CNAEFIS, 2008–2013; 95.2% (33,186) cases were
related to JE-L. JE vaccines were administered concurrently with
one or more other vaccines in 13,592 (39.0%) of cases (39.9% for
JE-L and 19.9% for JE-I, respectively). Both for JE-L and JE-I, the most
common concurrently administered vaccine was measles-
containing vaccines, with a proportion of 24.8% for JE-L (8226 cases
in 33,186 JE-L-related cases) and 17.5% for JE-I (297 cases in 1693
JE-I-related cases).
JE-L was listed as the ﬁrst suspected vaccine in 23,627 (71.2% of
the JE-L-associated AEFI cases). JE-I was the ﬁrst suspected vaccine
in 1357 (80.2% of JE-I-associated cases) (p < 0.05).
There were more cases in males than in females, with a sex ratio
of 1.3:1. More cases occurred in 1 years of age, with 66.4% of JE-L
and 60.8% of JE-I (Table 1). Of all 34,879 AEFI cases, 361 (1.0%) AEFI
cases were deﬁned as serious.
There were 146.7 million vaccination doses collected of JE vac-
cines from 2010 to 2013, in which 95.1% (139.5 million doses) was
JE-L. Since both JE-L and JE-I could be used as NIP vaccines and vol-
untary vaccines, among all JE vaccination doses, 91.5% (134.3 mil-
lion doses) were used as NIP vaccines, including 133.1 million of
JE-L and 1.2 million of JE-I. Using the doses administered from
2010 to 2013 as denominators, the overall reporting rates of AEFIs
per million were 214.4 for JE-L and 176.9 for JE-I (RR: 1.2, 95% CI:
1.1–1.3). the annual reporting rates increased substantially from
2010 to 2013 (Table 2). During 2010–2013, 271 serious AEFIs were
reported. The overall reporting rates of serious AEFIs were 1.8 per
million doses for JE-L and 2.8 per million doses for JE-I (RR: 0.7, 95%
CI: 0.4–1.0).
3.2. Clinical diagnosis of AEFIs
Of the 29,831 non-serious AEFIs, (86.4%) were diagnosed as
common and minor adverse reactions, such as fever, local redness,
and swelling.
Among serious AEFIs, the most frequently reported clinical
diagnosis were febrile convulsion (132, 36.6%), thrombocytopenic
purpura (39, 10.8%), encephalitis and meningitis (29, 8.0%),
Henoch-Schönlein purpura (28, 7.8%), and anaphylactic shock
(25, 6.9%). (Table 3) 22 death cases were reported during the study
period, only 4 cases were classiﬁed as related to vaccination due to
anaphylactic shock.
3.3. Disproportionality analysis
A total of 20,988 AEFIs with complete information on vaccine
and diagnosis were included in the disproportionality analysis.
All three methods, PRR, EB, and BCPNN, suggested JE-I and febrile
convulsion as the suspected SDRs (Table 3). For JE-L, there was
no diagnosis with disproportionally higher reporting.
Based on the results of Table 4, using the administered doses
from 2010 to 2013 as the denominator, the estimated reporting
rates of febrile convulsion after JE-L (as the only vaccine suspected)
and JE-I (as the only vaccine suspected) were calculated: 0.3 per
million doses for JE-L and 0.4 per million doses for JE-I (p = 0.5).
4. Discussion
We reviewed reported AEFIs after JE-L and JE-I in CNAEFIS by 3
levels of analysis: a description of the characteristics of AEFIs, dis-
proportionate reporting between JE-L and JE-I and estimated
reporting rates. The serious AEFIs only accounted for 1% of all
reported AEFIs, and there was also no statistical difference
between JE-L and JE-I in the reporting rates of serious AEFI in all
2010–2013. However in 2012, the reporting rates of serious AEFI
following JE-L were lower than JE-I. The increasing trend in the
reporting rates of AEFI following the immunization of JE-L and
JE-I may be related to the improved reporting to CNAEFIS during
2008–2013. The increased trends were similar to the reporting
rates of all AEFIs during the same period; the reporting rates of
all AEFIs in CNAEFIS of China continuously increased from 2010
to 2013 [22–25].
In previous CNAEFIS data analysis, only JE vaccines were
included in the study [20–23]. However, in our study, at least
one third of AEFIs had other concurrently administered vaccines.
In addition, in the 1-year group, which was the target group of
EPI, an in AEFI for JE-L, more than half the cases were related to
JE-L in combination with other vaccines. In these situations, it is
difﬁcult to determine the responsible vaccine for some adverse
events, such as allergic reactions. Since concurrent vaccination
could not be avoided, we included all AEFIs related to JE in the
CNAEFIS database.
The gender distribution of JE-L and JE-I AEFIs cases was sim-
ilar to all other vaccines [22–24], as there were more male than
female cases. Most reported cases were 1 year old, consistent
with the China Immunization schedule for EPI vaccines. Most
reported AEFIs were relatively mild and self-limiting, with a
diagnosis of common and minor adverse reactions, including
fever, local redness and swelling, and local induration. Besides
the mild and self-limiting adverse reactions, nearly 97% of cases
recovered, and only 22 death cases were reported during the
study period.
Currently, there are several JE vaccines used in China. About 8
domestic manufacturers in China produce JE-L and JE-I. In the
mainland of China, since 1968, JE-I vaccines (Hamster kidney cell
inactivated vaccine) were manufactured domestically. The mass
vaccination period of JE was after 1989, the year JE-L was devel-
oped and manufactured by Chengdu institute of biological prod-
ucts company, and until 2001, the yield of JE-L was more than
200 million doses in all. Following the positive assessment by the
WHO of China’s vaccine National Regulatory Authority in 2011
[25] and with the development of a vaccine manufactory in China
[26], JE-L was the ﬁrst vaccine in China to be prequaliﬁed by the
WHO [27]. Different JE vaccines have been used in other countries.
For example, the United States (US) used an inactivated mouse
brain-derived JE vaccine (JE-I) for travelers (most of them were
adults) from 1992 to 2009. Japan used JE-I for children. Takahashi
[4] reviewed the post-marketing surveillance of JE-I from Japan
and the US. The total adverse events rate was 2.8 per 100,000 doses
in Japan and 15.0 per 100,000 doses in the US.
JE-L was widely used in countries in the Western Paciﬁc region
and Asia (China, Korea, and India), but very limited data are avail-
able on the adverse effects of JE-L in these countries. An analysis of
the post-marketing surveillance of JE-L from 2009 to 2012 by the
Chinese National Center for Adverse Drug Reaction (ADR) Monitor-
ing [2] showed that in 6024 AEFIs, only 70 were considered severe.
The Global Advisory Committee on Vaccine Safety (GACVS) of the
WHO reviewed these data and noted that although there was no
evidence of a safety signal, the number of events recorded in the
AEFI reporting system was low, given that >70 million doses of
the vaccine have been administered [25].
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Table 1
Characteristics of AEFIs after JE-L and JE-I vaccination, China, 2008–2013.
JE-L JE-I
As most suspected*
N = 23627 (%)
Others
N = 9559 (%)
As most suspected
N = 1357 (%)
Others
N = 336 (%)
Serious Serious 244 1.03 66 0.69 51 3.76 0 0.00
Non-serious 23,383 98.97 9493 99.31 1306 96.24 336 100.00
Gender Female 13,444 56.90 5358 56.05 768 56.60 190 56.55
Male 10,183 43.10 4201 43.95 589 43.40 146 43.45
Age group 1 yr 13,306 56.32 8712 91.14 710 52.32 320 95.24
2–6 yrs 10,036 42.48 825 8.63 511 37.66 14 4.17
7 yrs 285 1.21 22 0.23 136 10.02 2 0.60
* There were at most three suspected vaccines were reported in one AEFI cases, the reporters will put one vaccine as the most suspected vaccines. JE as most suspected
means JE was most suspected related to adverse events in the reports.
Table 2
Number and estimated AEFI reporting rates of after JE-L and JE-I by severity* of AEFI, China, 2010–2013.
AEFI JE-L JE-I Rate ratios
Non-serious Serious Non-serious Serious Non-serious Serious
No. of
cases
Reporting
rates**
No. of
cases
Reporting
rates
No. of
cases
Reporting
rates
No. of
cases
Reporting
rates
(95% CI)
2010 2428 75.97 43 1.35 96 33.99 5 1.77 2.23 (1.83–
2.76)
0.74 (0.32–
2.17)
2011 5816 168.51 41 1.19 102 124.86 1 1.22 1.35 (1.12–
1.65)
0.85 (0.19–
19.85)
2012 8495 240.25 69 1.95 756 294.80 13 5.07 0.82 (0.76–
0.88)
0.38 (0.22–
0.72)
2013 12908 343.11 98 2.60 308 295.79 1 0.96 1.16 (1.04–
1.30)
2.37 (0.54–
54.72)
2010–
2013
29647 212.60 251 1.80 1262 174.15 20 2.76 1.22 (1.15–
1.29)
0.65 (0.42–
1.05)
* The severity of AEFI were classiﬁed according to national AEFI guidelines. Serious AEFIs include, but are not limited to, allergic shock, allergic laryngeal edema, allergic
purpura, thrombocytopenic purpura, localized allergic necrotic reaction (Arthus reaction), febrile convulsion, epilepsy, brachial neuritis, polyneuritis, Guillain–Barre syn-
drome, encephalopathy, encephalitis and meningitis, syncope, toxic shock syndrome, and systemic purulent infection.
** Reporting rates: per million vaccination doses given
Table 3
Clinical Diagnosis of serious AEFI after the immunization of JE-L and JE-I, China, 2008–2013.
Clinical diagnosis JE-L JE-I*
First suspected,
N = 244 (%)
Not ﬁrst suspected,
N = 66 (%)
First suspected,
N = 51 (%)
Febrile convulsion 83 34.02 16 24.24 33 64.71
Thrombocytopenic purpura 22 9.02 15 22.73 2 3.92
Encephalitis and meningitis 23 9.43 5 7.58 1 1.96
Henoch-Schönlein purpura 18 7.38 6 9.09 4 7.84
Anaphylactic shock 21 8.61 1 1.52 3 5.88
Apsychia 11 4.51 4 6.06 5 9.80
Seizure 16 6.56 1 1.52 1 1.96
Laryngeal edema 4 1.64 1 1.52 1 1.96
Acute Disseminated Encephalomyelitis (ADEM) 5 2.05 0 0.00 0 0.00
Arthus reaction 3 1.23 1 1.52 0 0.00
Guillain Barre Syndrome (GBS) 1 0.41 1 1.52 0 0.00
Others 37 15.16 15 22.73 1 1.96
* For JE-I, There was no cases coded as serious AEFIs when administered in combination with other vaccines.
Table 4
Suspected SDR of JE using 3 DPA methods, China, 2008–2013.
Methods (criteria) Results
PRR (lower limit of 95% CI of PRR > 1 & n > 3) JE-I - febrile convulsion
PRR = 7.44, Lower limit of 95% CI = 1.59
EB (EB05 > 2 & n > 3) JE-I - febrile convulsion
EB05 = 3.27
BCPNN (lower limit of 95% CI of IC > 1 & n > 3) JE-I - febrile convulsion
Lower limit of 95% CI of IC = 1.64
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One of the primary goals of AEFI passive surveillance is to detect
vaccine safety signals and generate hypotheses for further studies.
Using vaccination doses as a denominator, AEFI incidence rates are
calculated. Through a comparison with historic data and published
studies, emerging vaccine safety signals are detected. However,
since serious AEFIs are very rare, and it is difﬁcult to determine
the background incidence rate, in recent decades, researchers on
pharmacovigilance have applied data mining methods in the
detection of drug adverse events’ signals on vaccines [28]. One of
the main analysis methods is disproportionality analysis. In the
US, PRR [15,16], which was also used in the UK Yellow Card
Scheme (YCS) (the spontaneous reporting system in the UK), and
the Gamma Poisson Shrinkage model (GPS), which was also noted
as EB data mining, has been used to screen Vaccine Adverse Events
Reporting System (VAERS) data and generate signals, including sig-
nals from seasonal inﬂuenza vaccines and from newly licensed
vaccines [18–20]. The WHO Uppsala Monitoring Center (UMC)
has used a similar data mining method, BCPNN, to detect safety
signals [17,29]. These methods were not used as routine SDR
screening in CNAEFIS, but we applied the methods to compare
the SDR between JE-L and JE-I as supplementary analysis to evalu-
ate the safety of JE in China. Febrile convulsions are the commonest
type of seizure in children occurring in 2–5% of all children, 2–5% of
young children in North America and Europe, and 6–9% in Japan
[30,31]. It usually occurs between 3 months and 5 years, with a
peak incidence at 18 months [32], which was also the target age
of vaccinations, especially for JE-L and JE-I. Generally, at least
50% of children who present with febrile convulsion will have no
identiﬁed risk factors [33]. As elevated body temperature is fre-
quently observed following immunization, and febrile seizures
are the most common seizure disorder in infants and children, they
are the most common type of non-epileptic seizure observed fol-
lowing immunization [33]. The signal of febrile convulsion has
been found after measles-mumps-rubella combined vaccine
(MMR), diphtheria-tetanus-pertussis combined vaccine (DTP),
and seasonal inﬂuenza vaccine in some countries, such as the US
and Australia [34–37]. However, an increased risk of febrile con-
vulsion after JE has rarely been reported. In a randomized trial with
26,239 subjects, within 30 days follow-up, the incidence propor-
tion of seizure was 0.1%, and fever lasting more than 3 days was
2.7% in the group vaccinated with JE-L. There was no statistically
signiﬁcant difference between vaccinated and unvaccinated groups
for seizure or fever lasting more than 3 days [38]. In our study,
using the 3 data-mining methods, an SDR: JE-I and febrile convul-
sion was detected compare with JE-L. This indicated that there was
a disproportionality in reports of febrile convulsion after JE-I com-
pared to JE-L. However, when comparing the overall estimated
reporting rates of febrile convulsion after both vaccines, there
was no signiﬁcant difference. In addition, febrile seizures after JE
were less common than after measles-contained vaccines and vari-
cella vaccines [36]. Therefore, the SDR of JE-I and febrile convulsion
should be interpreted with caution.
CNAEFIS, as a national passive surveillance system, has its
strengths and limitations. Even if it serves as a useful source for
vaccination safety evaluation in China, the ﬁndings in CNAEFIS
should be interpreted with caution. The natural limitations of pas-
sive surveillance include over- and under-reporting, biased report-
ing, and inconsistency in the quality and completeness of reports
among others [37]. Meanwhile, the clinical diagnosis of AEFI cases
varied in provinces of China, as we did not have a standard proce-
dure or deﬁnition of AEFI diagnosis, and we did not use the stan-
dard deﬁnitions created by the Brighton Collaboration [39]. In
our analysis, since CNAEFIS were case-based reporting system,
and vaccination doses were collected based on summarized tables
from vaccination clinics, these 2 data resources were not exact
matched. There were no information on whether the vaccine used
as NIP vaccine or voluntary vaccines in CNAEFIS, and no gender and
age information on vaccination doses, all those related incidence
could not be estimated using current data.
In conclusion, during the study period of 2008–2013, the major-
ity of AEFIs following JE vaccines were minor and common adverse
reactions, and there was no signiﬁcant difference between the esti-
mated reporting rates of serious AEFI following JE-I and JE-L. For
serious AEFIs, more than 97% of cases recovered. We recommend
consider further study to discern effects of concurrent vaccination
with JE vaccines and take more sensitive methods to detect signals.
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